Small and Large Bowel

Anal High-Grade Squamous Intraepithelial Lesions (HSIL): BJS | March 2026

Introduction: Anal squamous cell carcinoma is an increasingly common but largely preventable cancer. Most cases arise from persistent high-risk human papillomavirus (HPV) infection, progressing through high-grade squamous intraepithelial lesions (HSIL). This comprehensive review summarizes the current approach to screening, diagnosis, classification, and management of anal HSIL. Why was this review needed? The incidence of anal cancer is steadily increasing worldwide. High-risk groups can now be clearly identified for targeted screening. Classification and management of anal dysplasia have evolved considerably. High-resolution anoscopy (HRA) has become the cornerstone for diagnosis and treatment. Recent evidence supports active treatment of HSIL to prevent anal cancer. Key Takeaways: Persistent high-risk HPV (especially HPV-16 and HPV-18) is the principal cause of anal HSIL and anal squamous cell carcinoma. High-risk populations include people living with HIV, immunosuppressed patients, men who have sex with men, and transplant recipients. Low-grade squamous intraepithelial lesions (LSIL) often regress spontaneously, whereas HSIL carries a substantial risk of progression and warrants treatment. Screening high-risk individuals enables early detection and significantly reduces the risk of invasive anal cancer. High-resolution anoscopy (HRA) is the preferred diagnostic technique, allowing accurate identification, biopsy, and treatment of precancerous lesions. Treatment of HSIL is now recommended because it has been shown to reduce progression to invasive anal cancer. HPV vaccination is expected to substantially reduce the future burden of anal cancer but will not eliminate disease in currently at-risk adults. Artificial intelligence has the potential to improve HRA interpretation, increase diagnostic accuracy, and shorten the learning curve for clinicians. Clinical Impact: Anal cancer is increasingly viewed as a preventable malignancy. Targeted screening of high-risk populations, timely treatment of HSIL, wider HPV vaccination, and expanding access to high-resolution anoscopy have the potential to dramatically reduce anal cancer incidence over the coming decades. Bottom Line: Anal HSIL is a treatable precancerous condition. Early identification using high-resolution anoscopy, combined with timely treatment and HPV vaccination, represents the most effective strategy for preventing anal squamous cell carcinoma.

Post-Infection DGBI (PI-DGBI): Gut | July 2026

Introduction: Acute infectious gastroenteritis can trigger persistent gastrointestinal symptoms long after the infection has resolved, leading to post-infection disorders of gut-brain interaction (PI-DGBI). This global Rome Foundation study evaluated the prevalence, risk factors, and clinical characteristics of these disorders across 26 countries. Why was this study needed? The global burden of PI-DGBI has not been well defined. Risk factors for developing chronic GI symptoms after gastroenteritis remain incompletely understood. International epidemiological data are needed to guide prevention and management. PI-DGBI may have distinct clinical and psychological characteristics compared with other DGBIs. Better recognition may improve long-term patient care. Results: Approximately 1 in 10 patients with a disorder of gut-brain interaction reported a post-infectious onset, confirming acute gastroenteritis as an important trigger for chronic gastrointestinal disease. Younger age, male sex, urban residence, anxiety, and higher somatic symptom burden were independently associated with PI-DGBI. Patients with PI-DGBI experienced greater psychological distress and poorer physical health, with functional dyspepsia, irritable bowel syndrome, and anorectal disorders being the most common clinical presentations. Clinical Impact: This study reinforces that acute gastroenteritis is not always a self-limited illness. A significant proportion of patients develop chronic gut-brain disorders with substantial effects on quality of life. Early recognition, patient education, and multidisciplinary management—including psychological assessment when appropriate—may improve long-term outcomes. Bottom Line: Post-infection disorders of gut-brain interaction are common and clinically significant. Acute gastroenteritis can trigger long-lasting functional gastrointestinal disorders, highlighting the importance of prevention, early diagnosis, and comprehensive long-term care.

FMT in IBS: Gastroenterology | July 2026

Introduction: Gut microbiota alterations have been implicated in the pathogenesis of irritable bowel syndrome (IBS), making fecal microbiota transplantation (FMT) a promising therapeutic strategy. However, clinical trials have reported conflicting results. This updated meta-analysis evaluated the efficacy and safety of FMT in patients with IBS. Why was this study needed? Previous FMT trials in IBS have reported inconsistent outcomes. The role of gut microbiota modulation in IBS remains uncertain. Larger pooled analyses are needed to clarify the true efficacy of FMT. Variability in donor selection, FMT protocols, and patient populations has limited interpretation. Clear evidence is required before recommending FMT in routine IBS practice. Results: FMT did not significantly improve IBS symptoms compared with placebo in the primary intention-to-treat analysis. Although some patients who completed treatment appeared to benefit, the overall quality of evidence was very low, with substantial variation across studies. FMT was generally safe, with adverse events comparable to placebo, but current evidence does not support its routine use for IBS. Clinical Impact: This comprehensive meta-analysis suggests that FMT should not be routinely offered for IBS outside clinical trials. Future research should focus on identifying the patients most likely to benefit and standardizing donor selection, stool preparation, and treatment protocols. Bottom Line: Current evidence does not demonstrate a clear clinical benefit of FMT for IBS. While the procedure appears safe, its routine use cannot be recommended until higher-quality, standardized clinical trials identify the appropriate patients and optimal treatment strategies.

Laparoscopic vs Open Adhesiolysis for Bowel Obstruction: JAMA Surgery | June 2026

Introduction: Laparoscopic adhesiolysis offers several short-term advantages over open surgery for adhesive small bowel obstruction (ASBO). However, its long-term impact on recurrence, quality of life, and incisional hernia remains uncertain. The LASSO trial provides the first randomized evidence comparing these two approaches. Why was this study needed? Long-term outcomes after laparoscopic adhesiolysis have not been well established. Previous studies have largely focused on short-term recovery. Whether laparoscopy reduces recurrent bowel obstruction remains unclear. Evidence from randomized controlled trials has been lacking. Long-term patient-centered outcomes are important when selecting the surgical approach. Results: Recurrence of small bowel obstruction was similar after laparoscopic and open adhesiolysis over 1.5 years of follow-up. Quality of life and incisional hernia rates did not differ between the two surgical approaches. The study found no long-term advantage of laparoscopy over open adhesiolysis. Clinical Impact: While laparoscopy may still provide short-term benefits in carefully selected patients, surgeons should not expect improved long-term outcomes regarding recurrence, quality of life, or incisional hernia. The choice of approach should therefore be guided by patient characteristics, surgeon expertise, and intraoperative findings. Bottom Line: The LASSO trial—the first randomized study in this field—demonstrates that laparoscopic adhesiolysis offers no significant long-term advantage over open surgery for adhesive small bowel obstruction. Short-term benefits remain important, but long-term outcomes are comparable.

DPP-4 Inhibition Targets the Gut–Brain Axis in Parkinson's Disease: Gut | July 2026

Introduction: Growing evidence suggests that Parkinson's disease (PD) may originate in the gut, with pathological α-synuclein spreading to the brain through the vagus nerve. This study investigated whether sitagliptin, a widely used DPP-4 inhibitor for diabetes, could interrupt this gut–brain disease pathway. Why was this study needed? Although DPP-4 inhibitors have shown neuroprotective signals in previous studies, the underlying mechanisms remain unclear. Understanding whether these drugs can modify gut inflammation, α-synuclein propagation, and gut microbiota could open new opportunities for drug repurposing in PD. What did the study show? Sitagliptin reduced intestinal inflammation by suppressing TLR2-mediated immune activation. Treatment significantly decreased α-synuclein accumulation in the gut, vagus nerve, and brain. Neuronal loss in the medulla and midbrain was reduced, with corresponding improvement in motor function. Sitagliptin favorably altered the gut microbiome toward a profile associated with reduced PD pathology. The neuroprotective effects persisted even after GLP-1 receptor blockade, suggesting mechanisms independent of GLP-1 signaling. The findings identify the gut–brain axis as a potential therapeutic target for DPP-4 inhibitors. Clinical Impact: This study supports the concept of repurposing DPP-4 inhibitors as disease-modifying therapies for Parkinson's disease. By targeting gut inflammation, α-synuclein propagation, and microbiome dysbiosis, these agents may offer benefits beyond glucose control, although human clinical trials are needed. Take-Home Message: Sitagliptin attenuated gut inflammation, reduced α-synuclein spread from the gut to the brain, and improved neurological outcomes in a Parkinson's disease model. These findings highlight DPP-4 inhibitors as promising candidates for gut–brain axis–targeted therapy in Parkinson's disease.

Bedside Ultrasound Outperforms Abdominal X-Ray in Neonatal Necrotizing Enterocolitis: Frontiers in Pediatrics | July 2026

Introduction: Necrotizing enterocolitis (NEC) is one of the most serious gastrointestinal emergencies in neonates. Early identification of infants requiring surgical intervention is critical but remains challenging. This study compared bedside abdominal ultrasonography (US) with abdominal radiography (AXR) in predicting the need for surgery. Why was this study needed? Abdominal radiography has traditionally been the first-line imaging modality for NEC, but it has limited sensitivity in detecting bowel ischemia and perforation. Bedside ultrasound may provide additional information to improve surgical decision-making. What did the study show? The study included 509 neonates with NEC, including 88 who required surgery. Bedside ultrasound predicted the need for surgery significantly better than abdominal radiography. Combining ultrasound with radiography further improved classification of patients at borderline risk. Complex peritoneal fluid was the strongest ultrasound predictor of surgical intervention. All imaging models demonstrated good calibration, supporting their clinical reliability. Ultrasound provided valuable real-time assessment of bowel viability and intra-abdominal complications beyond conventional X-ray findings. Clinical Impact: Bedside abdominal ultrasound should be incorporated into the routine assessment of neonates with NEC, particularly when the need for surgery is uncertain. Combining ultrasound with radiography can improve risk stratification and facilitate earlier surgical consultation. Take-Home Message: Bedside abdominal ultrasound is superior to abdominal radiography in identifying neonates with NEC who require surgery. Used alongside conventional X-rays, it enhances clinical decision-making and may enable more timely surgical intervention.

Common Drugs and Clostridioides difficile Infection: Gut | July 2026

Introduction: Antibiotic exposure is the best-established risk factor for Clostridioides difficile infection (CDI). However, the contribution of many commonly prescribed non-antibiotic medications has remained uncertain. This large Swedish population-based study evaluated the association between a wide range of medications and the risk of developing CDI. Why was this study needed? As polypharmacy becomes increasingly common, especially among older adults, understanding which medications influence CDI risk is essential for preventing avoidable infections and promoting safer prescribing practices. What did the study show? Lincosamides (particularly clindamycin) carried the highest risk of CDI, followed by broad-spectrum penicillins, cephalosporins, and trimethoprim-sulfamethoxazole. Tetracyclines were not associated with an increased CDI risk. Among non-antibiotic medications, antidiarrheals showed the strongest association with CDI. Corticosteroids and proton pump inhibitors (PPIs) were independently associated with increased CDI risk. Higher CDI risk was also observed with H2-receptor antagonists, antidepressants, nervous system drugs, constipation medications, and beta-blockers. Lipid-lowering agents (mainly statins) and aspirin were associated with a modest reduction in CDI risk. Nonsteroidal anti-inflammatory drugs (NSAIDs) were not associated with an increased CDI risk. Clinical Impact: Beyond antibiotic stewardship, clinicians should regularly review non-antibiotic medications that may increase CDI risk, particularly in elderly patients, hospitalized individuals, and those receiving multiple medications. Judicious use of PPIs, corticosteroids, and antidiarrheals may help reduce preventable CDI. Take-Home Message: CDI risk extends beyond antibiotics. Careful medication review—including PPIs, corticosteroids, antidiarrheals, and other commonly prescribed drugs—should become an integral part of CDI prevention, especially in patients with multiple risk factors or polypharmacy.

Seated Anorectal Manometry Better Predicts Balloon Expulsion Success: AJG |June 2026

Dyssynergic defecation is commonly evaluated using anorectal manometry, traditionally performed in the left lateral decubitus position. However, defecation normally occurs in the seated position, raising questions about whether conventional testing accurately reflects real-world anorectal function. This study evaluated 384 adults undergoing high-resolution anorectal manometry and compared bear-down patterns in both lateral and seated positions. A small but clinically important subgroup of patients demonstrated dyssynergic patterns in the lateral position that normalised when tested while seated. Approximately 4% of patients showed normalisation of dyssynergia in the seated position. These patients had a dramatically higher likelihood of successfully completing the balloon expulsion test (BET), one of the most important physiological markers of normal evacuation. Normalisation in the seated position was strongly associated with successful balloon expulsion within one minute. The findings suggest that some patients may be incorrectly classified as having dyssynergic defecation when assessed only in the traditional lateral position. Seated testing may better reproduce physiological defecation mechanics and pelvic floor behaviour. This has important implications for diagnostic accuracy, particularly when anorectal manometry findings and balloon expulsion test results appear discordant. Incorporating seated assessment into routine anorectal physiology testing may improve identification of clinically relevant evacuation disorders. The study supports a growing movement toward more physiologic testing conditions during anorectal function evaluation. Bottom line: High-resolution anorectal manometry performed in the seated position may provide a more accurate assessment of defecatory function than traditional lateral testing, with normalisation of dyssynergic patterns strongly predicting successful balloon expulsion.

DOTATATE PET in Poorly Differentiated Extrapulmonary NEC: JNM | June 2026

Somatostatin receptor (SSTR) imaging with ⁶⁸Ga-DOTATATE PET is a cornerstone for well-differentiated neuroendocrine tumors, but its role in poorly differentiated neuroendocrine carcinoma (NEC) has remained uncertain. Previous retrospective studies suggested that up to 40% of NECs might demonstrate strong somatostatin receptor expression, raising interest in peptide receptor radionuclide therapy (PRRT) for these patients. This prospective study was designed to provide a more accurate assessment by evaluating an unselected cohort of metastatic extrapulmonary NEC patients. Thirty patients with metastatic extrapulmonary NEC underwent ⁶⁸Ga-DOTATATE PET, and most also underwent ¹⁸F-FDG PET. Primary tumor sites included pancreas, colorectum, uterus, and cancers of unknown primary origin. Histologies included both small-cell and large-cell neuroendocrine carcinoma. The key finding was that uniform, high-level somatostatin receptor expression was uncommon. Only 13% of patients demonstrated strong, homogeneous DOTATATE uptake consistent with high SSTR expression. The vast majority of tumors showed either: Absent SSTR expression Patchy/heterogeneous receptor expression Predominantly FDG-avid biology These findings suggest that most poorly differentiated NECs retain aggressive glycolytic behavior rather than the receptor-rich phenotype typically seen in well-differentiated NETs. The study challenges previous reports that may have overestimated SSTR positivity because of selection bias or inclusion of tumors with lower Ki-67 indices. Clinically, this means that routine DOTATATE PET scanning is unlikely to identify large numbers of poorly differentiated NEC patients suitable for PRRT. However, a small subset of NEC patients may still demonstrate strong receptor expression and could remain candidates for receptor-targeted therapies. Dual-tracer imaging with FDG PET and DOTATATE PET may be particularly useful when considering individualized treatment strategies. The findings reinforce the biological distinction between well-differentiated NETs and poorly differentiated NECs. Bottom line: Strong and uniform somatostatin receptor expression is present in only a small minority of patients with metastatic extrapulmonary poorly differentiated NEC. Most NECs remain predominantly FDG-avid tumors, limiting the routine applicability of DOTATATE-based imaging and PRRT in this population.

F. prausnitzii Counters CRC Progression : Gastroenterology | Jun 2026

Introduction: The gut microbiome plays a central role in colorectal cancer (CRC) development, influencing inflammation, metabolism, immune responses, and tumor behavior. While several microbial species have been implicated in CRC, the mechanisms through which beneficial and harmful bacteria interact with the host to promote or suppress tumor progression remain incompletely understood. Deciphering these host–microbe metabolic interactions may reveal novel biomarkers and therapeutic strategies for CRC prevention and treatment. Problem Statement: Although enterotoxigenic Bacteroides fragilis has been consistently associated with colorectal carcinogenesis, the protective mechanisms exerted by beneficial commensal organisms are less clearly defined. Understanding how microbial metabolites influence tumor biology and counteract pro-carcinogenic bacterial pathways is essential for developing microbiome-based interventions in CRC. Summary: This comprehensive multi-omics study identified a key antagonistic relationship between Faecalibacterium prausnitzii, a beneficial gut commensal, and enterotoxigenic Bacteroides fragilis in CRC. The investigators demonstrated that F. prausnitzii metabolizes dietary tryptophan into picolinic acid (PIA), a bioactive metabolite that suppresses tumor-promoting effects induced by B. fragilis. Mechanistic analyses revealed that enterotoxigenic B. fragilis enhances the expression of genes linked to aggressive tumor behavior and recurrence, whereas PIA counteracts these effects by promoting tumor cell apoptosis and downregulating these oncogenic pathways. Importantly, the findings were validated across independent patient cohorts, organoid systems, and animal models, strengthening the biological relevance of this pathway. The study further showed that a tryptophan-rich diet increased circulating PIA levels, highlighting a potential nutritional approach to modulate host–microbe interactions and reduce CRC progression. These findings define a novel microbe–metabolite–host regulatory axis, namely the F. prausnitzii–PIA pathway, as a natural defense mechanism against B. fragilis-driven carcinogenesis. The work provides compelling evidence that microbiome-targeted therapies, dietary interventions, and strategies aimed at restoring beneficial microbial communities may become important components of future CRC prevention and treatment paradigms.

Retatrutide in Type 2 Diabetes: Triple Agonist Delivers Powerful HbA1c and Weight Reduction: The Lancet | June 2026

* Retatrutide is a once-weekly injectable triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. * TRANSCEND-T2D-1 evaluated retatrutide as monotherapy in adults with type 2 diabetes inadequately controlled with diet and exercise alone. * The study included 537 patients with early type 2 diabetes, mean HbA1c of 7.9%, mean diabetes duration of 2.5 years, and mean BMI of 35.8 kg/m². * Retatrutide produced significant HbA1c reductions at all tested doses compared with placebo. * Mean HbA1c reduction at 40 weeks was –1.69% with 4 mg, –1.86% with 9 mg, and –1.94% with 12 mg, compared with –0.81% with placebo. * Weight loss was substantial and dose-related, which is especially relevant because weight reduction is often harder to achieve in patients with type 2 diabetes. * Mean bodyweight reduction was –11.5% with 4 mg, –13.9% with 9 mg, and –15.3% with 12 mg, compared with –2.6% with placebo. * The magnitude of weight loss suggests that retatrutide may become important not only for glycaemic control, but also for obesity-driven metabolic disease. * No severe hypoglycaemia was reported, which is reassuring for a therapy used without insulin or sulfonylureas. * The most common adverse events were gastrointestinal, generally mild to moderate, and tended to reduce over time. * Treatment discontinuation due to adverse events was low, occurring in 2%–5% of retatrutide-treated patients. * The study population had relatively early diabetes and was not on background glucose-lowering therapy, so results may not directly apply to patients with long-standing or insulin-treated diabetes. * Long-term cardiovascular, renal, hepatic, and real-world tolerability data will be important before defining its exact place in therapy. * For gastroenterologists, the key relevance is the broader metabolic impact: powerful weight loss may influence future management of MASLD, obesity-related GI disease, and cardiometabolic risk. Bottom line: Retatrutide produced impressive dual benefits in early type 2 diabetes—nearly 2% HbA1c reduction and up to 15% bodyweight loss over 40 weeks—supporting its potential as a major next-generation metabolic therapy.

MLCK1 Targeting Separates ICI Colitis from Antitumor Immunity : Gut | May 2026

Introduction Immune Checkpoint Inhibitors have transformed cancer treatment across multiple malignancies, but immune-related adverse events remain major limitations to durable therapy. Among these toxicities, Immune Checkpoint Inhibitor Colitis is particularly important because it frequently necessitates immunosuppression, treatment interruption or permanent discontinuation of anticancer therapy. Problem Statement Current approaches to immune checkpoint inhibitor colitis broadly suppress immune activity and may compromise antitumor efficacy. Mechanism-specific strategies capable of controlling intestinal toxicity without impairing anticancer immunity remain an unmet clinical need. Summary This mechanistic translational study identifies long myosin light chain kinase 1 (MLCK1) as a central regulator of immune checkpoint inhibitor-induced intestinal barrier dysfunction and demonstrates that targeting this pathway can suppress colitis without reducing antitumor immune activity. Using single-cell RNA sequencing and spatial transcriptomics from human biopsy samples, the investigators demonstrated profound disruption of intestinal tight junction integrity in checkpoint inhibitor colitis. Similar findings were reproduced in murine models designed to closely mimic human immune-mediated colitis. The study showed that immune checkpoint blockade activates an MLCK1-dependent epithelial leak pathway, resulting in impaired intestinal barrier function and enhanced gut permeability. This barrier disruption emerged as a key initiating event driving intestinal inflammation. Mechanistically, tumour necrosis factor released by activated CD4+ and CD8+ T cells was identified as a major upstream trigger of MLCK1 activation. The resulting epithelial tight junction disruption amplified intestinal inflammation and promoted clinically significant colitis. Importantly, genetic deletion of MLCK preserved tight junction architecture and substantially reduced inflammation in murine models, directly confirming MLCK1 as a functional disease driver rather than merely a downstream inflammatory marker. A major translational advance was the identification of Epicatechin as a pharmacologic inhibitor capable of disrupting MLCK1-FKBP8 interaction. This intervention prevented MLCK1 recruitment to the perijunctional actomyosin ring and preserved epithelial barrier integrity. Most importantly, epicatechin-mediated barrier restoration ameliorated checkpoint inhibitor colitis without compromising antitumor efficacy in melanoma and colorectal cancer models. This uncoupling of intestinal toxicity from anticancer immunity represents the study’s most clinically significant finding. The work fundamentally shifts the conceptual framework for immune checkpoint inhibitor colitis. Rather than viewing toxicity solely as uncontrolled systemic immune activation, the study positions epithelial barrier dysfunction as a critical mechanistic amplifier of intestinal inflammation. Clinically, the findings are highly relevant because current management strategies rely predominantly on corticosteroids and systemic immunosuppressants, which may attenuate anticancer immune responses and increase infectious complications. Barrier-directed therapy could therefore represent an entirely new therapeutic paradigm in immune-related adverse event management, focusing on preservation of epithelial integrity rather than broad immune suppression. The study also reinforces the increasingly recognized role of intestinal barrier biology in systemic inflammatory and immune-mediated diseases. Tight junction regulation appears to function as a critical checkpoint controlling mucosal immune amplification during checkpoint inhibitor therapy. Another important implication is the potential role of intestinal permeability biomarkers in predicting or monitoring immune-mediated gastrointestinal toxicity. Early detection of barrier dysfunction could eventually support preemptive intervention strategies. From an oncologic perspective, the ability to maintain effective immunotherapy while minimizing gastrointestinal toxicity could substantially improve treatment durability and patient outcomes across multiple cancer types. Although further clinical validation remains necessary, the findings provide one of the clearest mechanistic demonstrations to date that immune-related toxicity and antitumor efficacy may be biologically separable. Overall, this study identifies MLCK1-mediated epithelial barrier dysfunction as a key driver of immune checkpoint inhibitor colitis and demonstrates that targeted barrier restoration can suppress intestinal inflammation without impairing anticancer immunity, establishing a promising new direction for toxicity-specific immunotherapy management.

Gut Microbiota-Driven NETosis Promotes Endometriosis : Gut | May 2026

Introduction Endometriosis is a chronic inflammatory gynecological disease characterized by ectopic implantation of endometrial tissue and associated with pelvic pain, infertility and impaired quality of life. Although immune dysregulation and gut microbiota alterations have both been implicated in disease pathogenesis, the mechanistic link between intestinal dysbiosis and peritoneal lesion formation has remained poorly understood. Problem Statement The causal mechanisms through which gut microbiota influence peritoneal inflammation and lesion progression in endometriosis remain unclear, particularly regarding microbial translocation, neutrophil activation and the role of Neutrophil Extracellular Traps. Summary This translational study identifies a novel gut–peritoneum axis in endometriosis whereby translocated gut microbiota trigger NETosis and promote lesion development through activation of a distinct proinflammatory neutrophil population. Using single-cell RNA sequencing of peritoneal immune cells, the investigators identified a membrane metalloendopeptidase-positive neutrophil subset enriched in endometriosis and primed for NET formation. These neutrophils released extracellular traps in response to bacterial lipopolysaccharide stimulation, directly enhancing endometrial cell proliferation, migration and lesion establishment. Mechanistically, NETs acted not merely as inflammatory byproducts but as active structural and signaling platforms that facilitated ectopic endometrial implantation and persistence. Importantly, inhibition of NETosis or enzymatic degradation of NETs markedly suppressed endometriosis progression in murine models, highlighting NETosis as a functionally relevant disease driver rather than an epiphenomenon. A major strength of the study was the integration of microbiome source-tracking analyses with functional experimental validation. Faecal microbiota transplantation from patients with endometriosis disrupted intestinal barrier integrity in mice and promoted microbial translocation into the peritoneal cavity. Among translocating organisms, Pseudomonas aeruginosa emerged as a particularly important pathogenic driver. GFP-tagged bacterial experiments demonstrated migration of Pseudomonas into peritoneal lesions, where bacterial lipopolysaccharides triggered NETosis and amplified inflammatory lesion development. These findings significantly expand the emerging concept of microbiota-driven extraintestinal inflammatory disease. Rather than acting indirectly through systemic metabolites alone, gut microorganisms may physically translocate across impaired intestinal barriers into distant compartments, directly driving local immune activation. The work also positions NETosis as a central mechanistic bridge linking microbial dysbiosis, innate immunity and ectopic tissue remodeling in endometriosis. Similar NET-mediated pathways are increasingly recognized across inflammatory, autoimmune and cancer-related conditions, suggesting broader relevance of this inflammatory circuitry. Clinically, the study opens several potentially important therapeutic avenues. Strategies targeting intestinal permeability, selective microbial modulation, Pseudomonas suppression or NETosis inhibition may eventually emerge as novel disease-modifying approaches in endometriosis management. The findings are particularly interesting because they move beyond traditional hormone-centric models of endometriosis pathogenesis. While estrogen signaling remains fundamental, the disease increasingly appears to involve complex immune-microbiome interactions capable of sustaining chronic inflammatory lesion progression. From a translational perspective, the study additionally reinforces the growing importance of cross-disciplinary convergence between gastroenterology, microbiome science, immunology and reproductive medicine. The gut–peritoneum axis described here resembles broader gut-organ inflammatory networks increasingly implicated across systemic diseases. The identification of a disease-associated neutrophil subset also raises the possibility of future biomarker development using immune phenotyping or microbial signatures for disease stratification and therapeutic monitoring. Overall, this study defines a novel gut microbiota–NETosis pathway in endometriosis, demonstrating that translocated gut-derived Pseudomonas activates proinflammatory neutrophils and drives lesion progression through pathogenic NET formation. The findings establish the gut–peritoneum immune axis as a potentially important therapeutic target in endometriosis.

High-Quality Colonoscopic Surveillance Reveals Distinct Neoplasia Patterns in Lynch Syndrome : Gut | May 2026

Introduction Lynch Syndrome remains the most common inherited colorectal cancer predisposition syndrome and is associated with markedly elevated lifetime risk of Colorectal Cancer. High-quality colonoscopic surveillance is central to cancer prevention and early detection in Lynch syndrome, yet much of the historical evidence guiding surveillance intervals and risk stratification derives from cohorts with variable colonoscopy quality standards. Problem Statement Reliable genotype-specific neoplasia detection data from modern high-quality surveillance programs remain limited. Understanding lesion characteristics and risk factors within optimized surveillance settings is essential for refining precision surveillance strategies in Lynch syndrome. Summary This tertiary-center study evaluated nearly 1,000 surveillance colonoscopies performed in patients with Lynch syndrome under exceptionally high-quality colonoscopy standards. The cohort achieved excellent procedural metrics, including very high caecal intubation and bowel preparation adequacy rates, providing a robust framework for accurate neoplasia detection analysis. The study demonstrated a substantial adenoma burden, with adenomas detected in nearly one-third of surveillance procedures. Importantly, most adenomas were located in the proximal colon, reinforcing the well-established right-sided predominance of neoplasia in Lynch syndrome and highlighting the necessity of meticulous proximal colonic examination during surveillance. A notable finding was the predominance of non-advanced and flat adenomas. Flat morphology can make lesions more difficult to detect, emphasizing the importance of optimized withdrawal technique, adequate inspection time and enhanced endoscopic vigilance in hereditary cancer surveillance programs. Despite lower adenoma detection rates in carriers of MLH1 Mutation, this subgroup accounted for half of all colorectal cancers identified. This suggests that carcinogenesis in MLH1-associated Lynch syndrome may proceed more rapidly or through biologically aggressive pathways, potentially narrowing the window for adenoma detection before malignant transformation. Conversely, higher serrated lesion detection rates were observed among MSH6 and PMS2 carriers, suggesting important genotype-specific differences in neoplastic pathways. These findings support the emerging concept that Lynch syndrome is not a single biologic entity but rather a spectrum of molecularly distinct syndromes with differing carcinogenic trajectories. Several clinical factors influenced neoplasia detection. Older age and elevated body mass index were associated with higher adenoma detection rates, while male sex and non-white ethnicity were associated with increased colorectal cancer detection. These observations may help refine individualized surveillance intensity and risk stratification approaches. The study is particularly important because it evaluates surveillance outcomes under modern quality benchmarks. Historically reported interval cancer rates and lesion detection patterns may have been confounded by suboptimal bowel preparation, incomplete examinations or inconsistent withdrawal practices. This work demonstrates that even within high-quality surveillance systems, substantial neoplastic burden persists in Lynch syndrome patients. Clinically, the findings strongly support continued emphasis on colonoscopy quality metrics within hereditary cancer surveillance programs. High-definition imaging, careful proximal inspection and detection of subtle flat lesions remain critical. The data additionally strengthen the rationale for genotype-tailored surveillance protocols rather than uniform surveillance intervals across all mismatch repair gene carriers. The observation that MLH1 carriers developed disproportionate colorectal cancer burden despite lower adenoma detection may eventually justify even more intensive surveillance strategies or adjunctive preventive approaches in selected high-risk genotypes. Overall, this study demonstrates that patients with Lynch syndrome continue to harbor substantial colorectal neoplastic burden despite high-quality surveillance. The findings highlight distinct genotype-specific phenotypes, proximal and flat lesion predominance, and the importance of precision surveillance strategies guided by both colonoscopy quality and underlying mismatch repair genotype biology.

Gut–Testis Axis and Male Reproductive Health : Int J Mol Sci | May 2026

Introduction Emerging evidence suggests that the gut microbiome may play a central regulatory role in male reproductive physiology through a proposed “gut–testis axis.” This concept integrates microbial metabolism, systemic inflammation, endocrine signalling and immune regulation as interconnected determinants of spermatogenesis and sperm quality. With idiopathic infertility accounting for a substantial proportion of male infertility cases, understanding microbiome-mediated reproductive dysfunction has become an important translational research priority. Problem Statement Although associations between diet, metabolic disease and impaired fertility are increasingly recognised, the mechanistic pathways linking gut microbial dysbiosis to testicular dysfunction remain incompletely understood. Existing human studies are largely observational, and causal relationships between microbiome alterations and reproductive impairment require further validation. Summary This comprehensive review synthesises current mechanistic, translational and clinical evidence linking gut microbial dysbiosis to impaired male reproductive health. The authors propose that disruption of intestinal microbial homeostasis contributes to infertility through multiple converging pathways involving endocrine dysfunction, oxidative stress, inflammation, barrier disruption and altered microbial metabolite production. Central to this framework is the concept that beneficial commensal bacteria, particularly short-chain fatty acid (SCFA)-producing taxa such as Bifidobacterium, Lactobacillus and Faecalibacterium, maintain intestinal integrity, regulate immune homeostasis and support metabolic signalling. SCFAs, especially butyrate, appear critical for preserving blood–testis barrier integrity, Sertoli cell maturation and seminiferous tubule development. Germ-free animal models demonstrated impaired gonadotropin production, increased blood–testis barrier permeability and defective spermatogenesis, all of which improved following colonisation with butyrate-producing organisms. The review further highlights amino acid-derived microbial metabolites, particularly L-citrulline, as regulators of testicular homeostasis and nitric oxide signalling. Dysbiosis-associated depletion of L-citrulline impaired Sertoli cell function, promoted oxidative stress and disrupted spermatogenesis in experimental models. Restoration of these pathways through dietary supplementation improved sperm quality and DNA repair responses, supporting a direct microbiota–metabolism–testis connection. Conversely, expansion of proinflammatory pathobionts and endotoxin-producing Gram-negative bacteria was strongly linked to reproductive dysfunction. Lipopolysaccharide-mediated activation of Toll-like receptor pathways in Leydig cells, Sertoli cells and spermatozoa induced inflammatory cytokine production, oxidative stress and apoptosis. These processes impaired testosterone synthesis, disrupted hypothalamic–pituitary–gonadal axis regulation and reduced sperm motility, viability and fertilisation capacity. Several fecal microbiota transplantation studies provided important causal evidence for the gut–testis axis. Transfer of dysbiotic microbiota from high-fat diet, alcohol exposure or metabolic syndrome models into healthy animals reproduced impaired spermatogenesis, reduced sperm motility, mitochondrial dysfunction and inflammatory activation within reproductive tissues. In contrast, microbiota-restorative interventions including high-fibre diets, alginate oligosaccharides, probiotics and microbiota transplantation from healthy donors improved microbial composition, enhanced antioxidant pathways, restored retinoid and bile acid metabolism, and improved sperm quality. Human evidence remains relatively limited but supports similar trends. Western dietary patterns rich in saturated fats, processed foods and refined sugars were consistently associated with poorer semen parameters, while omega-3 fatty acids, fruits and vegetables correlated with improved sperm morphology and motility. Men with metabolic disorders and testosterone deficiency exhibited enrichment of proinflammatory and endotoxin-producing taxa alongside reduced beneficial SCFA-producing organisms. Several microbial taxa, including Prevotella and Ruminiclostridium, demonstrated associations with abnormal sperm parameters and systemic inflammatory profiles. Importantly, the review emphasises major limitations in the field, including heterogeneity in microbiome profiling techniques, lack of longitudinal studies, substantial confounding variables and incomplete mechanistic understanding of how microbial metabolites influence testicular physiology. Despite these limitations, the accumulating evidence strongly supports the gut microbiome as a promising therapeutic target for male infertility and reproductive dysfunction.

Gut Microbiota Diet Index Linked to Lower Mortality and Slower Biological Aging : J Nutr Health Aging | Jun 2026

Introduction The intestinal microbiome has emerged as a major regulator of metabolic health, inflammation and healthy aging. Dietary patterns strongly influence microbial diversity and metabolite production, with fiber-rich and plant-based diets generally promoting beneficial microbial ecosystems. The Dietary Index for Gut Microbiota (DI-GM) was developed to quantify the impact of habitual diet on gut microbial health and has previously been associated with favorable metabolic outcomes in selected disease populations. Problem Statement Although microbiota-supportive dietary patterns may influence longevity, the relationship between DI-GM and premature mortality in the general population has not previously been established. Furthermore, whether biological aging mediates the association between gut microbiota–oriented dietary patterns and survival outcomes remains unclear. Summary This large longitudinal NHANES-based cohort study evaluated more than 15,000 U.S. adults and demonstrated a strong inverse relationship between DI-GM scores and both premature and all-cause mortality. Each one-point increase in DI-GM was associated with approximately 9% lower premature mortality risk and 10% lower overall mortality risk after multivariable adjustment. Individuals with the highest DI-GM scores had substantially lower mortality risk compared with those with the poorest microbiota-associated dietary patterns. Kaplan–Meier analyses and smooth curve modeling further demonstrated a consistent linear relationship between higher DI-GM scores and improved survival outcomes across multiple demographic subgroups. Importantly, the study identified biological aging as a major mediator of this protective association. Measures including PhenoAge acceleration, Klemera–Doubal biological age acceleration and homeostatic dysregulation partially explained the relationship between DI-GM and mortality. Among these, PhenoAge acceleration demonstrated the strongest mediating effect, accounting for more than one-third of the association with premature mortality. Higher DI-GM scores were consistently associated with lower biological age acceleration and reduced physiologic dysregulation. Mechanistically, diets associated with higher DI-GM scores emphasized fiber-rich plant foods, whole grains, legumes, fermented dairy products, tea and coffee while minimizing processed meats, refined grains and high-fat dietary patterns. These dietary profiles likely promote short-chain fatty acid production, improved metabolic homeostasis and reduced chronic inflammation through favorable modulation of gut microbial diversity. Conversely, lower-quality diets may increase production of harmful microbial metabolites such as trimethylamine N-oxide, which has been linked to cardiovascular disease and mortality. Overall, this study strengthens the concept that microbiota-oriented dietary patterns may influence longevity partly through modulation of biological aging processes. The findings support growing interest in gut microbiome–targeted nutritional strategies as scalable public health interventions for promoting healthy aging and reducing premature mortality.

Plant-Based Hospital Menus Maintain Nutritional Adequacy : Frontline Gastroenterol | May 2026

Introduction Healthcare systems are increasingly recognizing the environmental impact of hospital food services, particularly the high carbon footprint associated with meat-heavy diets. At the same time, maintaining adequate nutritional quality for hospitalized patients remains essential, especially in acute care settings where malnutrition and increased metabolic demands are common. Problem Statement Concerns persist that reducing meat-based meals in hospital settings could compromise protein intake and overall nutritional adequacy. Evidence evaluating whether plant-based or meat-free hospital menus can maintain comparable nutritional standards remains limited. Summary This comparative nutrient analysis evaluated whether meat-free and plant-based alternatives could replace traditional meat-based hospital meals without compromising nutritional quality. The original inpatient menu consisted predominantly of meat-containing meals, with a substantial proportion derived from ruminant meats such as beef and lamb, which are associated with high environmental burden. The redesigned menu significantly reduced ruminant meat offerings and incorporated plant-based protein sources including legumes, dairy and eggs. Importantly, the alternative menu maintained comparable caloric, protein and fat content relative to the original menu, demonstrating that nutritionally balanced hospital meals can be achieved with substantially lower meat dependence. In addition, the plant-forward menu provided higher fibre content and modestly lower salt levels, potentially offering additional cardiometabolic benefits. The findings challenge the perception that meat reduction in hospital nutrition necessarily compromises protein adequacy or meal quality. Beyond nutrition, the study emphasizes the broader sustainability responsibilities of healthcare systems such as the NHS, which serve millions of meals annually and exert major influence on food procurement practices. The authors propose that environmentally conscious menu redesign can be implemented using currently available catering infrastructure without sacrificing patient nutritional standards. Although clinical outcomes and patient acceptability were not assessed, the study provides important proof-of-concept evidence supporting sustainable hospital nutrition strategies that align environmental stewardship with nutritional adequacy in modern healthcare systems.

Barriers to Prescription Therapy Persist in Chronic Idiopathic Constipation Care : Gastro Hep Advances | May 2026

Introduction Chronic idiopathic constipation (CIC) is one of the most common disorders of gut–brain interaction and is associated with substantial impairment in quality of life, healthcare utilization and economic burden. Although multiple effective prescription therapies are now available, real-world management of CIC continues to rely heavily on lifestyle modification and over-the-counter treatments. Problem Statement Despite evolving treatment options and updated clinical guidelines, limited real-world data exist regarding treatment decision-making, barriers to therapy access, patient perceptions and financial burden in CIC care. Understanding the disconnect between healthcare provider practices and patient experiences is essential for improving long-term disease management and treatment accessibility. Summary This large US real-world survey highlights important gaps between physician treatment strategies and patient experiences in chronic idiopathic constipation management. Most healthcare professionals reported following guideline-based escalation from lifestyle and dietary modification to over-the-counter agents and eventually prescription medications. However, a substantial proportion of patients who had never received prescription therapy were still considered clinically eligible for such treatment, suggesting underutilization of advanced therapies. Physicians prioritized long-term efficacy and improvement in quality of life when selecting treatment strategies, whereas patients emphasized symptom relief, affordability and treatment safety. Notably, patients frequently identified difficulty obtaining specialist appointments, limited awareness of available prescription medications and inadequate insurance coverage as major barriers to care. In contrast, physicians viewed medication cost and insurance authorization complexity as the primary prescribing obstacles. The study also demonstrated persistent reliance on lifestyle interventions despite relatively modest patient-perceived efficacy. Among prescription agents, linaclotide was generally viewed most favorably by clinicians, although overall patient satisfaction with available prescription therapies was high. Importantly, direct healthcare costs—including physician visits and medication co-payments—remained a meaningful financial burden. Overall, the study underscores that access limitations, insurance barriers and inadequate patient awareness continue to significantly influence CIC management despite the availability of effective pharmacologic therapies.

Serrated Polyposis Syndrome Requires Improved Detection and Personalized Surveillance : Endoscopy | May 2026

Introduction Serrated polyposis syndrome (SPS) is now recognized as the most common colorectal polyposis syndrome and an important precursor condition for colorectal cancer (CRC). The syndrome is characterized by multiple serrated colorectal lesions, including sessile serrated lesions and traditional serrated adenomas, which contribute substantially to colorectal carcinogenesis through the serrated neoplasia pathway. Problem Statement Despite its clinical importance, SPS remains significantly underdiagnosed because serrated lesions are frequently subtle, flat and historically misclassified during colonoscopy. In addition, uncertainty persists regarding optimal endoscopic resection techniques and long-term surveillance strategies, with most current recommendations still based on expert opinion rather than high-quality prospective evidence. Summary This review provides a contemporary overview of the evolving understanding and management of serrated polyposis syndrome, emphasizing the central role of improved endoscopic detection in reducing colorectal cancer risk. Advances in high-definition colonoscopy, chromoendoscopy, prolonged withdrawal times and refined lesion classification systems have substantially improved recognition of serrated lesions, particularly sessile serrated lesions that often present with indistinct borders and mucus caps. The review reinforces cold snare polypectomy as the preferred technique for most small nondysplastic serrated lesions because of its favorable safety profile and effective complete resection rates. For larger or dysplastic lesions, endoscopic mucosal resection remains the preferred strategy, although comparative evidence regarding cold, hot and underwater techniques specifically for serrated lesions remains limited. The article also highlights the growing shift toward individualized surveillance strategies in SPS. Although annual colonoscopy following colon clearance remains guideline standard, emerging evidence suggests that selected low-risk patients may safely undergo biennial surveillance, potentially reducing procedural burden without compromising cancer prevention. Overall, the review underscores that serrated neoplasia represents a major but still incompletely understood pathway in colorectal carcinogenesis and calls for further research to optimize detection, resection and surveillance strategies aimed at reducing interval and preventable colorectal cancers.

Persistent Diet–Microbiome–Epithelial Abnormalities Continue During Crohn’s Disease Remission : Gastroenterology | May 2026

Introduction Modern biologic therapies have significantly improved remission rates in Crohn’s disease (CD), primarily through suppression of mucosal immune activation. However, despite clinical and endoscopic remission, many patients continue to experience recurrent disease flares, suggesting that deeper pathogenic mechanisms may persist even under effective immune-targeted treatment. Problem Statement Current treatment paradigms in CD focus heavily on immune suppression, yet little is known about the residual dietary, microbial, metabolic and epithelial abnormalities that remain during remission. Understanding these persistent nonimmune perturbations may explain the relapsing nature of CD and identify adjunct therapeutic targets beyond biologic therapy alone. Summary This comprehensive multiomics study demonstrates that substantial abnormalities in diet, gut microbiota, metabolome and ileal epithelial biology persist in Crohn’s disease despite effective clinical remission and advanced biologic therapy. Patients in remission showed marked suppression of adaptive T-cell and innate granulocyte pathways, reflecting strong immune inhibition, yet simultaneously exhibited persistent activation of epithelial antibacterial pathways including DUOX2, CEACAM6 and REG family genes. Increased goblet-cell and mucin glycosylation signatures were also observed, potentially representing a compensatory epithelial response to ongoing microbial disruption. Importantly, remission was still characterized by persistent dysbiosis, reduced microbial diversity and metabolomic abnormalities similar to those observed in active disease. Dietary analysis revealed sustained unhealthy dietary patterns during remission, particularly higher intake of ultra processed foods and lower consumption of fiber, vegetables and micronutrients. Exposure to ultra processed foods correlated strongly with microbial dysbiosis and negatively correlated with genes involved in mucin glycosylation and epithelial barrier maintenance, whereas Mediterranean dietary adherence showed favorable associations. Notably, higher epithelial antibacterial and mucus-related signatures, greater dysbiosis and increased ultra processed food exposure were associated with subsequent clinical flare risk. Overall, the study supports a major conceptual shift in CD management by demonstrating that immune suppression alone may not fully normalize gut biology and that adjunctive strategies targeting the diet–epithelium–microbiome axis could be essential for achieving deeper and more durable remission states.

Seronegative Enteropathies: FG | May 2026

Introduction Seronegative enteropathies (SNEs) represent a challenging group of disorders characterised by villous atrophy with negative coeliac serology. They include both seronegative coeliac disease (SNCD) and a broad spectrum of non-coeliac enteropathies such as infections, immune disorders, and drug-related causes. Their rarity, overlapping features, and lack of specific biomarkers make diagnosis difficult in routine practice. Problem Statement The biggest clinical issue is misdiagnosis. Many patients with non-coeliac enteropathies are incorrectly labelled as seronegative coeliac disease and started on a gluten-free diet. This leads to unnecessary lifelong dietary restriction, delayed diagnosis of the true underlying condition, and risk of poor outcomes. Differentiating SNCD from other causes of villous atrophy remains complex due to overlapping clinical and histological findings. Summary This review provides a practical framework for evaluating and managing SNEs. The key principle is systematic exclusion of non-coeliac causes before diagnosing SNCD. A definitive diagnosis of SNCD requires clinical and histological response to a gluten-free diet after other etiologies are ruled out. Non-coeliac enteropathies must be actively considered, including infections, immune-mediated diseases, medications, and malignancies. Accurate diagnosis is essential, as these conditions often require entirely different treatments. Long-term outcomes vary significantly. While appropriately treated SNCD has a favorable prognosis, misdiagnosed or untreated non-coeliac enteropathies may lead to serious complications and increased mortality. Overall, this review emphasizes a structured diagnostic approach, cautious use of gluten-free diet, and tailored management strategy to improve patient outcomes and avoid diagnostic pitfalls.

Rome V Anorectal Disorders: Gastroenterology | May 2026

The Rome V Anorectal Disorders chapter introduces several important revisions that substantially modernize the diagnostic and therapeutic approach to anorectal disorders within the disorders of gut–brain interaction (DGBI) framework. The chapter integrates symptom-based diagnosis with objective physiology, updates terminology, refines diagnostic thresholds, and more clearly defines the role of anorectal testing and neuromodulation in routine practice. 1. “Functional” Has Been Removed From Anorectal Disorders Terminology One of the most important Rome V conceptual changes is the removal of the term “functional” from anorectal disorders, consistent with the broader Rome V framework. This change applies across the anorectal disorders chapter: functional anorectal disorders → anorectal disorders functional defecation disorder → dyssynergic defecation functional anorectal pain → anorectal pain disorders This is more than semantic. It reflects the modern recognition that these disorders have measurable pathophysiology involving: sensorimotor dysfunction, pelvic floor discoordination, visceral sensory dysfunction, and gut–brain dysregulation. 2. Rome V Reclassifies Anorectal Disorders Into 4 Major Categories Rome V organizes anorectal disorders into 4 major categories: Fecal incontinence (FI) Anorectal pain disorders Dyssynergic defecation (DD) Anorectal sensory dysfunction disorders This classification is more clinically coherent and better aligned with anorectal physiology and test-based phenotyping than prior Rome versions. 3. Fecal Incontinence Criteria Have Been Refined and Tightened Rome V substantially revises the diagnostic framework for fecal incontinence (FI). FI is now defined as: two or more episodes of uncontrolled passage of fecal material, with ≥1 episode/month documented on a 4-week stool diary, for the last 3 months, with symptom onset ≥6 months before diagnosis. This is an important refinement because prior definitions used the term “recurrent,” which was vague and poorly standardized. Rome V replaces this with a measurable frequency threshold to improve: clinical consistency, epidemiologic precision, and trial enrollment standardization. 4. Stool Diary Documentation Is Now Built Into FI Diagnosis One of the most practical updates is that Rome V explicitly incorporates a 4-week stool diary into the diagnostic criteria for FI. This is clinically important because stool diaries: reduce recall bias, improve symptom quantification, improve phenotyping, and align diagnosis with trial methodology. Rome V moves FI toward a more objective symptom-documentation model. 5. Fecal Incontinence Is Explicitly Recognized as a Heterogeneous Disorder Rome V emphasizes that FI is heterogeneous and multifactorial, rather than simply a sphincter disorder. The chapter highlights multiple contributing mechanisms: internal anal sphincter weakness, external anal sphincter dysfunction, puborectalis dysfunction, rectal hyposensitivity, rectal hypersensitivity, impaired rectal compliance, neuropathy, impaired rectosigmoid brake, and psychological comorbidity. This is a major conceptual advance because it shifts FI from a purely structural disorder to a multidimensional neurogastroenterologic disorder. 6. Rome V Strengthens the Role of Objective Physiology in FI Rome V gives stronger emphasis to physiology-guided evaluation in FI. Key tests include: anorectal manometry (ARM), anal ultrasound (AUS), MRI, defecography, and neurophysiology testing. The evidence summary table on pages 4–5 (Table 2) is one of the most clinically useful additions because it grades diagnostic utility and clarifies which tests are useful versus overused. Most important takeaways: ARM = high clinical utility (A1) AUS = useful for structural sphincter injury PNTML = rarely useful clinically translumbosacral anorectal magnetic stimulation = emerging neurophysiology tool. 7. PNTML Is De-emphasized; Modern Neurophysiology Is Favored Rome V de-emphasizes pudendal nerve terminal motor latency (PNTML) because of: methodological limitations, low sensitivity, and interobserver variability. This is a meaningful de-escalation. Instead, Rome V highlights translumbosacral anorectal magnetic stimulation as a more promising neurophysiologic tool for detecting lumbosacral neuropathy in: fecal incontinence, levator ani syndrome, spinal cord injury, and mixed anorectal dysfunction. 8. Biofeedback Is Strongly Reinforced as First-Line Therapy in FI Rome V gives stronger and more explicit support to biofeedback therapy (BT) for fecal incontinence. This is one of the most important practical messages in the chapter. Biofeedback is recommended because it: improves anal squeeze strength, improves squeeze duration, improves rectal sensory discrimination, corrects dyssynergia when present, and improves quality of life. The RCT summary on pages 8–14 (Table 3) is highly practice-relevant and shows consistent efficacy of biofeedback across multiple controlled trials. 9. Home Biofeedback Is Now Validated A highly practical Rome V update is formal recognition that home biofeedback is non-inferior to office biofeedback in selected patients. This is a major translational advance because it improves: accessibility, scalability, adherence, and real-world delivery of pelvic floor rehabilitation. This is one of the most clinically implementable Rome V updates. 10. Neuromodulation Is Upgraded in FI Management Rome V substantially expands the role of neuromodulation in FI management. Major updates: Sacral nerve stimulation (SNS) remains an important option in refractory FI Percutaneous tibial nerve stimulation has weak evidence Translumbosacral neuromodulation therapy (TNT) emerges as a promising newer therapy with sham-controlled supportive data. The therapeutic schematic on page 7 (Figure 1) is especially useful because it visually summarizes current and emerging neuromodulation strategies. 11. Levator Ani Syndrome Is Better Defined and Mechanistically Reframed Rome V improves the diagnostic clarity of levator ani syndrome (LAS). LAS is now defined by: chronic/recurrent anorectal pain, episodes lasting ≥30 minutes, puborectalis tenderness, and exclusion of structural causes. Rome V removes older restrictive descriptors (such as posterior traction emphasis) and broadens tenderness assessment to reflect more accurate examination findings. Mechanistically, LAS is reframed as involving: pelvic floor hypertonicity, dyssynergia, and lumbosacral neuropathy, rather than being considered merely idiopathic pain. 12. Biofeedback Is Now the Preferred Therapy for Levator Ani Syndrome One of the most clinically important updates in anorectal pain is that biofeedback is now the preferred evidence-based therapy for levator ani syndrome, especially when levator tenderness is present. This is one of the clearest Rome V therapeutic upgrades. In the cited RCT: 87% improved with biofeedback, versus 45% with electrical stimulation, and 22% with massage. This makes biofeedback the strongest supported intervention for LAS. 13. Proctalgia Fugax Criteria Are Refined but Management Remains Conservative Rome V retains proctalgia fugax with clearer criteria: sudden severe anorectal pain, lasting seconds to minutes, complete resolution between episodes, unrelated to defecation. Management remains conservative: reassurance is first-line, inhaled salbutamol may help severe prolonged attacks, but evidence remains limited. 14. Dyssynergic Defecation Is One of the Most Important Rome V Revisions The Rome V revision of dyssynergic defecation (DD) is one of the most clinically important updates in the chapter. Rome V makes several major changes: removes “functional” broadens symptom entry criteria removes EMG from core diagnostic requirements simplifies physiologic confirmation eliminates older subtype complexity. This is a major simplification with direct clinical relevance. 15. Rome V Lowers the Threshold for Diagnosing DD This is one of the most practice-changing updates. Rome V now allows diagnosis of DD when: the patient has symptoms of difficult evacuation, and one abnormal physiologic test is present. Previously, Rome IV required ≥2 abnormal tests. Rome V now classifies: probable DD = 1 abnormal test definite DD = ≥2 abnormal tests. This is a major practical simplification that reduces diagnostic friction and unnecessary testing. 16. Rome V Prioritizes ARM and BET as Core Tests for DD Rome V clarifies that the most useful core tests for DD are: anorectal manometry (ARM) balloon expulsion test (BET) These are now the central diagnostic tests for routine evaluation. Defecography is repositioned as: supportive, adjunctive, and mainly useful when ARM/BET are inconclusive. This is one of the most practical diagnostic updates in the chapter. 17. Biofeedback Remains the Gold Standard for Dyssynergic Defecation Rome V strongly reinforces that biofeedback is the most effective treatment for DD. This remains one of the strongest evidence-based interventions in all DGBI. Across multiple RCTs, biofeedback consistently outperformed: laxatives, diazepam, sham therapy, counseling, and standard care. This remains one of the strongest therapeutic recommendations in Rome V. 18. Rome V Formally Defines Anorectal Sensory Disorders Rome V now gives clearer diagnostic identity to anorectal sensory dysfunction disorders: rectal hyposensitivity rectal hypersensitivity This is an important conceptual advance because these disorders are now formally recognized as distinct sensorimotor phenotypes rather than secondary physiologic observations. Clinical Bottom Line The Rome V Anorectal Disorders chapter modernizes anorectal DGBI by integrating symptom-based diagnosis with objective physiology, simplified testing pathways, and mechanism-based therapy. The most practice-changing updates are: “functional” terminology removed anorectal disorders reorganized into 4 physiologic categories FI criteria now standardized with stool diary incorporation FI recognized as a heterogeneous sensorimotor disorder PNTML is de-emphasized biofeedback is strengthened as first-line therapy in FI, LAS, and DD home biofeedback is validated TNT emerges as a promising neuromodulation strategy DD diagnosis is simplified (1 abnormal test = probable DD) ARM + BET are now the core tests for DD anorectal sensory disorders are formally recognized as distinct diagnostic entities.

Rome V Bowel Disorders: Gastroenterology | May 2026

The Rome V Bowel Disorders chapter is one of the most clinically relevant revisions in Rome V because it substantially updates the diagnostic framework for disorders of gut–brain interaction (DGBI) involving bowel symptoms. The major conceptual advance is a shift away from exclusion-based diagnosis and rigid “functional” terminology toward positive symptom-based diagnosis, biologically plausible phenotyping, and pragmatic treatment pathways. Rome V also reframes bowel disorders as a spectrum of overlapping DGBI, rather than isolated, mutually exclusive syndromes. 1. “Functional Bowel Disorders” Are Now Renamed “Bowel Disorders” A major Rome V conceptual change is the abandonment of the term functional bowel disorders in favor of bowel disorders (BDs). This aligns with the broader Rome V movement away from the term “functional,” which has long been criticized as mechanistically vague, scientifically outdated, and often stigmatizing for patients. This change reflects a modern DGBI framework: symptoms are biologically real, mechanisms are multifactorial, and absence of structural disease does not imply absence of pathophysiology. 2. Rome V Reclassifies Bowel Disorders Into 6 Distinct Categories Rome V now classifies bowel disorders into 6 categories: Irritable bowel syndrome (IBS) Chronic constipation (CC) Functional diarrhea (FDr) Functional abdominal bloating (FAB) Unclassified bowel disorder (U-BD) Opioid-induced constipation (OIC) This classification is important because it better reflects clinical overlap and real-world symptom clusters. The spectrum diagram on page 2 (Figure 1) is particularly useful because it visually demonstrates how constipation, diarrhea, pain/discomfort, bloating, and distension overlap across syndromes rather than existing as isolated entities. 3. IBS Criteria Have Been Broadened: “Discomfort” Is Reintroduced This is one of the most important Rome V changes. Rome V reintroduces “abdominal discomfort” into the diagnostic criteria for IBS, reversing one of the most debated Rome IV decisions. Under Rome IV, IBS required abdominal pain at least 1 day/week. Rome V now defines IBS by: recurrent, but not continuous, abdominal pain and/or discomfort at least 3 days/month for the last 3 months, with symptom onset ≥6 months before diagnosis, associated with ≥2 stool-related features. This is a major and clinically sensible revision because: many true IBS patients report discomfort rather than pain, symptom language varies across cultures, and Rome IV likely underdiagnosed IBS by being too restrictive. 4. Rome V Lowers the IBS Symptom Frequency Threshold Rome V lowers the IBS frequency threshold from ≥1 day/week (Rome IV) to ≥3 days/month. This is a highly practical and evidence-based change. The Rome Foundation Global Epidemiology Study showed that Rome IV significantly reduced IBS prevalence largely because the pain threshold was too stringent. Rome V corrects this by lowering the threshold and restoring diagnostic sensitivity without abandoning specificity. 5. IBS Pain Must Be “Recurrent, Not Continuous” Rome V now explicitly states that IBS symptoms should be recurrent, not continuous. This is an important refinement because it helps distinguish IBS from centrally mediated abdominal pain syndrome, where pain is more continuous and less clearly linked to bowel function. This is a subtle but clinically useful diagnostic discriminator. 6. IBS Is Explicitly a Positive Diagnosis—Not a Diagnosis of Exclusion Rome V strongly reinforces one of the most important modern DGBI principles: IBS should be diagnosed positively based on symptoms, not by exclusion. This is a major practice message. When Rome V criteria are met and alarm features are absent: diagnostic confidence should be high, testing should be selective, and clinicians should avoid reflex over-investigation. Rome V strongly discourages exhaustive exclusionary workups in routine IBS. 7. Diagnostic Testing in IBS Should Be Selective and Targeted Rome V recommends limited, targeted testing in suspected IBS rather than broad exclusionary panels. Most clinically relevant recommendations: Fecal calprotectin is useful to exclude IBD (high negative predictive value) Celiac serology should be considered, especially in IBS-D stool infection testing only when epidemiologically indicated colonoscopy only when alarm features exist or microscopic colitis is suspected routine stool microbiome/SIBO testing is not recommended. The stepwise diagnostic algorithm on page 7 (Figure 4) is one of the most clinically useful figures in the chapter because it operationalizes efficient diagnostic triage. 8. Rome V Does Not Recommend Routine SIBO Testing in IBS This is one of the most important practical updates. Rome V explicitly states that routine breath testing for SIBO (or intestinal methanogen overgrowth) is not recommended in the initial diagnostic evaluation of IBS. The rationale is strong: poor test standardization, limited diagnostic accuracy, inconsistent clinical utility, insufficient evidence that testing improves outcomes. This is an important de-escalation in an overused area of practice. 9. Bile Acid Malabsorption Is Repositioned as a Selective Secondary Consideration Rome V does not recommend routine initial testing for bile acid malabsorption (BAM) in IBS-D, but advises considering it in: chronic diarrhea, refractory IBS-D, post-cholecystectomy patients, or when standard therapy fails. This is a practical and evidence-aligned change that appropriately narrows BAM testing. 10. Chronic Constipation Replaces “Functional Constipation” Rome V replaces functional constipation (FC) with chronic constipation (CC). This is both a linguistic and conceptual update: more clinically intuitive, less stigmatizing, and more consistent with contemporary DGBI terminology. Rome V also explicitly notes that: CC, FC, and CIC are largely interchangeable in practice, but CC is now preferred nomenclature. 11. The Main Distinction Between IBS-C and CC Is Predominant Pain Rome V clarifies that the key clinical distinction between IBS-C and CC is not constipation severity—it is whether abdominal pain/discomfort is the predominant symptom. This is one of the most clinically useful practical clarifications in the chapter. IBS-C = constipation + predominant abdominal pain/discomfort CC = constipation with minimal/non-predominant pain 12. Rome V Delays Anorectal and Transit Testing in Chronic Constipation Rome V recommends that anorectal physiology and transit testing should not be part of the initial routine evaluation in most patients with chronic constipation. Instead: begin with symptom-based diagnosis, initiate empiric therapy, reserve anorectal testing for refractory symptoms or suspected defecatory disorder. This is a major practical simplification. 13. Functional Diarrhea Is Preserved but More Clearly Distinguished From IBS-D Rome V retains functional diarrhea (FDr) and clarifies that it differs from IBS-D because abdominal pain is not the predominant symptom. This distinction mirrors the IBS-C vs CC separation and improves internal diagnostic consistency across bowel disorders. 14. Functional Abdominal Bloating Is Now a Formal Standalone Disorder Rome V formally recognizes functional abdominal bloating (FAB) as a distinct bowel disorder rather than merely a secondary symptom construct. This is an important upgrade because bloating/distension is: highly prevalent, often the dominant symptom, and frequently underrecognized in routine practice. Rome V also formally distinguishes: bloating = subjective sensation distension = objective measurable increase in girth 15. Abdominophrenic Dyssynergia Is Highlighted as a Key Mechanism of Bloating One of the most important mechanistic additions in Rome V is the recognition of abdominophrenic dyssynergia as a major pathophysiologic driver of visible abdominal distension. This is a highly important mechanistic update. Rome V emphasizes that many patients with bloating do not have excess intestinal gas. Instead, visible distension may result from: paradoxical diaphragmatic contraction, abdominal wall relaxation, and altered viscerosomatic reflexes. This is one of the most important physiologic advances in the chapter. 16. Rome V Formalizes a Stepwise, Multidisciplinary Treatment Pyramid The treatment pyramid on page 7 (Figure 5) is one of the most practical additions in Rome V. It formalizes a stepwise approach to bowel disorders: diagnosis and explanation reassurance and symptom framing dietary intervention symptom-targeted pharmacotherapy brain–gut behavioral therapies multidisciplinary care This figure is one of the most clinically useful Rome V additions because it operationalizes modern DGBI care. 17. Rome V Strongly Emphasizes Brain–Gut Behavioral Therapies Rome V gives stronger support than prior iterations to: CBT, gut-directed hypnotherapy, mindfulness, digital behavioral therapies. This is a major management evolution and reinforces DGBI as a gut–brain disorder rather than a purely bowel-localized condition. Clinical Bottom Line The Rome V Bowel Disorders chapter modernizes bowel DGBI by replacing rigid exclusionary frameworks with positive diagnosis, selective testing, symptom phenotyping, and multidisciplinary care. The most practice-changing updates are: “functional bowel disorders” renamed bowel disorders IBS now includes pain and/or discomfort IBS threshold lowered to ≥3 days/month IBS must be recurrent, not continuous IBS is a positive diagnosis, not exclusionary routine SIBO testing is discouraged CC replaces functional constipation IBS-C vs CC distinction is based on predominant pain FAB is now a formal standalone disorder abdominophrenic dyssynergia is recognized as a key bloating mechanism care is formalized through a stepwise multidisciplinary treatment pyramid.

Rome V Process: Gastroenterology | May 2026

The Rome V process represents the most rigorous methodological evolution in the history of the Rome Foundation and marks a major conceptual maturation in how disorders of gut–brain interaction (DGBI) are defined, classified, and managed. Compared with Rome IV, Rome V is not simply a criteria revision; it is a full conceptual modernization of DGBI, integrating updated pathophysiology, evidence-based diagnostic refinement, stigma-sensitive terminology, and a stronger biopsychosocial therapeutic framework. 1. Rome V Reframes DGBI as a Positive, Biology-Based Clinical Entity The most fundamental conceptual advance in Rome V is the continued and complete transition away from the older term “functional gastrointestinal disorders (FGID)” toward “disorders of gut–brain interaction (DGBI)”, with Rome V explicitly recommending that FGID should no longer be used. This is one of the most important changes in the Rome V process because it directly addresses the long-standing stigma associated with the term “functional,” which historically implied: non-organic disease, psychosomatic illness, psychiatric illness, or illegitimate symptoms. Rome V fully adopts DGBI as the preferred term because it is: more biologically accurate, more mechanistically grounded, less stigmatizing, and more acceptable to patients, clinicians, regulators, and industry. This change is not semantic—it is foundational. Rome V explicitly frames DGBI as disorders arising from measurable disturbances in: motility, visceral sensitivity, mucosal/immune function, gut microbiota, and central nervous system processing. This is the core scientific identity of Rome V. 2. Rome V Is the Most Evidence-Driven Rome Iteration to Date Rome V was developed over 7 years (2019–2026) by 144 international experts from 27 countries across 25 committees, making it the largest and most rigorous Rome effort to date. A major methodological advance is that Rome V moved even further away from consensus-only expert opinion and toward prospective and retrospective evidence synthesis, using consensus only when evidence was insufficient. Compared with prior Rome iterations: earlier Rome versions were largely consensus-based, Rome IV introduced stronger evidence requirements, Rome V applies the most stringent evidence threshold yet. This is one of the most important process-level changes in Rome V and strengthens the scientific legitimacy of the criteria. 3. Rome V Officially Shifts From Research Criteria to Clinical Criteria One of the most practice-changing methodological innovations in Rome V is the explicit distinction between: Rome V research criteria, and Rome Foundation clinical criteria. This is a major advance because Rome acknowledges that strict research thresholds are often too rigid for real-world clinical practice. Rome V recognizes three major limitations of standard Rome research criteria: A. Subdiagnostic Symptom Burden Is Clinically Real Rome V highlights that a large proportion of patients have clinically meaningful GI symptoms but do not meet full Rome criteria. A major global study cited in Rome V showed: 41.4% met formal Rome criteria, 33.4% had no GI symptoms, but nearly 25% had clinically important “subdiagnostic” GI symptoms. These patients still had: impaired quality of life, higher anxiety/depression, greater healthcare use, and significant work/life burden. Rome V therefore explicitly recognizes that these patients still warrant diagnosis and treatment. B. Symptom Overlap Is the Rule, Not the Exception Rome V formally recognizes that multiple overlapping DGBI are common and clinically important, rather than confounding noise. This is a major clinical advance because patients frequently present with overlapping: esophageal, gastroduodenal, bowel, and centrally mediated pain disorders. Rome V emphasizes that overlapping DGBI are associated with: worse symptom severity, greater psychosocial burden, poorer quality of life, more medical utilization. This is highly clinically relevant and improves real-world applicability. C. “Bothersomeness” Is Elevated as a Clinical Standard Rome V introduces bothersomeness as a formal clinical principle. This is one of the most clinically important practical changes in the entire document. Rather than relying rigidly on research-style duration/frequency thresholds, Rome V states that in clinical care, diagnosis is justified when: symptom quality matches the Rome phenotype, organic disease is sufficiently excluded, and symptoms are sufficiently bothersome to impair life or prompt care-seeking. This is a major real-world improvement and makes Rome V far more clinically usable. 4. Rome V Reinforces Positive Diagnosis Over Diagnosis by Exclusion Rome V strongly reinforces one of the Rome Foundation’s most important philosophical contributions: DGBI should be diagnosed positively, not merely by exclusion. This remains a central Rome principle, but Rome V strengthens it further through: updated symptom-based criteria, stepwise diagnostic algorithms, selective testing, and physiology-supported phenotyping. The major practical implication is clear: clinicians should not pursue endless exclusionary testing once a positive DGBI diagnosis is established and alarm features are absent. 5. Rome V Expands the Role of Diagnostic Algorithms Rome V formalizes diagnostic algorithms for all DGBI categories and integrates them into the 3rd edition of Rome V Diagnostic Algorithms for Common GI Symptoms. This is a major methodological advance because Rome criteria alone define syndromes, but algorithms now provide: structured evaluation pathways, symptom-to-test sequencing, rational exclusion of mimics, and more reproducible clinical decision-making. This is one of the most clinically actionable changes in Rome V. 6. Rome V Strengthens the Multidimensional Clinical Profile (MCP) Rome V explicitly acknowledges that diagnosis alone is insufficient for management and strengthens the Multidimensional Clinical Profile (MCP) as a central clinical framework. This is a major practical and conceptual advance because Rome V emphasizes that treatment must be individualized using: symptom phenotype, physiologic mechanisms, psychosocial comorbidity, illness severity, quality-of-life burden, and healthcare impact. This is one of the clearest statements in Rome V that DGBI care must move beyond diagnosis into structured personalized phenotyping. 7. Rome V Deepens the Biopsychosocial Model The biopsychosocial conceptual model remains the intellectual core of Rome V and is more robustly developed than in Rome IV. The diagram on page 8 explicitly maps the interaction among early life factors, psychosocial factors, physiology, DGBI presentation, and outcomes, emphasizing bidirectional brain–gut signaling rather than linear causality. This remains one of the most important conceptual strengths of Rome V. Rome V strengthens mechanistic integration of: early life influences, psychosocial stress, visceral hypersensitivity, immune activation, microbiome, food/diet, autonomic dysfunction, and central pain modulation. The key message is that DGBI are not “psychological disorders” and not merely “motility disorders”; they are multisystem disorders of integrated gut–brain dysregulation. 8. Rome V Makes the Therapeutic Relationship Part of Treatment One of the most clinically important but often underappreciated Rome V advances is the explicit positioning of the therapeutic relationship as treatment. Rome V devotes a full section to the 12 steps to enhance the therapeutic relationship, emphasizing that clinician behavior directly affects: symptom severity, healthcare utilization, treatment adherence, quality of life, and outcomes. This is a major practical advance and one of the strongest reaffirmations in Rome V that communication is not ancillary—it is therapeutic. 9. Rome V Formalizes Severity-Stratified Care Rome V more explicitly links treatment intensity to illness severity and formalizes a mild–moderate–severe framework for DGBI management. This is clinically important because it aligns treatment with disease burden: Mild: education, reassurance, diet/lifestyle Moderate: symptom monitoring, targeted pharmacotherapy, brain–gut behavioral therapy Severe: neuromodulators, structured psychosocial care, multidisciplinary DGBI referral This is one of the most clinically practical therapeutic frameworks in Rome V. Clinical Bottom Line The Rome V process is not merely a criteria update—it is a full modernization of DGBI science and clinical care. Its most important advances are: full replacement of FGID with DGBI, strongest evidence-based Rome methodology to date, separation of research vs clinical criteria, recognition of subdiagnostic and overlapping DGBI, formal use of bothersomeness in clinical diagnosis, expanded diagnostic algorithms, stronger multidimensional clinical profiling, deeper biopsychosocial integration, and formal recognition that the therapeutic relationship itself is part of treatment. The single most important Rome V process advance is this: DGBI are now framed not as diagnoses of exclusion, but as positive, biology-informed, clinically actionable disorders requiring structured biopsychosocial care.

Rome V Pediatric Lower DGBI: Gastroenterology | May 2026

Rome V reframes pediatric lower gastrointestinal disorders of gut–brain interaction (DGBI) around symptom clusters and anatomic domains rather than age-based groupings, a clinically important shift that better reflects how these disorders present in practice across childhood and adolescence. The lower DGBI spectrum is now organized into abdominal pain disorders, defecation and anorectal disorders, and discomfort disorders, allowing clinicians to approach symptoms according to dominant physiology rather than rigid age cutoffs. This revision also formally recognizes several entities that pediatric gastroenterologists have long encountered but previously lacked standardized pediatric definitions for, including biliary pain syndrome, centrally mediated abdominal pain syndrome, proctalgia fugax, and functional abdominal bloating. The practical consequence is earlier recognition, reduced diagnostic ambiguity, and less exposure to inappropriate testing or empiric treatment in children with otherwise poorly classified symptoms. Irritable Bowel Syndrome: Pain Becomes the Diagnostic Anchor Rome V sharpens the pediatric definition of irritable bowel syndrome (IBS) by making abdominal pain, rather than bowel habit disturbance alone, the dominant diagnostic feature. This is a clinically meaningful departure from Rome IV, particularly in children with constipation. Rather than requiring a trial of constipation treatment to separate IBS-C from functional constipation, Rome V now distinguishes the two by symptom dominance: when abdominal pain is the primary complaint and is linked to stooling, IBS is favored; when bowel dysfunction predominates and pain is secondary, functional constipation is more appropriate. This change better reflects real-world pediatric presentations and avoids prolonged diagnostic uncertainty. The criteria also now exclude pain occurring solely during menses, reducing misclassification of dysmenorrhea as IBS in adolescent girls. Mechanistically, pediatric IBS is increasingly understood as a disorder of altered gut–brain signaling rather than a purely motility-based condition. Rome V reinforces the relevance of early-life programming, including antibiotic exposure, neonatal interventions, early infection, and adverse psychosocial experiences, all of which may prime visceral hypersensitivity and dysregulated central pain processing. Children with IBS show lower rectal sensory thresholds, increased intestinal permeability, low-grade mucosal immune activation, altered microbial composition, and food-triggered symptom amplification. These mechanistic insights are clinically relevant because they support individualized therapy rather than symptom suppression alone. In practice, evaluation should be directed by phenotype. IBS-D warrants screening for celiac disease, inflammatory markers, and selective evaluation for bile acid malabsorption or carbohydrate malabsorption. IBS-C requires differentiation from primary defecatory disorders. The strongest therapeutic evidence remains for gut–brain therapies, particularly cognitive behavioral therapy and hypnotherapy, both of which should be considered first-line in children with clinically significant IBS. Adjunctive therapies such as percutaneous electrical nerve field stimulation, selected probiotics, enteric-coated peppermint oil, psyllium, and subtype-specific bowel therapies can be layered according to phenotype and severity. Abdominal Pain Syndrome–Not Otherwise Specified: The Intermittent Pain Phenotype Rome V replaces functional abdominal pain–not otherwise specified with abdominal pain syndrome–not otherwise specified (APS-NOS), clarifying this as an intermittent pain disorder that does not meet criteria for IBS, functional dyspepsia, abdominal migraine, or biliary pain syndrome. The distinction is clinically useful because it captures children with recurrent abdominal pain who often undergo extensive evaluation but do not fit a better-defined Rome phenotype. Rome V also explicitly distinguishes APS-NOS from centrally mediated abdominal pain syndrome by emphasizing intermittent rather than continuous pain. Pain occurring exclusively with meals, bowel movements, or menses should prompt alternative diagnoses. From a mechanistic standpoint, APS-NOS likely shares many pathophysiologic pathways with IBS, including altered visceral perception, dysregulated autonomic signaling, and psychosocial amplification, but without a defining stool pattern or meal association. In practice, evaluation is guided by exclusion of inflammatory, structural, and celiac pathology when clinically indicated, followed by reassurance and early symptom-directed management. The therapeutic approach parallels IBS, with strongest evidence for CBT, hypnotherapy, and neuromodulation strategies rather than escalating diagnostic testing. Biliary Pain Syndrome: A New Pediatric Rome Diagnosis With Major Clinical Implications Biliary pain syndrome is one of the most important additions in Rome V because it introduces a formal pediatric diagnostic framework for children previously labeled with “biliary dyskinesia,” a term widely used but poorly standardized. Rome V intentionally moves away from the surgical shorthand of biliary dyskinesia and instead defines a symptom-based DGBI characterized by episodic right upper quadrant pain, often postprandial, severe enough to prompt acute evaluation, in the absence of gallstones or structural biliary disease. This is highly relevant in pediatric practice, where increasing rates of cholecystectomy have often been driven by nonspecific symptoms and unreliable gallbladder ejection fraction studies. The Rome V position is clinically decisive: gallbladder ejection fraction should not be used diagnostically in isolation, and cholecystectomy should not be reflexive. Evaluation should prioritize exclusion of stones, biliary tract pathology, pancreatobiliary structural disease, and biochemical abnormalities through ultrasound, selective MRCP, and liver-pancreatic biochemistry. In many children, conservative management may outperform surgery over time, and spontaneous improvement is well documented. Rome V therefore shifts pediatric practice toward diagnostic restraint and away from surgery-first decision making. This is likely to reduce unnecessary cholecystectomy in adolescents with functional pain syndromes. Abdominal Migraine: Episodic Neuroenteric Pain, Not Functional Dyspepsia Rome V retains abdominal migraine unchanged, reflecting continued confidence in its construct as a stereotyped episodic pain syndrome within the migraine spectrum. This remains an important diagnosis in children with severe recurrent periumbilical or diffuse pain accompanied by pallor, nausea, vomiting, headache, or photophobia. The practical importance lies in recognizing abdominal migraine as a neuroenteric episodic disorder rather than misclassifying it as refractory dyspepsia or recurrent unexplained abdominal pain. The mechanistic model is increasingly aligned with cyclic vomiting syndrome and migraine biology, involving neuronal hyperexcitability, altered gastric motor function, and possibly mitochondrial dysfunction. Clinically, this diagnosis matters because it reframes treatment away from repeated gastrointestinal investigation and toward trigger identification, migraine-style prophylaxis, and selected abortive therapy. In children with frequent disabling attacks, cyproheptadine, propranolol, pizotifen, and flunarizine remain practical preventive options, while severe attacks may respond to triptan-based or antiemetic rescue strategies. Centrally Mediated Abdominal Pain Syndrome: Recognizing the Continuous Pain Phenotype Centrally mediated abdominal pain syndrome (CAPS) is another major addition in Rome V and fills a longstanding gap in pediatric DGBI classification. CAPS identifies children with continuous abdominal pain and functional impairment in whom central pain amplification, rather than peripheral gastrointestinal dysfunction, is likely the dominant driver. This diagnosis is clinically important because it validates a phenotype that is often over-investigated, mislabeled, or treated as refractory IBS despite a distinct pain biology. The practical implication is that continuous pain should prompt a different clinical strategy than intermittent pain syndromes. CAPS requires a multidisciplinary model centered on functional restoration, pain neuroscience education, school reintegration, and targeted brain–gut therapies. Psychological assessment is essential, not to psychologize symptoms, but to identify pain-specific cognitions, maladaptive coping, family responses, and disability drivers. Neuromodulators, including tricyclics, SSRIs, mirtazapine, gabapentinoids, and behavioral therapies, are mechanistically aligned with CAPS and should be prioritized over repeated diagnostic escalation. Functional Constipation: Clarified Criteria, Stronger Clinical Precision Rome V preserves functional constipation as a distinct entity but improves diagnostic precision by clarifying stool retention behaviors, stool form descriptors, and symptom frequency. Most importantly, Rome V explicitly separates constipation from IBS by emphasizing that when abdominal pain is the dominant symptom and improves with defecation, IBS should be favored. This distinction is highly relevant in pediatric practice, where constipation and pain frequently overlap and are often conflated. Rome V continues to support a clinically grounded approach: diagnosis is usually made from history and examination, not imaging. Routine abdominal radiographs remain low-yield and should not be used reflexively. Treatment remains structured and pragmatic, beginning with education, disimpaction, maintenance laxative therapy, toileting behavior, and escalation to stimulant laxatives or newer agents such as linaclotide in selected refractory cases. The guideline also reinforces that refractory constipation is a separate management problem requiring escalation to motility-focused interventions rather than indefinite cycling of standard laxatives. Functional Diarrhea and Functional Abdominal Bloating: Symptom-Led, Mechanism-Aware Diagnosis Rome V broadens functional diarrhea across the pediatric age spectrum and provides a more clinically useful distinction from IBS-D by emphasizing that diarrhea without pain is functional diarrhea, whereas pain-predominant diarrhea is IBS-D. This distinction is especially useful in adolescents, where overlap is common and symptom labeling has therapeutic consequences. Evaluation should remain conservative but targeted, focusing on malabsorption, inflammation, and dietary contributors only when clinically justified. Functional abdominal bloating is newly recognized and clinically valuable because it legitimizes a symptom complex commonly encountered in practice but often poorly classified. Rome V acknowledges that bloating and visible distension may reflect distinct mechanisms including gas handling abnormalities, carbohydrate fermentation, abdominophrenic dyssynergia, pelvic floor dysfunction, visceral hypersensitivity, and behavioral stool retention. This is particularly relevant in adolescents with distension out of proportion to stool burden or gas volume. Management should therefore move beyond empiric simethicone and include attention to fermentation load, posture, evacuation mechanics, and in selected cases, biofeedback-directed correction of abdominophrenic discoordination. Infant Distress Syndrome: A More Accurate Framework Than “Infantile Colic” Rome V replaces “infantile colic” with infant distress syndrome (IDS), a clinically and conceptually important change. The term “colic” implied pain of colonic origin without evidence; IDS instead frames excessive crying as a multifactorial disorder of gut–brain regulation in early infancy. This is more biologically plausible and clinically useful. Rome V also removes the rigid 3-hour crying threshold from routine clinical diagnosis, recognizing that caregiver burden, not just crying duration, determines clinical significance. This change has practical value in pediatric care because it validates distressed infants who previously fell below arbitrary research cutoffs but still caused major caregiver dysfunction. Evaluation remains focused on exclusion of red flags and caregiver assessment rather than indiscriminate investigation. IDS is best managed through reassurance, caregiver support, normalization of symptom trajectory, and selective use of low-risk interventions such as Limos lactobacillus reuteri or cow’s milk elimination in selected infants. The shift from “colic” to IDS is not merely semantic; it reframes the condition from presumed intestinal pain to early-life dysregulation of gut–brain function and caregiver-infant interaction.

IBD with IBS-Like Symptoms (Rome Foundation & IOIBD Joint Consensus): Gastroenterology | May 2026

Introduction A significant number of patients with inflammatory bowel disease in remission continue to report symptoms such as abdominal pain, bloating, and altered bowel habits. These symptoms often mimic irritable bowel syndrome, creating confusion in clinical practice. Physicians frequently struggle to differentiate between ongoing subclinical inflammation and functional symptoms, leading to variability in management. This joint consensus from the Rome Foundation and the International Organisation for the Study of IBD provides a structured, evidence-based approach to defining, evaluating, and managing these patients. Why This Guideline Was Required The absence of standardised terminology and diagnostic criteria has led to a major clinical problem: patients with quiescent IBD are often misclassified as having active disease, resulting in unnecessary escalation of immunosuppressive or biologic therapies. At the same time, failure to recognise functional symptoms may delay appropriate therapies such as dietary interventions or brain–gut behavioral treatments. This consensus aims to bridge this gap by clearly separating inflammatory activity from functional symptom burden. Key Takeaways for Clinicians 1. Standard Terminology Is Essential The preferred term is “IBD with IBS-like symptoms.” This reflects the coexistence of functional symptoms in the absence of active inflammation, avoiding misleading labels such as “IBS in IBD.” 2. Definition Requires Exclusion of Active Disease Symptoms such as abdominal pain, bloating, and altered bowel habits should only be attributed to IBS-like mechanisms after ruling out active inflammation or structural complications. 3. Combine Clinical Criteria with Objective Assessment Diagnosis should integrate Rome criteria for IBS along with objective evidence of remission, including biomarkers, endoscopy, histology, or imaging. 4. Do Not Escalate IBD Therapy Based on Symptoms Alone Symptoms alone are insufficient to justify escalation of biologics or immunosuppressants. Objective confirmation of inflammation is mandatory before changing disease-modifying therapy. 5. Biomarkers Play a Central Role Faecal calprotectin and CRP should be used routinely to assess inflammatory activity and help distinguish functional symptoms from active IBD. 6. Endoscopic and Histologic Remission Matter For research and precision care, deeper remission definitions—including endoscopic and histologic healing—are encouraged to improve diagnostic clarity. 7. Consider Overlapping Mechanisms IBS-like symptoms in IBD may result from visceral hypersensitivity, altered motility, microbiome changes, or central pain processing, rather than inflammation alone. 8. Psyllium Can Be First-Line Therapy Soluble fibre, such as psyllium, is recommended in appropriate patients, provided there is no stricture or obstruction risk. 9. Low FODMAP Diet Has a Role A short-term low FODMAP diet can help reduce bloating and functional symptoms, but long-term restriction should be avoided. 10. Use Targeted Pharmacologic Therapy Selected patients may benefit from antispasmodics, neuromodulators, or gut-directed therapies, tailored to symptom profile. 11. Brain–Gut Behavioural Therapies Are Important Psychological interventions such as cognitive behavioural therapy and gut-directed hypnotherapy are effective and should be integrated into care. 12. Multidisciplinary Care Is Ideal Management often requires collaboration between gastroenterologists, dietitians, and psychologists for optimal outcomes. 13. Avoid Over-Investigation Once adequate exclusion of inflammation is achieved, repeated invasive testing should be minimised unless new red flags emerge. 14. Patient Education Is Critical Patients should be reassured that symptoms do not necessarily indicate disease flare, reducing anxiety and improving adherence. 15. Research Definitions Should Be Standardised The consensus proposes candidate thresholds for remission (endoscopic, histologic, biomarker, imaging) to ensure uniformity in future trials. 16. Recognise Heterogeneity Not all patients behave similarly; management should be individualised based on symptom pattern and disease history. Practical Clinical Message This guideline shifts the focus from reflex escalation of IBD therapy to a more nuanced, evidence-based approach that distinguishes inflammation from functional symptoms. It reinforces the importance of objective disease assessment and encourages the use of IBS-directed therapies when appropriate. For practising gastroenterologists, this represents a major step toward precision medicine in IBD, where treatment is guided not just by symptoms but by underlying pathophysiology. Conclusion This first joint Rome Foundation and IOIBD consensus establishes a clear framework for diagnosing and managing IBD with IBS-like symptoms. By emphasising objective assessment, appropriate terminology, and targeted therapies, it aims to reduce overtreatment, improve symptom control, and enhance patient outcomes.

Gastrointestinal Involvement in Scleroderma: Gastroenterology | May 2026

Summary Systemic sclerosis (SSc), the systemic form of scleroderma, is a multisystem disorder characterised by fibrosis, vasculopathy, and immune dysregulation. Gastrointestinal involvement is extremely common, affecting up to 90% of patients, with the oesophagus being the most frequently involved organ. However, the disease can affect the entire gastrointestinal tract—from the oesophagus to the anorectum. The central pathophysiological process is smooth muscle atrophy and fibrosis, leading to impaired motility. This results in stasis, dilation, and a cascade of complications. Clinically, patients may present with dysphagia and reflux due to oesophagal involvement, gastroparesis and gastric vascular lesions, small intestinal bacterial overgrowth and pseudo-obstruction, and colonic dysmotility causing constipation or megacolon. Anorectal involvement may lead to faecal incontinence due to sphincter weakness. A key challenge is that symptoms often correlate poorly with objective pathology, making diagnosis and monitoring difficult. Furthermore, therapeutic evidence is limited, and most treatment strategies are extrapolated from non-scleroderma populations. Management requires a high index of suspicion, segment-wise evaluation, and individualised therapy, focusing on symptom control and prevention of complications. Gastroenterologists must recognise that gastrointestinal disease in SSc is not isolated but part of a systemic fibrotic and vascular disorder, requiring a tailored and multidisciplinary approach.

Antibiotic-Associated Diarrhea in ICU: JGH | March 2026

Introduction Antibiotic-associated diarrhea (AAD) is a frequent and clinically significant complication of antimicrobial therapy, particularly in critically ill patients. The pathogenesis primarily involves disruption of the gut microbiota, leading to impaired intestinal barrier function and altered metabolism. In the intensive care unit (ICU), this risk is amplified due to severe illness, frequent use of broad-spectrum antibiotics, immunosuppression, and prolonged hospital stays. A substantial proportion of cases are related to Clostridioides difficile infection, which carries higher morbidity and mortality. However, data specific to ICU populations regarding incidence and risk stratification remain limited. Problem Statement The burden and predictors of antibiotic-associated diarrhea in critically ill patients are not well defined, limiting early identification and prevention strategies in ICU settings. Summary This meta-analysis highlights that AAD is highly prevalent in critically ill patients, affecting nearly 29%, while CDI-associated diarrhea occurs in approximately 12%. These figures confirm that diarrhea is not a minor complication but a major clinical issue in ICU practice. Several important risk factors were identified. Patient-related factors such as older age, male sex, diabetes, and hypertension increase susceptibility. Treatment-related factors—including use of high-risk antibiotics (cephalosporins, carbapenems, glycopeptides), combination antibiotic therapy, antifungals, and prolonged antibiotic duration—significantly elevate risk. Critical illness severity, reflected by higher APACHE II scores and longer ICU stays, further compounds this risk. Interventions like mechanical ventilation, enteral nutrition, and parenteral nutrition also contribute, particularly for CDI. Interestingly, the study also underscores the complexity of preventive strategies, with conflicting signals regarding commonly used interventions such as probiotics and proton pump inhibitors. Clinically, this study emphasizes the need for risk-based antibiotic stewardship, early identification of high-risk patients, and tailored preventive strategies in ICU settings to reduce morbidity, mortality, and healthcare burden

Probiotics in IBS: JGH | March 2026

Introduction Irritable bowel syndrome is a highly prevalent functional gastrointestinal disorder with significant impact on quality of life and healthcare costs. Despite multiple therapeutic options, management remains challenging due to heterogeneity in symptoms and underlying pathophysiology. Increasing recognition of the gut microbiome’s role has driven interest in probiotics as a potential treatment. While numerous randomized trials suggest benefit, clinical guidelines remain cautious due to inconsistent and low-certainty evidence. Problem Statement Despite multiple trials and meta-analyses, the true efficacy of probiotics in IBS remains uncertain due to heterogeneity, methodological limitations, and lack of conclusive cumulative evidence. Summary This updated meta-analysis of 40 randomized trials suggests that probiotics may modestly improve symptom severity in IBS, as reflected by a statistically significant reduction in IBS Symptom Severity Score. However, there was no meaningful improvement in quality of life, highlighting a disconnect between symptom relief and overall patient well-being. Importantly, trial sequential analysis revealed that the available evidence is still insufficient to draw definitive conclusions. The cumulative data did not cross thresholds for benefit, harm, or futility, indicating that current findings may be underpowered or potentially inconclusive. Furthermore, the overall certainty of evidence was rated as low, largely due to variability in probiotic strains, dosing regimens, and patient populations. Clinically, this study reinforces a cautious approach. While probiotics may be considered in selected patients, they cannot yet be recommended as standard therapy. The key future direction lies in standardization—identifying specific strains, doses, and patient subgroups most likely to benefit, supported by high-quality, adequately powered trials.

Clostridioides difficile Infection: AMJ, March 2026

This review highlights that CDI management now requires both accurate diagnosis and a strategy to prevent recurrence. Diagnosis should not rely on a single test alone, because PCR is highly sensitive but may detect colonization, whereas toxin EIA is more specific but less sensitive. Therefore, the preferred approach is algorithmic testing with PCR or GDH screening followed by toxin EIA, interpreted in the right clinical context. For initial CDI, vancomycin and fidaxomicin are the main first-line therapies. Metronidazole now has a much smaller role because of inferior efficacy, more side effects, and higher recurrence risk; it is mainly reserved for selected nonsevere cases or as part of combination therapy in fulminant disease. Fidaxomicin is attractive because it better preserves the microbiota and reduces recurrence, although cost remains an issue. Vancomycin remains the practical standard in many settings. For fulminant CDI, management should be aggressive: ICU-level care, surgical input, oral vancomycin plus intravenous metronidazole, and rectal vancomycin if ileus is present. For recurrent CDI, treatment extends beyond antibiotics. After a first recurrence, fidaxomicin or a vancomycin taper/pulse regimen is recommended. After second recurrence or in high-risk patients, microbiota restoration therapy becomes central. Options now include fecal microbiota, live-jslm (Rebyota) and fecal microbiota spores, live-brpk (Vowst), both of which reduce recurrence substantially. Conventional FMT still has an important role, especially in severe or fulminant CDI, although FDA policy and stool-bank access have made this more complicated. Overall, the key principle is: treat the acute vegetative infection with antibiotics, then restore the microbiome to prevent relapse.

IBS Pharmacotherapy Safety: AMJ, March 2026

Introduction Choosing drug therapy for irritable bowel syndrome (IBS) requires balancing symptom benefit against treatment-related adverse effects. While clinicians often use the number needed to treat (NNT) to compare efficacy, the number needed to harm (NNH) offers an equally important perspective by estimating how many patients need to be treated before one stops therapy because of an adverse event. This systematic review and meta-analysis evaluated the safety of commonly used IBS medications by focusing on discontinuation due to adverse events, a pragmatic marker of tolerability. Summary This meta-analysis included 54 placebo-controlled clinical trials involving 33,538 patients and assessed IBS-C, IBS-D, and global symptom therapies. The primary outcome was NNH, derived from treatment discontinuation due to adverse events. Among IBS-C therapies, the NNH was 35 for linaclotide, 53 for lubiprostone, 59 for plecanatide, 58 for tegaserod, and 16 for tenapanor. For IBS-D therapies, the NNH was 14 for alosetron and 32 for eluxadoline, while rifaximin and ramosetron had negative, nonsignificant NNH values, meaning placebo groups had numerically higher discontinuation rates than active treatment groups. For global IBS symptom therapy, tricyclic antidepressants had an NNH of 24. Overall, tenapanor, alosetron, and tricyclics had the greatest risk of treatment discontinuation due to adverse events, whereas rifaximin appeared to be the safest pharmacotherapy studied. The most common adverse effects reflected mechanism of action: diarrhea and nausea for IBS-C drugs, constipation for IBS-D drugs, and anticholinergic or sedative effects for tricyclics. Importantly, many adverse events were transient and nonserious. This study emphasizes that IBS treatment decisions should not rely on efficacy alone. Safety, tolerability, and patient preference should be central when selecting among multiple reasonable drug options.

Global Dietary Patterns Influence Severity of IBS: CGH, March 2026

The role of habitual diet in the global epidemiology of irritable bowel syndrome (IBS) remains incompletely understood. In this large international analysis from the Rome Foundation Global Epidemiology Study, investigators evaluated whether regional dietary patterns are associated with variations in IBS prevalence and symptom severity. A total of 54,127 participants from 26 countries completed questionnaires assessing Rome IV IBS criteria and frequency of intake of 10 food groups. Using latent class analysis, researchers identified four distinct dietary pattern clusters. These clusters demonstrated significant differences in both IBS prevalence and symptom severity. Clusters A (5.6%) and B (4.5%) had the highest IBS prevalence and symptom severity, and were largely represented by countries such as Egypt, Brazil, Colombia, Argentina, Germany, Poland, and the United States. In contrast, clusters C (3.4%) and D (2.6%), predominantly from Europe and Asian countries, showed lower IBS prevalence and milder symptoms. These findings suggest that regional dietary habits may contribute to global variations in IBS burden. Understanding population-specific dietary patterns may help design culturally appropriate dietary interventions for IBS management worldwide.

Mucus Brushing and SIBO: Frontline Gastroenterology, March 2026

Introduction Upper small intestinal bacterial overgrowth (USIBO) is characterised by excessive bacterial colonisation in the duodenum or proximal jejunum, often leading to symptoms such as bloating, abdominal distension, and dyspepsia. Diagnosing USIBO remains challenging. Current methods include breath tests (glucose or lactulose hydrogen testing) and duodenal fluid aspiration, but both have important limitations. Breath tests have variable sensitivity and specificity, while aspirate cultures can be difficult to obtain and are prone to contamination and dilution, resulting in false-positive rates of up to 20%. These challenges have prompted exploration of alternative diagnostic techniques. Summary This study revisits the duodenal mucus brushing technique, an older but largely overlooked method for detecting bacterial overgrowth. During endoscopy, a cytology brush is used to collect mucus directly from the duodenal or proximal jejunal mucosa, targeting bacteria adherent to the mucosal surface rather than bacteria suspended in luminal fluid. In a cohort of 92 patients with suspected USIBO, bacterial growth was detected in 24% of cases using this technique. Streptococcus species were the most commonly identified organisms, followed by coliform bacteria. Importantly, contamination testing demonstrated a false-positive rate of only 8%, significantly lower than that reported with traditional duodenal aspiration. The authors propose that bacteria involved in USIBO preferentially adhere to the mucosal mucus layer, making mucus sampling a more accurate diagnostic source. The brushing technique is simple, reproducible, and can be performed during routine endoscopy, potentially improving the detection of small intestinal bacterial overgrowth in patients lacking duodenal fluid samples.

Defecography Metrics in Chronic Constipation: Gastroenterology | March 2026

Introduction Chronic constipation is frequently evaluated using physiologic testing such as fluoroscopic defecography and high-resolution anorectal manometry to identify pelvic floor dysfunction and evacuation disorders. A recent study combined these techniques to define a synchronous “proctomanometric” signature of constipation. However, concerns have been raised about the methodological assumptions used to classify evacuation patterns. Accurate definitions and patient phenotyping are crucial because diagnostic thresholds and analytic models can strongly influence the interpretation of anorectal physiology and the clinical diagnosis of pelvic floor dyssynergia. Summary The correspondence highlights three methodological issues. First, the study defined “successful evacuation” as expelling ≥25% of rectal barium within three attempts lasting ≤17 seconds, a threshold that may be overly restrictive and physiologically unrealistic. Prior studies demonstrate that even healthy individuals may take >30 seconds to evacuate similar volumes, suggesting that strict time limits could generate false-positive diagnoses of impaired evacuation. Second, the study combined functional constipation (FC) and constipation-predominant IBS (IBS-C) using older Rome III criteria, despite Rome IV guidelines recognizing important pathophysiologic differences between these conditions. Pooling them may confound interpretation of anorectal pressure patterns. Third, the study applied machine-learning models with many predictors but limited sample size, raising concerns about overfitting and lack of reproducibility. The author proposes more physiologic evacuation metrics, Rome IV–based patient stratification, and more robust statistical validation to improve translation of these findings into clinical practice.

Colonoscopy is the Best for CRC Screening: Gastroenterology | March 26

Introduction Colonoscopy has become the dominant colorectal cancer (CRC) screening test in the United States, credited with major reductions in CRC incidence and mortality through detection and polypectomy. Yet CRC screening uptake targets remain unmet, alternative tests (especially FIT) have strong evidence, and health systems are increasingly shifting from opportunistic to programmatic screening—raising an uncomfortable but necessary question: should colonoscopy still be promoted as “the best” screening choice? Summary This commentary argues that while colonoscopy is the most comprehensive colorectal examination and the “final common pathway” for all screening strategies, it cannot be automatically crowned the best population-wide screening test. The authors highlight that real-world effectiveness is not only about test efficacy, but also about participation, feasibility, adherence over time, and colonoscopy quality (which is operator dependent). In many countries, organised screening programs favour FIT because it is inexpensive, noninvasive, scalable, and can achieve high participation, with colonoscopy reserved for positive tests. The authors emphasise that programmatic stool-based screening—when repeated and paired with reliable follow-up colonoscopy—can deliver prevention benefits comparable to colonoscopy-based strategies. They point to recent randomised evidence, including COLONPREV, showing that invitations to FIT can achieve CRC incidence and mortality outcomes comparable to invitations to colonoscopy, while requiring fewer colonoscopies due to higher participation and triage. The piece also addresses the financial realities in US gastroenterology and the potential conflict of interest when colonoscopy is preferentially promoted. The conclusion is clear: gastroenterologists should champion CRC screening broadly, simplify choices where needed (often to colonoscopy vs stool-based testing), and align messaging with population-level effectiveness rather than defending colonoscopy as universally “best.”

SAPP Defines “Gut Health”: Nature Reviews Gastro & Hepatol | Feb. 2026

“Gut health” is widely used by clinicians, researchers, industry, and the public—but until now lacked a unified, clinically usable definition. This ISAPP consensus statement convened an interdisciplinary expert panel to clarify what “gut health” should mean and how it should be measured, particularly in the context of diet, fermented foods, probiotics, prebiotics, and microbiome research. The panel proposes a pragmatic definition: gut health is “a state of normal gastrointestinal function without active gastrointestinal disease and gut-related symptoms that affect quality of life.” Crucially, the definition is not limited to absence of diagnosis: a patient with IBD or coeliac disease may still have gut health during remission. Equally, poor gut health can exist without obvious symptoms or without measurable abnormalities—highlighting the gap between patient experience and current objective testing. The statement emphasizes that gut health is multidimensional, spanning functional physiology (motility, secretion, absorption), microbiome-related functions, barrier integrity, immune homeostasis, gut endocrine function, and the gut–brain axis. The authors also review clinically accessible metrics and caution that many emerging “gut health tests” lack validated normal ranges or correlate poorly with meaningful outcomes. This consensus provides a needed foundation for consistent clinical communication and for designing dietary/biotic intervention trials with clearer endpoints and more defensible claims. 20 Key Takeaways Gut health needed a standard definition—the term has been used inconsistently across science, medicine, and marketing. ISAPP defines gut health as normal GI function without active GI disease and symptoms that impair quality of life. Disease diagnosis ≠ absence of gut health: remission states (e.g., IBD in remission) can meet gut health criteria. Conversely, poor gut health can exist without symptoms (subclinical dysfunction) or without measurable abnormalities. The framework integrates subjective experience + objective function—both matter. The concept applies to the entire GI tract, from mouth to anus. “Gut health” is considered broadly synonymous with gastrointestinal health, and includes digestive health. Transient symptoms from normal physiology (stress diarrhea, travel constipation) should be distinguished from persistent QOL-impacting symptoms. Quality of life impact is central—symptoms become “clinically important” when they are bothersome and impair daily living. The statement organizes gut health into six functional domains: digestion/physiology, microbiome, barrier, immunity, endocrine, gut–brain axis. Many objective measures (e.g., permeability tests, microbiome indices) lack validated normal ranges and have variable reproducibility. Microbiome testing currently cannot define an individual’s gut health reliably in clinical practice. “Dysbiosis” is a problematic term—microbiome patterns vary widely by geography, age, and context. Barrier function (“leaky gut”) is often overinterpreted; all guts are selectively permeable, and many claims exceed evidence. Stool tools like Bristol stool form scale and symptom frequency/duration remain highly practical clinical metrics. Inflammation assessment is best supported by histology when needed; noninvasive markers (CRP, fecal calprotectin) are helpful but not definitive. Diet is a major determinant, but responses are highly individualized; “one diet fits all” is unsupported. Research outcomes labeled “gut health” are often heterogeneous—this consensus encourages clarity about which domain is being targeted. The panel argues for development of core outcome sets to standardize gut health research and reduce reporting bias. This document is a starting point: future work must refine validated biomarkers, normal ranges, and determinants of future gut health risk.

The Fiesole Consensus report

The Fiesole Consensus Report refers to an international set of guidelines and recommendations on the diagnosis, management, and prevention of diverticular disease. This consensus was developed by a group of 32 experts from 14 countries, employing a structured Delphi process that adheres to the PICO (Population, Intervention, Comparison, Outcome) framework and GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology. The report is designed to standardize care and provide evidence-based guidance for clinicians dealing with this increasingly prevalent condition. ### Key Highlights of the Fiesole Consensus Report: #### 1. **Definitions and Epidemiology** - **Diverticulosis**: The presence of colonic diverticula (small pouches in the colon wall) without associated symptoms. - **Diverticular disease**: When diverticula are associated with symptoms or complications such as inflammation or infection. - Diverticulosis is the most common structural abnormality of the colon in developed countries, with an increasing prevalence worldwide. - Approximately 20–25% of individuals with diverticulosis develop symptoms that fall under diverticular disease. #### 2. **Risk Factors** - High dietary fiber intake is protective against diverticular disease. - Risk factors include: - Smoking - Obesity - Use of certain medications such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, opioids, and immunotherapy agents. #### 3. **Diagnosis** - Imaging is critical for diagnosing suspected acute diverticulitis. - **Ultrasound**: May be appropriate when performed by experienced clinicians. - **CT Scans**: Preferred for diagnosing complicated cases of diverticulitis. - Diverticulosis itself does not require any specific treatment or imaging unless symptoms or complications arise. #### 4. **Management of Diverticular Disease** - **Symptomatic Uncomplicated Diverticular Disease (SUDD)**: - Dietary fiber, selected probiotics, mesalazine, and rifaximin may help alleviate symptoms. - **Acute Uncomplicated Diverticulitis**: - Routine antibiotic use is *not* recommended. - **Complicated Diverticulitis**: - Imaging is essential to guide management. - **Elective Surgery**: - Should be individualized based on the patient's quality of life rather than the number of episodes of diverticulitis. #### 5. **Surgical Management** - Surgery is reserved for cases where complications arise or when symptoms significantly impair quality of life. - Decisions should prioritize the patient's preferences and overall well-being. #### 6. **Research Priorities** - The report emphasizes the need for further research into: - Microbiome characterization in diverticular disease. - Genetic risk profiling to better understand individual susceptibility. - Long-term outcomes of selective antimicrobial and surgical strategies. ### Conclusion The Fiesole Consensus Report aims to provide a comprehensive and standardized approach to the diagnosis, treatment, and prevention of diverticular disease. By integrating the latest evidence and expert opinions, the report seeks to optimize patient outcomes across diverse healthcare systems. It also identifies critical gaps in knowledge and highlights areas for future research, ensuring that the management of diverticular disease continues to evolve in alignment with emerging scientific insights.

Rome III vs Rome IV Criteria for IBS Diagnosis in Southeast Asia - J of JGH - Jan,26

The study published in the *Journal of Gastroenterology and Hepatology* (JGH) on January 26, titled "Rome III vs Rome IV Criteria for IBS Diagnosis in Southeast Asia," investigates how the adoption of the Rome IV diagnostic criteria has impacted the reported prevalence, demographic, and clinical characteristics of irritable bowel syndrome (IBS) in Southeast Asia, specifically in Malaysia and Indonesia. ### Key Findings of the Study: 1. **Prevalence Differences**: - The Rome IV criteria identified significantly fewer individuals with IBS compared to the Rome III criteria. - A substantial number of individuals previously diagnosed with IBS under Rome III were reclassified into other functional bowel disorder categories when Rome IV was applied. 2. **Demographic Shifts**: - IBS cases identified under Rome IV criteria were more likely to be younger and female, suggesting a notable shift in the demographic profile of those diagnosed. - This indicates that the Rome IV criteria may be more selective in identifying a narrower and more specific subgroup of IBS cases. 3. **Clinical and Psychological Characteristics**: - Individuals diagnosed with IBS under Rome IV experienced more severe gastrointestinal symptoms compared to those identified under Rome III. - Despite having more severe symptoms, these individuals reported lower levels of anxiety but poorer mental health-related quality of life. - This suggests that the Rome IV criteria may capture individuals with greater overall symptom burden and a more pronounced impact on quality of life. 4. **Healthcare Utilization**: - Patterns of healthcare utilization remained consistent between individuals diagnosed using the Rome III and Rome IV criteria, indicating that the shift in diagnostic criteria does not significantly affect healthcare-seeking behavior. 5. **Dietary Patterns**: - Participants diagnosed with IBS under the Rome IV criteria followed a more restricted diet, with lower intake across several major food groups. - This dietary restriction may reflect efforts to manage more severe symptoms or could be a consequence of the narrower diagnostic criteria. ### Implications: - The reduced sensitivity of the Rome IV criteria for diagnosing IBS in Southeast Asia highlights its limitations in identifying the broader spectrum of IBS cases that were previously captured under Rome III. - The Rome IV criteria appear to focus on a narrower subset of individuals with more pronounced symptoms and distinct demographic features, potentially underestimating the true prevalence of IBS in the population. - The findings underscore the importance of considering regional and cultural factors when applying global diagnostic criteria, as dietary habits, healthcare access, and symptom reporting can vary widely across populations. ### Conclusion: The transition from Rome III to Rome IV criteria has led to a significant reduction in IBS prevalence in Southeast Asia and has shifted the demographic and clinical profile of diagnosed cases. While Rome IV identifies individuals with greater symptom severity and reduced mental well-being, its lower sensitivity may overlook many individuals with milder or atypical forms of IBS. This raises questions about the appropriateness of the Rome IV criteria for diverse populations and highlights the need for region-specific adaptations or complementary diagnostic approaches in Southeast Asia.

Advances in Gut Microbiome and Metabolomics in IBD–Depression Comorbidity - J of JGH Jan,26

As of my training cutoff in October 2023, I cannot access or summarize the specific contents of the "Journal of Gastroenterology and Hepatology (JGH)" article dated January 26. However, based on the context provided, I can offer a detailed overview of advances in gut microbiome and metabolomics research related to IBD–depression comorbidity: ### Advances in Gut Microbiome and Metabolomics in IBD–Depression Comorbidity #### 1. **Microbiome Dysbiosis in IBD and Depression** - **IBD-Associated Dysbiosis**: Inflammatory bowel disease (IBD) is marked by reduced microbial diversity and depletion of beneficial taxa such as *Firmicutes* and *Faecalibacterium*. These changes exacerbate intestinal inflammation and compromise gut health. - **Depression-Associated Dysbiosis**: Depressive disorder similarly involves altered gut microbial composition, with reductions in microbial richness and beneficial bacteria such as *Bifidobacterium*. - **Shared Microbial Alterations**: IBD patients with comorbid depression exhibit more severe dysbiosis compared to those without depression. This highlights the bidirectional relationship between gut health and mental health. #### 2. **Key Microbial Metabolites and Their Roles** - **Short-Chain Fatty Acids (SCFAs)**: SCFAs like butyrate are critical for maintaining intestinal barrier integrity and regulating immune responses. Deficiencies in SCFAs are linked to worsened intestinal inflammation and depressive symptoms. - **Bile Acid Dysregulation**: Altered bile acid metabolism disrupts gut–brain communication, contributing to both mood disturbances and intestinal inflammation. - **Tryptophan Metabolism**: Enhanced tryptophan degradation in IBD affects serotonin synthesis, directly linking gut inflammation to depressive symptoms. Serotonin is a key neurotransmitter in mood regulation. #### 3. **Gut–Brain Axis as a Communication Pathway** - The microbiota–gut–brain axis integrates neural, immune, and endocrine signaling. Dysbiosis and inflammation in IBD can lead to neuroimmune crosstalk, where cytokines like TNF-α and IL-6 cross the blood–brain barrier, contributing to neuroinflammation and depressive symptoms. - Chronic stress and cytokine signaling overstimulate the hypothalamic-pituitary-adrenal (HPA) axis, increasing gut permeability and amplifying intestinal inflammation. #### 4. **Therapeutic Advances** - **Probiotics**: Strains like *Lactobacillus* and *Bifidobacterium* show promise in reducing inflammation and improving both gastrointestinal and psychological outcomes. These probiotics may help restore microbial balance and enhance SCFA production. - **Fecal Microbiota Transplantation (FMT)**: FMT is emerging as a potential therapy to alleviate intestinal inflammation and depressive symptoms by restoring microbial diversity and balance. - **Dietary Interventions**: Diets rich in fiber, such as Mediterranean-style diets, support microbial diversity, promote SCFA production, and reduce systemic inflammation. These diets may benefit both gut health and mental health in IBD patients. - **Personalized Microbiome-Based Therapies**: Advances in microbiome and metabolomics research pave the way for individualized treatments targeting specific microbial and metabolic profiles in IBD patients with comorbid depression. #### 5. **Future Directions** - **Integrative Research**: Combining microbiome, metabolomics, and neuroimmune studies will provide deeper insights into the complex interplay between gut health and mental health in IBD–depression comorbidity. - **Biomarker Development**: Identifying specific microbial and metabolic biomarkers may enable early diagnosis and targeted interventions for IBD patients at risk of depression. - **Precision Medicine**: Personalized approaches based on an individual's microbiome composition and metabolic profile could optimize treatment outcomes for both IBD and depression. If you are looking for specific findings or experimental data from the JGH article, I recommend accessing the publication directly through academic databases or institutional subscriptions.

Prevention of Acute Diverticulitis and DICA Score -Eur.J.Gastroenterol.Hepatol Jan 26

The prevention of acute diverticulitis (AD) based on the DICA (Diverticular Inflammation and Complication Assessment) score offers several key insights and takeaways for individualized management strategies. Below is a detailed summary: ### 1. **Introduction to the Problem** Acute diverticulitis (AD) is a common complication in patients with colonic diverticulosis, and its prevention remains a significant unmet clinical need. The DICA score provides an endoscopic stratification system to assess the risk of developing AD, enabling tailored interventions for patients based on their individual risk profiles. This study investigated the effectiveness of various preventive strategies, including no treatment, high-fibre diet, mesalamine, rifaximin, and a combination of mesalamine and rifaximin, in reducing the risk of AD over a 3-year period. --- ### 2. **Key Findings from the Study** #### **Overall Risk of Acute Diverticulitis** - During the 3-year follow-up, 140 cases of acute diverticulitis were documented. - The **lowest crude 3-year AD risk** was observed in the **no-treatment group (3.3%)**, followed by: - **High-fibre diet (5.9%)** - **Mesalamine alone (9.5%)** - **Rifaximin alone (11.8%)** - **Combination therapy (mesalamine + rifaximin) (17.1%)** #### **Effectiveness of Preventive Strategies** - **Mesalamine** showed a significant benefit in reducing the risk of AD compared to rifaximin and combination therapy: - Mesalamine reduced the hazard of AD by **58%** compared to rifaximin (HR 0.42; 95% CI 0.19–0.94). - Mesalamine reduced the hazard of AD by **63%** compared to combination therapy (HR 0.37; 95% CI 0.15–0.88). - **Rifaximin** was associated with a **higher hazard of AD** compared to no treatment, suggesting it lacks preventive benefits. - **Combination therapy** (mesalamine + rifaximin) showed the **highest crude incidence** of AD, indicating no synergistic benefit. #### **DICA Score-Based Stratification** - Treatment effects varied according to the DICA classification, emphasizing the importance of endoscopic risk stratification: - **DICA 2 Patients** derived the greatest benefit from mesalamine therapy. - Mesalamine reduced AD risk by **77%** compared with rifaximin (HR 0.23; 95% CI 0.08–0.62). - Mesalamine reduced AD risk by **84%** compared with combination therapy (HR 0.16; 95% CI 0.05–0.53). - In DICA 2 patients, mesalamine emerged as the most effective preventive strategy. - The benefit of mesalamine over no treatment was not clearly established across all DICA scores. --- ### 3. **Conclusion: DICA-Guided Individualized Approach** The findings support the use of a **DICA-guided individualized approach** to AD prevention rather than a uniform pharmacologic prophylaxis strategy. Key conclusions include: - Mesalamine demonstrates significant preventive benefits, particularly for patients with intermediate-risk disease (DICA 2 classification). - Rifaximin and combination therapy (mesalamine + rifaximin) are not effective and may even increase the risk of AD. - The no-treatment strategy showed the lowest crude risk of AD, raising questions about the necessity of pharmacologic interventions in certain patient groups. - Endoscopic risk stratification using the DICA score is essential for identifying patients who may benefit from targeted preventive measures, optimizing outcomes, and avoiding unnecessary treatments. In summary, **mesalamine therapy tailored to DICA 2 patients** is the most effective strategy for reducing AD risk, highlighting the importance of individualized, risk-based management approaches in clinical practice.

A Gut Feeling

"A Gut Feeling" refers to the intuitive understanding of the profound impact the gut microbiota has on overall health, including gastrointestinal (GI), immune, endocrine, metabolic, and even neurological functions. This phrase metaphorically captures the growing scientific awareness of the gut's critical role as a central hub for maintaining bodily homeostasis and influencing systemic health. ### The Gut Microbiota's Role in Health The gut microbiota is a diverse community of microorganisms, including bacteria, viruses, fungi, and archaea, primarily residing in the GI tract. It plays an essential role in regulating nutrient digestion, absorption, and excretion while also managing immune responses and endocrine functions. In a healthy individual, the gut microbiota maintains a balanced composition known as "eubiosis," which supports the body's defenses against pathogens and sustains overall health. However, when this balance is disrupted (a condition called "dysbiosis"), it can lead to inflammation, altered immune responses, and a range of diseases. ### Inflammasomes: The Gut's Master Regulators Inflammasomes are supramolecular complexes within innate immune cells that act as master regulators of immune responses. They are activated by microbial and environmental threats, ensuring cellular integrity and tissue homeostasis. However, in cases of dysbiosis, inflammasomes can become overactivated, leading to chronic inflammation and contributing to various GI and systemic diseases, including inflammatory bowel disease (IBD), cancer, obesity, cardiovascular diseases, and neurological disorders such as Parkinson's and Alzheimer's disease. ### Gut-Brain Axis (GBA) The gut-brain axis is a bidirectional communication network between the gut and the central nervous system (CNS), primarily mediated by the vagus nerve and the hypothalamic-pituitary-adrenal axis. Dysbiosis and inflammasome activation in the gut can influence brain health by altering cytokine secretion and stress responses. This connection explains why gut health is increasingly linked to neurological conditions like depression, anxiety, and neurodegenerative diseases. ### Artificial Intelligence (AI) in Gut Research AI is revolutionizing the study of gut microbiota and inflammasome interactions. By analyzing vast datasets, AI can uncover patterns, identify biomarkers, and predict disease outcomes more effectively than traditional methods. This approach is opening new avenues for therapeutic interventions, offering insights into the development of precision medicine for GI diseases, cancer, and neurological disorders. ### Implications for Research, Practice, and Policy The emerging understanding of the microbiota-inflammasome axis highlights the need for innovative therapeutic strategies targeting gut health. Researchers are exploring ways to modulate the microbiota composition or inflammasome activity to prevent or treat diseases. AI-driven models are enabling predictive diagnostics and personalized treatments, potentially transforming healthcare practices and policies. ### Conclusion "A Gut Feeling" underscores the critical importance of gut health in maintaining overall well-being. The intricate interplay between the gut microbiota, inflammasomes, and systemic health provides a promising area for research and therapeutic innovation, with AI serving as a powerful tool to unlock its full potential.

Long-Term Venous Thromboembolism Risk in Microscopic Colitis

The long-term risk of venous thromboembolism (VTE) in individuals with microscopic colitis (MC) has been evaluated in a nationwide Swedish cohort study. Microscopic colitis is an inflammatory bowel disorder characterized by chronic watery diarrhea despite normal endoscopic findings. While inflammatory bowel disease (IBD) is already known to increase thrombotic risk, there has been limited data regarding VTE risk in MC, despite the shared inflammatory mechanisms and the typically older, comorbidity-prone patient population. ### Study Overview: The study utilized the ESPRESSO cohort, which included 12,489 adults diagnosed with biopsy-confirmed microscopic colitis (MC) between 1990 and 2017. The cohort encompassed two subtypes of MC: collagenous colitis and lymphocytic colitis. These individuals were matched to 55,809 reference individuals without MC or prior VTE. Participants were followed until 2021 to assess the incidence of VTE events. The study adjusted for demographic factors, comorbidity burden, and celiac disease using Cox proportional hazards models to estimate risk. ### Key Findings: 1. **Increased Risk of VTE:** - Individuals with MC had a higher incidence of VTE compared to the matched controls (11.3 vs. 8.6 per 1,000 person-years). - MC was associated with a **21% increased risk of VTE** overall. 2. **Subtypes of MC:** - The increased VTE risk was similar for both collagenous colitis and lymphocytic colitis subtypes. 3. **Types of VTE Events:** - Elevated risks were observed for pulmonary embolism, deep vein thrombosis (DVT) of the legs, and other thromboses. 4. **Impact of Disease Severity:** - Patients treated with **budesonide** (a common treatment for MC) within one year of diagnosis, which served as a marker for more severe disease, had a notably higher risk of VTE. 5. **Subgroup and Sensitivity Analyses:** - These analyses generally supported the findings, though sibling comparisons showed weaker associations, suggesting some role for shared familial or genetic factors in the risk. ### Clinical Implications: - **Modest but Clinically Relevant Risk:** The study highlights that MC is associated with a modest yet significant long-term increase in VTE risk. This is particularly important given the older age and comorbidity-prone nature of the MC population. - **Heightened Clinical Awareness:** Healthcare providers should be aware of the increased VTE risk in patients with MC, especially in those with more severe disease or who require budesonide treatment. - **Risk Assessment:** Routine risk assessment for VTE may be warranted in this population, particularly for those with additional risk factors such as immobility, obesity, or a history of thrombosis. ### Conclusion: This study provides strong evidence that microscopic colitis is associated with a modest increase in long-term VTE risk. Given the potential complications of VTE, clinicians should consider proactive risk management strategies and maintain a high index of suspicion for thrombotic events in patients with MC.

Efficacy and Safety of Linaclotide vs Plecanatide for Chronic Idiopathic Constipation

Linaclotide and plecanatide are both guanylate cyclase-C (GC-C) agonists approved for the treatment of chronic idiopathic constipation (CIC) in adults. While both drugs share a similar mechanism of action and are effective in treating CIC, there are differences in their efficacy, safety profiles, and dosing that may influence their use in clinical practice. Below is a detailed comparison of their efficacy and safety: --- ### **Efficacy** 1. **Mechanism of Action**: - Both linaclotide and plecanatide act on GC-C receptors located on the intestinal epithelium, leading to increased intracellular cyclic guanosine monophosphate (cGMP). This promotes chloride and bicarbonate secretion through CFTR channels, resulting in increased intestinal fluid secretion and accelerated gastrointestinal transit. 2. **Linaclotide**: - **Dosing**: Approved for CIC at a dose of 145 mcg once daily, with a lower 72 mcg dose available for selected patients. - **Clinical Trials**: Two phase III trials demonstrated significant improvements in bowel movement frequency and abdominal symptoms compared to placebo. - **Efficacy Outcomes**: Linaclotide significantly improves spontaneous bowel movement (SBM) frequency, complete spontaneous bowel movements (CSBM), and reduces abdominal discomfort and bloating. 3. **Plecanatide**: - **Dosing**: Approved at a fixed dose of 3 mg once daily. - **Clinical Trials**: A large phase II randomized controlled trial showed that plecanatide significantly increased the proportion of CSBM responders, shortened the time to first CSBM, and improved SBM frequency and patient-reported constipation severity. - **Efficacy Outcomes**: Plecanatide also demonstrated significant improvements in bowel movement regularity, patient satisfaction, and reductions in constipation-related discomfort. 4. **Comparison**: - Both agents are comparably effective in improving bowel movement frequency, CSBM rates, and constipation-associated symptoms. - Plecanatide may have a slight edge in patient-reported satisfaction due to its tolerability, but clinical outcomes are largely similar. --- ### **Safety** 1. **Adverse Events**: - Both drugs are generally well tolerated, but diarrhea is the most common adverse event for both agents. 2. **Linaclotide**: - **Diarrhea Incidence**: Diarrhea occurs in up to 22% of patients, which is higher compared to plecanatide. - **Severity**: In some cases, diarrhea may be severe enough to require discontinuation of therapy. - **Systemic Absorption**: Minimal systemic absorption, but the higher incidence of diarrhea may limit its tolerability for some patients. 3. **Plecanatide**: - **Diarrhea Incidence**: Plecanatide has a lower incidence of diarrhea compared to linaclotide. - **Systemic Absorption**: Minimal systemic absorption, which contributes to its favorable safety profile. - **Other Adverse Events**: Rare adverse events have been reported, but overall plecanatide is well tolerated. 4. **Comparison**: - Plecanatide appears to have a better safety profile due to the lower incidence and severity of diarrhea. - Linaclotide’s higher rate of diarrhea may be a limiting factor for patients who are sensitive to this side effect. --- ### **Dosing and Patient-Specific Considerations** - **Linaclotide**: - Offers two dosing options (145 mcg and 72 mcg), which may be advantageous for patients who require a lower dose due to tolerability issues. - May be better suited for patients who can tolerate the higher risk of diarrhea and prefer flexibility in dosing. - **Plecanatide**: - Administered at a fixed dose of 3 mg once daily, which simplifies dosing for patients. - May be preferred for patients who prioritize tolerability and are concerned about diarrhea or other gastrointestinal side effects. --- ### **Conclusion** Both linaclotide and plecanatide are effective GC-C agonists for the treatment of CIC, with comparable efficacy in improving bowel movement frequency, CSBM rates, and associated symptoms. However, their safety profiles differ, with plecanatide demonstrating a lower incidence of diarrhea and better overall tolerability. The choice between the two agents should be guided by patient-specific factors, including tolerability, dosing preference, and individual responses to therapy. For patients who are particularly sensitive to diarrhea, plecanatide may be the preferred option, whereas linaclotide may be appropriate for those who can tolerate a higher risk of diarrhea and benefit from its flexible dosing options.

Study Maps Genes Tied to Targets in Irritable Bowel Syndrome

Yes, the study you are referring to provides groundbreaking insights into the genetic underpinnings of Irritable Bowel Syndrome (IBS) and identifies potential therapeutic targets. This large genome-wide association study (GWAS) analyzed data from over 80,000 individuals with IBS and more than one million controls, making it the most comprehensive genetic analysis of IBS to date. Its findings represent a significant step forward in understanding the biological mechanisms behind IBS, a disorder that affects 10%–15% of adults globally but has historically lacked well-defined biological pathways. Here are the key findings and contributions of the study: ### 1. **Genetic Loci and Risk Genes Identified** - The study identified **12 genetic loci** associated with IBS risk, including **five novel variants** that had not been previously reported. - A total of **22 high-confidence risk genes** were prioritized through advanced analyses, such as transcriptome-wide association, colocalization, and Mendelian randomization studies. - Of these 22 genes, **12 were newly implicated** in IBS, highlighting previously unknown genetic contributors to the disorder. ### 2. **Subtype-Specific Insights** - The research revealed distinct genetic signals for specific IBS subtypes, including **constipation-predominant IBS (IBS-C)** and **mixed-type IBS (IBS-M)**. - This subtype-specific analysis addresses a significant gap in prior research, as earlier studies often treated IBS as a single entity without accounting for its clinical heterogeneity. ### 3. **Biological Pathways** - Several of the identified genes, such as **CADM2, PCLO, PHF2, and SHISA6**, point to key biological mechanisms involved in IBS, including: - **Neuronal signaling**: Suggesting a role for gut–brain interaction in IBS pathophysiology. - **Epithelial barrier function**: Highlighting the importance of the gut lining in IBS. - **Calcium signaling**: Implicating cellular communication pathways. - **Immune interactions**: Indicating potential immune system involvement in IBS. ### 4. **Therapeutic Targets** - By cross-referencing the identified genes with major drug databases, the study identified **three promising therapeutic targets**. - Some of these targets are already linked to approved or investigational drugs, raising the possibility of **drug repurposing** for IBS treatment. - This approach could accelerate the development of **precision medicine** strategies tailored to the genetic profiles of IBS patients. ### 5. **Implications for Future Research and Treatment** - The study establishes a robust genetic framework for IBS, which can serve as a foundation for further research into the disorder. - By elucidating the biological pathways involved, it paves the way for more targeted and biologically informed treatments. - The findings also open opportunities for developing **new drugs** or repurposing existing ones to address the unmet needs of IBS patients. ### Conclusion This comprehensive study represents a major advance in IBS research by identifying genetic factors, biological pathways, and potential therapeutic targets. It underscores the importance of using large-scale genomic data to uncover the complex interplay of genetics, biology, and clinical manifestations in IBS. Ultimately, these findings hold promise for improving the diagnosis, management, and treatment of IBS through precision medicine approaches.

The Impact of Emulsifiers on GI Health

The impact of dietary emulsifiers on gastrointestinal (GI) health has become a growing concern, particularly as the consumption of ultraprocessed foods—where these additives are commonly found—has risen globally. Emulsifiers are detergent-like substances added to food products to enhance texture, stability, and shelf life. However, emerging evidence suggests that these additives may negatively affect gut health, potentially contributing to various GI-related diseases. ### Key Findings on Emulsifiers and GI Health: 1. **Preclinical Evidence:** - **Disruption of the Intestinal Barrier:** Studies in vitro (in a lab setting) and in animal models have shown that emulsifiers can thin the protective mucus layer in the gut, alter the tight junction proteins that maintain the integrity of the intestinal barrier, and reduce microbial diversity. - **Gut Microbiota Alterations:** Emulsifiers, particularly carboxymethylcellulose (CMC) and polysorbate 80, have been shown to disrupt the gut microbiota. These changes can lead to increased bacterial translocation (movement of bacteria from the gut into other parts of the body) and activation of pro-inflammatory pathways. - **Inflammatory Responses:** In genetically susceptible mice, these emulsifiers have been linked to colitis (inflammation of the colon), while in healthy animal models, they have been associated with metabolic inflammation. - **Role of Germ-Free Conditions:** The negative effects of emulsifiers appear to be mediated by changes in the gut microbiota, as these effects are not observed in germ-free animals (those lacking gut microbes). 2. **Human Studies:** - **Limited but Context-Dependent Data:** Research in humans is less extensive, but findings suggest that high-emulsifier diets may increase intestinal permeability, particularly under stress, and elevate inflammatory biomarkers. - **Crohn’s Disease Insights:** In individuals with Crohn’s disease, the effects of emulsifiers have been mixed. While some short-term studies show no significant impact, emerging trials suggest that low-emulsifier diets may improve remission rates in those with mild-to-moderate Crohn’s disease. - **Potential for Personalized Impact:** The effects of emulsifiers on GI health may vary depending on individual susceptibility, such as genetic predisposition or pre-existing gut conditions. 3. **Broader Implications:** - The rising consumption of ultraprocessed foods, which often contain emulsifiers, has coincided with an increase in GI-related diseases, including inflammatory bowel disease (IBD), functional GI disorders, and even GI cancers. - While evidence is not yet strong enough to warrant broad policy changes regarding emulsifier use, reducing the intake of ultraprocessed foods may be a prudent approach, particularly for individuals at higher risk of gut-related health issues. ### Conclusion: Although human evidence remains limited, preclinical studies suggest that dietary emulsifiers can negatively impact gut health by disrupting the intestinal barrier, altering gut microbiota, and promoting inflammation. For individuals with conditions like Crohn’s disease or those genetically predisposed to gut disorders, reducing emulsifier intake may be beneficial. Overall, minimizing the consumption of ultraprocessed foods, which are rich in emulsifiers, may support better GI health. Further research, particularly large-scale human studies, is needed to clarify the long-term effects of emulsifiers and their role in gut-related diseases.

Cost-effectiveness of Lynch Syndrome Screening in Colorectal Cancer

The study you are referring to evaluates the cost-effectiveness of different Lynch syndrome (LS) screening strategies in patients newly diagnosed with colorectal cancer (CRC). Lynch syndrome is a hereditary cancer syndrome that significantly increases the risk of colorectal and other cancers. Timely and accurate identification of LS is critical for both the patient and their at-risk family members, as it enables targeted screening, prevention, and treatment strategies. Below is a detailed breakdown of the study's findings regarding the cost-effectiveness of LS screening approaches: --- ### **1. Study Objective:** The study aimed to assess the cost-effectiveness of three strategies for identifying LS in CRC patients while addressing the issue of diagnostic attrition in real-world multistep testing pathways. Diagnostic attrition refers to the loss of patients at various stages of the testing process, which reduces the effectiveness of LS identification. --- ### **2. Screening Strategies Evaluated:** The study compared three different approaches: - **Current Standard-of-Care Sequential Tumor-Based Screening:** This involves a multistep process starting with tumor-based tests (e.g., microsatellite instability [MSI] testing or immunohistochemistry [IHC]) followed by confirmatory germline testing if the tumor-based results indicate a high likelihood of LS. - **Optimized Sequential Screening (CLEAR-LS Intervention):** This strategy incorporates a systems-based intervention to improve compliance and reduce diagnostic attrition in the sequential testing process. The intervention ensures more patients complete the necessary steps in the testing pathway. - **Upfront Universal Germline Testing:** This approach involves offering germline genetic testing to all newly diagnosed CRC patients, bypassing tumor-based screening entirely. --- ### **3. Methodology:** The study used a **lifetime decision-analytic model** with nested Markov cohorts to simulate the long-term costs and health outcomes of these strategies. It integrated data from multiple sources, including: - The **Prospective Lynch Syndrome Database** for clinical outcomes. - The **SEER (Surveillance, Epidemiology, and End Results) program** for population-level cancer statistics. - Data from pre- and post-intervention cohorts to evaluate the impact of the CLEAR-LS intervention. The analysis was conducted from the perspective of the U.S. healthcare system, considering lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). --- ### **4. Key Findings:** #### **a) Health Outcomes (QALYs):** - The **current standard-of-care** accrued the fewest QALYs due to high rates of diagnostic attrition and incomplete testing. - The **CLEAR-LS intervention** modestly increased QALYs by improving compliance with sequential testing. - **Upfront universal germline testing** yielded the highest QALYs, as it eliminates diagnostic attrition and ensures all patients are tested for LS. #### **b) Cost-Effectiveness (ICERs):** - The CLEAR-LS intervention was cost-effective, with a **favorable ICER** well within commonly accepted willingness-to-pay (WTP) thresholds (e.g., $50,000–$100,000 per QALY in the U.S.). - Upfront universal germline testing was also cost-effective, particularly when **cascade testing** of family members was included. Cascade testing refers to offering genetic testing to family members of individuals diagnosed with LS, which can prevent cancers in at-risk relatives. #### **c) Compliance and Attrition:** - Sequential testing was only cost-effective if compliance with genetic testing exceeded approximately **75%**, a level rarely achieved in real-world settings without structured system-level interventions like CLEAR-LS. - Universal germline testing was preferred when diagnostic attrition was high or when cascade testing was feasible. --- ### **5. Implications for Practice:** The study highlights that the current standard-of-care for LS screening is economically inefficient and leads to suboptimal health outcomes. To improve LS detection and population health outcomes, the following strategies should be considered: - **Systematic Interventions (e.g., CLEAR-LS):** Structured, system-level interventions can significantly improve compliance with sequential testing pathways, reducing diagnostic attrition and increasing cost-effectiveness. - **Universal Germline Testing:** Offering upfront germline testing to all CRC patients is an effective and cost-efficient strategy, particularly when combined with cascade testing of family members. - **Screening Beyond Age 50:** The findings suggest that LS screening should be considered even for CRC patients diagnosed after age 50, as this can still yield significant health benefits. --- ### **6. Sensitivity and Threshold Analyses:** The study conducted sensitivity analyses to test the robustness of its findings. Key results include: - Sequential testing becomes cost-effective only if compliance exceeds 75%. - Universal germline testing remains cost-effective in scenarios with high diagnostic attrition or when cascade testing is performed. --- ### **7. Conclusion:** The study concludes that the current standard-of-care for LS screening in CRC patients is suboptimal. To improve health outcomes and cost-effectiveness, healthcare systems should adopt either: - Systematic interventions like CLEAR-LS to enhance compliance with sequential testing, or - Universal germline testing for all CRC patients, especially when diagnostic attrition is high or cascade testing can be implemented. These strategies not only improve the detection of LS but also have the potential to prevent cancers in at-risk family members, enhancing population health outcomes.

Peyer’s Patch B Cells Drive Celiac Disease Autoimmunity

Yes, Peyer’s patch B cells play a critical role in driving celiac disease autoimmunity. Here is a detailed explanation based on the context provided: ### 1. **Role of Peyer’s Patches in Celiac Disease:** - Peyer’s patches are specialized lymphoid tissues located in the small intestine, acting as primary inductive sites for intestinal immune responses. - In celiac disease, Peyer’s patches are pivotal in initiating and sustaining the autoimmune response, particularly the production of disease-specific antibodies. ### 2. **TG2-Specific B Cells in Peyer’s Patches:** - TG2-specific B cells, which recognize and bind to transglutaminase 2 (TG2), are found in Peyer’s patches and gut-draining mesenteric lymph nodes. - These B cells are not tolerized (i.e., they are not rendered inactive or deleted), which allows them to contribute to the autoimmune process in celiac disease. ### 3. **Central T–B Cell Crosstalk:** - The pathogenesis of celiac disease depends on the interaction between gluten-specific CD4⁺ T cells and TG2-specific B cells. - TG2-specific B cells present gluten peptides to gluten-specific T cells, receiving help in the form of activation signals. This T–B cell cooperation is essential for the production of anti-TG2 autoantibodies. ### 4. **Antigen Sampling and Uptake:** - TG2-specific B cells in Peyer’s patches localize in the subepithelial dome (SED), where they directly sample antigens (gluten and TG2) from the gut lumen. - These B cells use their B-cell receptor (BCR) to take up TG2 directly, but this uptake is highly specific—it requires catalytically active TG2 and a matching TG2-specific BCR. ### 5. **Amplification of Autoimmune Responses:** - Increased levels of luminal TG2, potentially due to conditions like infections or heightened epithelial turnover, may amplify gluten-specific T-cell responses during active disease. - This amplification mechanism highlights the significance of Peyer’s patch B cells in perpetuating the immune response in celiac disease. ### 6. **Germinal Center and Extrafollicular Phenotypes:** - Activated TG2-specific B cells in Peyer’s patches display germinal center and extrafollicular phenotypes, indicating their involvement in both long-term antibody production and rapid immune responses. ### 7. **Therapeutic Implications:** - Given the central role of TG2-specific B cells in Peyer’s patches, targeting these cells or blocking TG2 activity could serve as a potential therapeutic strategy for celiac disease. - Approaches such as inhibiting TG2 enzymatic activity, disrupting T–B cell interactions, or depleting autoreactive B cells are being explored as treatments. ### Conclusion: Peyer’s patch B cells are key drivers of celiac disease autoimmunity through their ability to recognize TG2, interact with gluten-specific T cells, and produce disease-specific autoantibodies. These findings underscore the importance of Peyer’s patches as critical sites for the initiation and propagation of the autoimmune response in celiac disease.

Targeting Irritable Bowel Syndrome Through Diet and Mechanism-Based Therapies: A Pathophysiological Approach

The approach to targeting Irritable Bowel Syndrome (IBS) through diet and mechanism-based therapies emphasizes addressing the underlying pathophysiological mechanisms rather than merely managing symptoms. IBS is recognized as a heterogeneous functional gastrointestinal disorder with multiple interacting biological processes contributing to its manifestation. These include dysregulation of serotonergic signaling, gut microbiome imbalances, immune system activation, impaired intestinal barrier function, bile acid malabsorption, and disruptions in the gut–brain axis. These mechanisms collectively lead to symptoms such as altered bowel habits, visceral hypersensitivity, abdominal pain, and motility disturbances. ### Pathophysiological Approach to IBS Management: 1. **Dietary Interventions:** - **Low-FODMAP Diet:** The low-FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet is a well-researched intervention that reduces luminal triggers like gas production and water retention caused by poorly absorbed fermentable carbohydrates. This diet can alleviate symptoms such as bloating, diarrhea, and abdominal discomfort, especially when tailored to individual patient needs. - **Mediterranean Low-FODMAP Diet:** Combining the principles of the Mediterranean diet with low-FODMAP strategies offers additional benefits, including anti-inflammatory effects and improved overall gut health. - **Personalization of Diet:** Individualized dietary plans are critical, as different IBS subtypes (e.g., IBS-D for diarrhea-predominant, IBS-C for constipation-predominant, and IBS-M for mixed) may respond differently to dietary modifications. 2. **Gut Microbiota Modulation:** - **Probiotics and Psychobiotics:** Probiotics (beneficial live microorganisms) and psychobiotics (probiotics with mental health benefits) can help restore microbial balance, reduce inflammation, and improve gut–brain communication. - **Prebiotics:** Prebiotics (non-digestible food ingredients that promote the growth of beneficial gut bacteria) can enhance microbiota diversity and support gut health. - **Emerging Microbiota-Directed Therapies:** These include fecal microbiota transplantation (FMT) and precision probiotics tailored to individual microbiome profiles, which show promise in restoring gut microbial equilibrium. 3. **Vitamin D Supplementation:** - Vitamin D plays a role in immune regulation, maintaining epithelial barrier integrity, and modulating serotonergic pathways. Supplementation may support overall gut health and reduce IBS symptoms, particularly in individuals with vitamin D deficiency. 4. **Pharmacological Mechanism-Based Therapies:** - **Serotonergic Receptor Modulators:** These drugs target serotonin receptors to regulate gut motility and sensitivity, addressing symptoms like diarrhea, constipation, and pain. - **Bile Acid–Directed Therapies:** These therapies manage bile acid malabsorption, which is a common contributor to diarrhea in IBS-D. - **Neuroimmune Agents:** These target the neuroimmune interactions contributing to visceral hypersensitivity and inflammation, providing relief from abdominal pain and discomfort. 5. **Gut–Brain Axis Therapies:** - IBS is closely linked to disturbances in the gut–brain axis, which involves bidirectional communication between the gut and the central nervous system. Addressing this axis through stress management, cognitive behavioral therapy (CBT), and psychobiotics can significantly improve symptoms. ### Key Takeaways: - IBS is not a single-disease entity but a complex disorder with multiple overlapping mechanisms. Therefore, a one-size-fits-all approach is inadequate. - Mechanism-based therapies aim to target the specific biological processes contributing to IBS symptoms, offering a more rational and durable approach to treatment. - Dietary interventions, microbiota modulation, vitamin D supplementation, and targeted pharmacological therapies can be integrated into a personalized management plan. - The shift toward individualized and multidisciplinary approaches enables better symptom control, improved quality of life, and long-term outcomes for IBS patients. This pathophysiological and mechanism-based approach represents a paradigm shift in IBS management, focusing on the root causes of the disorder rather than just alleviating its symptoms.

Diagnostic accuracy of biomarkers for irritable bowel syndrome: a systematic review and meta-analysis

The systematic review and meta-analysis you are inquiring about focuses on evaluating the diagnostic accuracy of emerging biomarkers for irritable bowel syndrome (IBS). IBS is a common gastrointestinal disorder that has traditionally been diagnosed based on clinical symptoms and by excluding organic diseases. However, this approach often lacks diagnostic certainty and may lead to unnecessary investigations. The study aimed to determine whether objective biomarkers could reliably differentiate IBS from healthy individuals and other gastrointestinal disorders, thereby improving diagnostic confidence and streamlining the diagnostic process. ### Key Highlights of the Study: #### 1. **Comprehensive Literature Search and Study Inclusion:** - The authors conducted an extensive search across multiple databases to identify studies that assessed biomarker-based diagnostic tests for IBS. - They applied rigorous inclusion criteria to select eligible studies, ensuring that only high-quality research was included. - Methodological quality and risk of bias in the included studies were assessed using validated tools, ensuring the reliability of the meta-analysis. #### 2. **Types of Biomarkers Assessed:** The review identified several promising biomarkers for IBS diagnosis, including: - **Urinary Metabolic Markers:** These showed consistently high diagnostic accuracy across multiple studies. They are non-invasive and have potential as reliable tools for IBS diagnosis. - **Fecal Peptidase Activity:** This biomarker demonstrated balanced sensitivity and specificity, making it a promising candidate for distinguishing IBS from other conditions. - **RAID-IBS (a composite biomarker panel):** This also showed strong diagnostic performance, with the ability to differentiate IBS from other gastrointestinal disorders. #### 3. **Diagnostic Performance and Comparator Groups:** - The diagnostic accuracy of biomarkers varied depending on the comparator group: - When IBS was compared to **inflammatory bowel disease (IBD)**, the biomarkers demonstrated particularly strong discrimination. This highlights their potential utility in differentiating functional gastrointestinal disorders (like IBS) from inflammatory conditions (like IBD). - However, the accuracy was less pronounced when IBS was compared to other functional gastrointestinal disorders, indicating that additional refinement may be needed for these scenarios. #### 4. **Statistical Analysis:** - Advanced hierarchical models were used to synthesize data and provide robust pooled estimates of diagnostic performance. - Sensitivity and specificity were reported for each biomarker, offering insights into their ability to correctly identify IBS patients and exclude non-IBS cases. #### 5. **Clinical Implications:** - The findings suggest that certain biomarkers, particularly urinary metabolic markers, fecal peptidase activity, and RAID-IBS, hold strong potential for supporting IBS diagnosis in clinical practice. - These biomarkers could reduce the need for invasive or unnecessary testing by providing objective diagnostic evidence, thereby improving the overall diagnostic process for IBS. #### 6. **Limitations and Future Directions:** - While promising, the authors emphasize the need for further large-scale, well-designed studies to validate these biomarkers. - Standardization of testing methods and protocols is crucial to ensure consistent and reproducible results across different clinical settings. - The role of these biomarkers alongside established clinical diagnostic criteria (e.g., Rome IV criteria) needs to be clarified, as biomarkers are unlikely to replace clinical evaluation but could serve as complementary tools. ### Conclusion: The systematic review and meta-analysis provide compelling evidence that certain biomarkers, particularly urinary metabolic markers, fecal peptidase activity, and RAID-IBS, show strong diagnostic accuracy for IBS. These biomarkers have the potential to improve diagnostic confidence, reduce unnecessary investigations, and facilitate differentiation between IBS and other gastrointestinal disorders, especially inflammatory conditions like IBD. However, further research is necessary to validate these findings, standardize biomarker testing, and integrate these tools into clinical practice effectively.

Editorial: Diverticulitis – A neglected disease despite its clinical burden

The editorial titled "Diverticulitis – A neglected disease despite its clinical burden" sheds light on diverticulitis as a significant yet underappreciated gastrointestinal condition that imposes a substantial burden on both patients and healthcare systems. Despite its high prevalence and the frequent hospitalizations it causes, diverticular disease (DD) has not received adequate attention in research, particularly in terms of understanding its underlying mechanisms and developing optimal management strategies. ### Key Highlights of the Editorial: 1. **Spectrum of Disease and Pathophysiology**: - Diverticulosis and its symptomatic forms, such as symptomatic uncomplicated diverticular disease (SUDD) and acute diverticulitis, represent a spectrum of conditions with complex and poorly understood pathophysiology. - While diverticulosis itself is often asymptomatic, the transition to symptomatic forms remains poorly understood. Factors such as low-grade inflammation, gut microbiota imbalances, and altered bile acid metabolism are believed to contribute to symptom generation and disease progression. 2. **Contributing Factors**: - Both genetic predisposition and lifestyle factors, particularly those associated with Western societies (e.g., low-fiber diets, sedentary lifestyles), play a role in disease development. - However, the precise mechanisms that lead to the progression from asymptomatic diverticulosis to symptomatic disease remain elusive. 3. **Emerging Research and Insights**: - Recent studies have provided new insights into the mechanisms of diverticular disease: - Altered fecal bile acid handling may contribute to inflammation and symptoms in SUDD. - Post-biotic therapies, such as sodium butyrate, show promise in restoring gut microbiota balance, enhancing mucosal function, and alleviating abdominal pain. This suggests a shift toward more targeted, mechanism-based treatments rather than purely symptomatic relief. 4. **Management of Acute and Complicated Diverticulitis**: - Advances in the management of acute diverticulitis, especially complicated cases, are discussed. - The editorial highlights the importance of surgical decision-making, particularly for specific phenotypes like fistulating diverticulitis. These cases may share pathological features with Crohn’s disease and might require revised surgical strategies. - Rare forms of diverticulitis, such as jejunal diverticulitis, are identified as diagnostic challenges that often necessitate surgical intervention. 5. **Call for Greater Awareness and Research**: - The editorial emphasizes the need for increased clinical awareness of diverticulitis and its various manifestations. - Improved phenotyping and expanded research efforts are crucial to better understand the disease and develop personalized management strategies. - The authors advocate for a more mechanistic approach to therapy, moving away from a one-size-fits-all model to address the specific needs of individual patients. ### Conclusion: The editorial calls for a paradigm shift in how diverticulitis is perceived and managed. Despite its significant clinical and healthcare burden, diverticulitis remains a neglected disease in terms of research and clinical focus. Greater awareness, deeper understanding of its pathophysiology, and the development of personalized treatment approaches are essential steps toward improving outcomes for patients with this often-overlooked condition.

mt-sDNA is supior tool for CRC screening

Yes, multitarget stool DNA (mt-sDNA) is considered a superior tool for colorectal cancer (CRC) screening, especially for younger adults under 50, based on the findings of the study outlined in the context. Here's why mt-sDNA is superior: 1. **Higher Follow-Up Colonoscopy Adherence**: - Among individuals aged 45–49 with a positive stool-based test, follow-up colonoscopy (FU-CY) adherence within 12 months was significantly higher for mt-sDNA users (85.0%) compared to fecal immunochemical test/occult blood test (FIT/FOBT) users (35.2%). This indicates that mt-sDNA testing leads to better compliance with recommended follow-up procedures. 2. **Faster Follow-Up Timeliness**: - The mean time to colonoscopy after a positive test was shorter for mt-sDNA users (74.5 days) compared to FIT/FOBT users (90.8 days). This faster follow-up is crucial for timely detection and prevention of colorectal cancer progression. 3. **Benchmark Achievement**: - mt-sDNA users exceeded the US Multi-Society Task Force’s benchmark of 80% adherence for post-screening colonoscopy completion, demonstrating its effectiveness in ensuring adherence to screening protocols. 4. **Early Follow-Up Rates**: - Within the first 90 days after testing, a significantly higher percentage of mt-sDNA users (62.9%) completed their follow-up colonoscopy compared to FIT/FOBT users (22.8%). Early follow-up is critical for detecting early-onset colorectal cancer and improving outcomes. 5. **Target Population**: - The study specifically focused on adults aged 45–49, a group increasingly recognized for its risk of early-onset colorectal cancer. mt-sDNA testing proved to be a more effective screening tool for this younger population. 6. **Study Scale and Robustness**: - The findings are backed by robust data from the Komodo Research Data (KRD) database and Exact Sciences Laboratory (ESL), which together cover over 165 million lives. This large claims-based dataset adds credibility to the study's conclusions. In summary, mt-sDNA testing outperforms FIT/FOBT in terms of follow-up adherence, timeliness, and overall effectiveness as a screening tool for colorectal cancer prevention in younger adults. Its ability to ensure timely and consistent follow-up after a positive test makes it a superior choice for CRC screening, particularly for individuals under 50.

Why immunotherpay often fails in CRC

Colorectal cancer (CRC) is one of the most common types of cancer worldwide, and its treatment often involves surgery, chemotherapy, and radiation therapy. However, metastatic colorectal cancer (advanced-stage cancer that spreads to other parts of the body) is particularly challenging to treat, especially with immunotherapy, which has shown limited success in this type of cancer. Immunotherapy is a type of cancer treatment that empowers the immune system to recognize and attack cancer cells. Despite its success in other cancers, colorectal cancer has developed mechanisms to evade immune system attacks, making immunotherapy less effective. ### Why Immunotherapy Often Fails in Colorectal Cancer: Colorectal cancer employs two major defense mechanisms to avoid immunotherapy, both controlled by the hormone TGF-β (Transforming Growth Factor Beta): 1. **Blocking T-cell Entry to the Tumor:** - T cells are immune cells responsible for identifying and killing cancer cells. - Colorectal cancer creates a barrier that prevents enough T cells from reaching the tumor through the bloodstream. This is akin to putting up a "no entry" sign at the tumor site, effectively isolating the tumor from immune system attacks. 2. **Weakening T-cell Function Inside the Tumor:** - For the few T cells that do manage to enter the tumor, colorectal cancer manipulates nearby macrophages (another type of immune cell) to release a protein called **osteopontin**. - Osteopontin suppresses T-cell growth and weakens their ability to attack the cancer cells, creating a hostile environment that neutralizes the immune system's efforts. These two barriers, both regulated by TGF-β, make colorectal cancer particularly resistant to immunotherapy. As a result, standard immunotherapy approaches like immune checkpoint inhibitors (e.g., PD-1/PD-L1 blockers) often fail in metastatic colorectal cancer. ### Promising Research and Solutions: Recent studies have identified potential strategies to overcome these barriers and make immunotherapy more effective for colorectal cancer patients: 1. **Blocking TGF-β:** - Researchers have found that inhibiting TGF-β can help dismantle the tumor's defenses. Blocking TGF-β allows immune cells, especially T cells, to infiltrate the tumor and resume their attack on cancer cells. - TGF-β inhibitors are currently being studied as potential adjuncts to immunotherapy. 2. **Targeting Osteopontin:** - Another approach is to block the downstream effects of TGF-β, such as the production of osteopontin. By preventing osteopontin from suppressing T-cell growth, researchers aim to restore the immune system's ability to fight colorectal cancer. 3. **Combination Therapies:** - Combining TGF-β blockers or osteopontin inhibitors with standard immunotherapy (like checkpoint inhibitors) has shown promising results in preclinical studies. This dual approach helps immune cells infiltrate the tumor and remain active against cancer cells. ### Future Outlook: The combination of TGF-β inhibitors or osteopontin blockers with immunotherapy could represent a breakthrough in the treatment of metastatic colorectal cancer. Researchers believe that these advancements could significantly improve outcomes for patients who currently have few effective treatment options. Clinical trials are underway to test these combinations and determine their safety and efficacy. In summary, while colorectal cancer has developed sophisticated mechanisms to evade immunotherapy, targeting TGF-β and its downstream effects offers a promising path forward. These innovative strategies could potentially redefine the way metastatic colorectal cancer is treated in the future, offering hope to many patients.

Salmonella Paratyphi A Vaccine

The study you are asking about focuses on the development and testing of a promising oral live attenuated vaccine, named CVD 1902, specifically designed to prevent Salmonella Paratyphi A infections. Here's a detailed summary of the study and its findings: ### Overview of the Study: 1. **Disease Burden**: Salmonella Paratyphi A causes over 2 million cases of enteric fever annually worldwide. Despite the high disease burden, there is currently no licensed vaccine available to prevent infections caused by this specific pathogen, unlike Salmonella Typhi for which vaccines exist. 2. **Study Design**: This was a double-blind, randomized, placebo-controlled trial using a controlled human infection model to evaluate the efficacy and safety of the CVD 1902 vaccine. 3. **Participants**: The study enrolled 72 healthy adults (median age of 32 years, range 20–54) from the UK, with 46% of participants being women. 4. **Vaccination Protocol**: Participants were randomly assigned in a 1:1 ratio to receive two oral doses of the CVD 1902 vaccine or a placebo, administered 14 days apart. 5. **Challenge Phase**: To test the vaccine's protective efficacy, all participants were orally challenged with Salmonella Paratyphi A 28 days after receiving the second dose of the vaccine or placebo. 6. **Primary Endpoint**: The main outcome measured was the rate of infection with Salmonella Paratyphi A within 14 days following the challenge. ### Key Findings: 1. **Safety Profile**: The vaccine was well-tolerated, with similar adverse event rates between the vaccine and placebo groups. No serious vaccine-related side effects were reported, confirming that the vaccine has a favorable safety profile. 2. **Immunogenic Response**: The CVD 1902 vaccine induced strong serum IgG and IgA antibody responses targeting the O antigen of Salmonella Paratyphi A, whereas the placebo group showed no such immune response. 3. **Vaccine Efficacy**: - The vaccine demonstrated **73% efficacy** (95% CI, 46–86) in the intention-to-treat analysis. - It showed **69% efficacy** (95% CI, 42–84) in the per-protocol analysis. - Both analyses showed statistically significant results (P < 0.001), indicating robust protection against infection. 4. **Conclusion**: A two-dose regimen of the CVD 1902 vaccine provided significant protection against Salmonella Paratyphi A infection in healthy adults without raising safety concerns. These findings suggest that the vaccine holds promise for further development and eventual use in populations at risk. --- ### Why is a Salmonella Paratyphi A Vaccine Needed? While vaccines for Salmonella Typhi (such as Typhoid vaccines) are available and effective, they do *not* protect against Salmonella Paratyphi A. These are two distinct pathogens, both causing enteric fever but differing in their biology and immune response. Salmonella Typhi vaccines target the Typhi strain specifically, leaving individuals vulnerable to Paratyphi A infections, which account for a significant proportion of enteric fever cases in many regions, particularly in South Asia and other endemic areas. Given the high disease burden associated with Salmonella Paratyphi A and the absence of a preventive vaccine, developing a vaccine like CVD 1902 is critical to reducing the global impact of enteric fever.

Diverticulitis

Diverticulitis is a medical condition characterized by the inflammation or infection of small, bulging pouches (diverticula) that can form in the lining of the digestive system, most commonly in the colon. It is a more serious condition compared to diverticulosis, which refers to the presence of these pouches without inflammation or symptoms. Below is a comprehensive explanation of diverticulitis, derived from the provided context: --- ### **Definition and Overview** - **Diverticulosis**: The condition where multiple small pouches (diverticula) form in the lining of the intestine, typically in the colon. It is often asymptomatic. - **Diverticulitis**: The inflammation or infection of these diverticula, which can cause significant symptoms and complications. --- ### **Prevalence** - **Annual Incidence**: In the U.S., the annual incidence of diverticulitis is approximately 180 cases per 100,000 people. - **Healthcare Impact**: Diverticulitis accounts for around 200,000 hospitalizations yearly in the U.S., with an estimated financial burden of $6.3 billion in healthcare costs. --- ### **Risk Factors** 1. **Age**: More common in individuals over 65 years old. 2. **Genetics**: Variants in the *TNFSF15* gene are associated with increased risk. 3. **Connective Tissue Disorders**: Conditions like Marfan syndrome and Ehlers-Danlos syndrome increase susceptibility. 4. **Obesity**: A body mass index (BMI) of 30 or higher is a significant risk factor. 5. **Medications**: Use of opioids, steroids, and nonsteroidal anti-inflammatory drugs (NSAIDs). 6. **Chronic Diseases**: Hypertension and type 2 diabetes are associated with a higher risk. --- ### **Progression from Diverticulosis to Diverticulitis** - Only **1–4%** of individuals with diverticulosis develop acute diverticulitis in their lifetime. - **Symptoms of Diverticulitis**: - Left lower quadrant abdominal pain - Fever - Nausea and vomiting - Leukocytosis (elevated white blood cell count) --- ### **Diagnosis** - **Preferred Diagnostic Tool**: A contrast-enhanced abdominal and pelvic CT scan is the gold standard for diagnosing diverticulitis. - Sensitivity: 98–99% - Specificity: 99–100% --- ### **Types of Diverticulitis** 1. **Uncomplicated Diverticulitis**: - Accounts for approximately **85% of cases**. - Defined by the absence of complications such as abscess, perforation, fistula, or obstruction. 2. **Complicated Diverticulitis**: - Involves complications like abscess formation, perforation, fistulas, or intestinal obstruction. - Requires more intensive treatment, including possible surgical intervention. --- ### **Management of Uncomplicated Diverticulitis** 1. **Initial Treatment**: - Observation and monitoring. - Pain control using **acetaminophen**. - A **clear liquid diet** to allow the bowel to rest. 2. **Antibiotic Use**: - Antibiotics are not routinely required unless systemic symptoms develop. - Criteria for antibiotic use include: - Fever and chills - Elevated white blood cell count - Age over 80 years - Pregnancy - Immunocompromised state - Chronic diseases such as chronic kidney disease (CKD), cirrhosis, or heart failure. 3. **Oral Antibiotic Regimens**: - **Amoxicillin/clavulanic acid**. - **Cefalexin** plus **metronidazole**. 4. **Intravenous (IV) Antibiotic Regimens** (if oral intake is not possible): - **Cefuroxime** or **ceftriaxone** plus **metronidazole**. - **Ampicillin/sulbactam**. --- ### **Management of Complicated Diverticulitis** 1. **IV Antibiotics**: - **Ceftriaxone** plus **metronidazole**. - **Piperacillin-tazobactam**. 2. **Procedures**: - **Percutaneous Abscess Drainage**: For localized abscesses. - **Colon Resection Surgery**: - **Elective Surgery**: Performed in stable patients. - **Emergent Surgery**: Required for severe cases with generalized peritonitis. --- ### **Surgical Intervention and Mortality** - **Emergent Surgery**: Laparotomy with colonic resection is indicated for generalized peritonitis. - Postoperative mortality is **10.6%** for emergent surgeries. - **Elective Surgery**: Associated with a much lower postoperative mortality rate of **0.5%**. --- ### **Key Takeaways (20 Points)** 1. Diverticulosis is the presence of small pouches in the colon, while diverticulitis is their inflammation or infection. 2. Diverticulitis affects around 180 per 100,000 people annually in the U.S. 3. Diverticulitis leads to approximately 200,000 hospitalizations and $6.3 billion in healthcare costs each year. 4. Only 1–4% of people with diverticulosis progress to diverticulitis in their lifetime. 5. Risk increases with age, especially in those over 65 years. 6. Genetic factors, particularly the *TNFSF15* gene, may predispose individuals to diverticulitis. 7. Connective tissue disorders, such as Marfan syndrome and Ehlers-Danlos syndrome, increase risk. 8. Obesity (BMI ≥30) is a significant risk factor. 9. Medications like opioids, steroids, and NSAIDs are associated with a higher risk. 10. Chronic conditions like hypertension and type 2 diabetes increase susceptibility. 11. Symptoms of diverticulitis include left lower quadrant pain, fever, nausea, vomiting, and elevated WBC. 12. A contrast-enhanced CT scan is the preferred diagnostic tool, with near-perfect sensitivity and specificity. 13. 85% of diverticulitis cases are uncomplicated, meaning they lack severe complications. 14. Uncomplicated diverticulitis is managed with observation, pain control, and a clear liquid diet. 15. Antibiotics are not routinely required for uncomplicated cases unless systemic symptoms are present. 16. Antibiotics are indicated for patients with fever, elevated WBC, advanced age, pregnancy, immunosuppression, or chronic diseases. 17. Oral antibiotics include amoxicillin/clavulanic acid or cefalexin plus metronidazole. 18. IV antibiotics include cefuroxime or ceftriaxone plus metronidazole, or ampicillin/sulbactam. 19. Complicated diverticulitis may require IV antibiotics, percutaneous abscess drainage, or colon resection surgery. 20. Postoperative mortality is 0.5% for elective surgeries and 10.6% for emergent surgeries. --- ### **Conclusion** Diverticulitis is a potentially serious condition that requires prompt diagnosis and appropriate management. While most cases are uncomplicated and can be managed conservatively, complicated cases may require surgical intervention. Early recognition of symptoms and risk factors is crucial to prevent progression and complications.

Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis - NEJM Publication

The study on intravenous (IV) rehydration for severe acute malnutrition (SAM) with gastroenteritis was published in the *New England Journal of Medicine (NEJM)* and provides critical insights into the management of severely malnourished children with dehydration. Below is a detailed summary of the trial findings and their implications: ### Study Aim: The trial aimed to evaluate whether IV rehydration improves survival outcomes in children with SAM and gastroenteritis compared to oral rehydration therapy (ORT), challenging the longstanding concerns and restrictions against IV fluids in such cases. ### Background and Concerns: - According to current World Health Organization (WHO) guidelines, IV fluids are discouraged for children with SAM due to fears of cardiac failure and fluid overload. - However, these concerns are not strongly evidence-based, and this study sought to rigorously test the efficacy and safety of IV rehydration in this vulnerable population. ### Study Design: - **Type:** Factorial, open-label, randomized superiority trial. - **Locations:** Conducted in six hospitals across Uganda, Kenya, Niger, and Nigeria. - **Participants:** 272 children aged 6 months to 12 years diagnosed with SAM, gastroenteritis, and dehydration. - **Groups:** Participants were randomized into three groups: 1. **Oral Rehydration:** Received oral rehydration solution (ORS) via nasogastric tubes as needed. 2. **Rapid IV Rehydration:** Received lactated Ringer’s solution (100 mL/kg) over 3–6 hours. 3. **Slow IV Rehydration:** Received lactated Ringer’s solution (100 mL/kg) over 8 hours. ### Primary Outcome: - Mortality at 96 hours was the primary endpoint. ### Secondary Outcomes: - 28-day mortality. - Physiological responses, including electrolyte normalization, weight gain, hydration improvement, and adverse events. ### Key Findings: 1. **Mortality Outcomes:** - **96-hour mortality:** 8% in the oral group and 7% in the pooled IV groups — no significant survival difference (Relative Risk [RR]: 1.02; 95% CI: 0.41–2.52). - **28-day mortality:** Similar rates between oral rehydration (12%) and IV rehydration groups (10%) (Hazard Ratio [HR]: 0.85; 95% CI: 0.41–1.78). 2. **Safety Results:** - No cases of pulmonary edema, heart failure, or fluid overload were observed in any group. - Serious adverse events occurred in 23% of oral rehydration patients, 21% of rapid IV patients, and 15% of slow IV patients — favoring IV treatment slightly. 3. **Electrolyte Balance:** - IV rehydration corrected severe hyponatremia faster (subhazard ratio: 1.55; 95% CI: 1.14–2.09). - Potassium normalization was slower in IV groups compared to oral therapy. 4. **Weight and Hydration Gains:** - By day 3, children in the IV groups gained slightly more weight (+0.1 kg) than those on oral therapy, but this difference disappeared by day 7. 5. **Nasogastric Tube Use:** - 93% of oral rehydration patients required nasogastric tubes versus 65% in IV groups, highlighting practical advantages of IV routes in hospitals with limited staffing. 6. **Shock Management:** - Fewer new cases of shock developed in IV-treated children (5%) compared to oral rehydration patients (9%), indicating better hemodynamic stability. 7. **Baseline Conditions:** - Over 50% of children had severe hyponatremia or hypokalemia, and 38% presented with altered consciousness — reflecting the severity of illness in the study population. 8. **No Cardiac Compromise:** - Physiological monitoring confirmed that malnourished children tolerated IV fluids well, countering WHO concerns about cardiac failure or fluid overload. ### Strengths of the Study: - Strict monitoring, high adherence to protocols, and balanced baseline characteristics enhanced the study's internal validity. - The trial was conducted across multiple sites in sub-Saharan Africa, ensuring real-world applicability. ### Limitations: - The overall mortality rate (11%) was lower than expected, reducing the statistical power to detect smaller differences in survival outcomes. - The study did not compare IV fluids to no rehydration therapy, focusing only on oral versus IV methods. ### Clinical Implications: - The findings challenge long-held restrictions against IV rehydration for malnourished children with gastroenteritis. - IV therapy is demonstrated to be safe and effective, potentially simplifying management in hospitals with limited staff where oral feeding is difficult. - Faster correction of electrolyte imbalances and reduced reliance on nasogastric tubes may make IV rehydration a more practical option in certain clinical settings. ### Core Conclusion: In severely malnourished children with gastroenteritis, IV rehydration (both rapid and slow methods) is as safe and effective as oral therapy. The study provides robust evidence to reconsider WHO guidelines and supports the use of IV fluids in this vulnerable population. This landmark trial is expected to influence global clinical practices and guidelines for managing severe acute malnutrition in children.

Genetic Risk Assessment and Testing for GI Cancers and Polyposis

Genetic risk assessment and testing for gastrointestinal (GI) cancers and polyposis syndromes are critical components of modern clinical practice. They aim to identify individuals and families at increased risk of developing hereditary cancer syndromes, enabling targeted prevention, early detection, and personalized management strategies. Below is a detailed overview addressing genetic risk assessment and testing for GI cancers and polyposis: ### **1. Clinical Importance of Genetic Risk Assessment** Gastrointestinal clinicians play a pivotal role in identifying patients with hereditary cancer syndromes. These syndromes predispose individuals to colorectal, gastric, pancreatic, and other GI cancers. Early identification allows for tailored surveillance, risk-reducing interventions, and improved outcomes. ### **2. Underutilization of Genetic Testing** Despite advancements in sequencing technologies and reduced costs, genetic testing remains underutilized. This results in missed opportunities to identify high-risk individuals and families who could benefit from preventive care. ### **3. Barriers to Genetic Testing Integration** Several barriers limit the integration of genetic testing into routine GI practice: - **Lack of awareness** among healthcare providers and patients. - **Cost concerns** despite decreasing prices of testing. - **Limited access to genetic counseling services** for interpretation and guidance. - **Absence of structured implementation pathways** in healthcare systems. ### **4. Prevalence of Genetic Risk** Approximately **1 in 20 GI patients presenting for endoscopy** meet criteria for genetic evaluation for a cancer susceptibility syndrome. This highlights the importance of systematic risk assessment in GI clinics. ### **5. Common Hereditary Syndromes and Their Management** #### **Lynch Syndrome** - Caused by mutations in mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2, EPCAM). - The most common hereditary colorectal cancer syndrome, affecting **1 in 279 individuals**. - **Screening Recommendations:** Surveillance colonoscopy every 1–3 years starting in early adulthood significantly reduces mortality. Additional screening for gastric and pancreatic cancers may be indicated. - **Chemoprevention:** Daily aspirin use has been shown to reduce colorectal cancer risk by 44% in Lynch syndrome patients. #### **Familial Adenomatous Polyposis (FAP)** - Caused by mutations in the APC gene. - Characterized by hundreds to thousands of adenomas in the colon. - **Screening Recommendations:** Early colonoscopy starting at age 10–15 and eventual colectomy based on polyp burden. #### **MUTYH-Associated Polyposis (MAP)** - Inherited recessively due to mutations in the MUTYH gene. - Presents with fewer adenomas (10–100). - **Screening Recommendations:** Colonoscopy every 1–2 years; surgery may be required for extensive disease. #### **Hamartomatous Polyposis Syndromes** - Includes Juvenile Polyposis Syndrome and Peutz-Jeghers Syndrome. - Associated with elevated risks for colorectal, gastric, pancreatic, and other cancers. - **Screening Recommendations:** Require both colonoscopic and upper GI surveillance. #### **Serrated Polyposis Syndrome** - Defined clinically by multiple serrated lesions. - **Screening Recommendations:** Colonoscopy every 1–3 years. - Most cases lack identifiable germline variants, though RNF43 mutations are occasionally implicated. #### **Gastric Cancer Syndromes** - Mutations in CDH1 and CTNNA1 genes increase risk for diffuse-type gastric cancers. - **Management:** Prophylactic gastrectomy is often recommended but may be replaced by intensive surveillance in select cases. #### **Pancreatic Cancer Risk Genes** - High-risk mutations include STK11, CDKN2A, BRCA1/2, PALB2, and ATM. - **Screening Recommendations:** MRI or endoscopic ultrasound (EUS) annually from ages 45–50, or earlier depending on family history. ### **6. Risk Assessment Process** Comprehensive risk assessment involves: - Collecting a detailed family history, including first- and second-degree relatives. - Tumor-based MMR testing to identify hereditary cancer risk. ### **7. Genetic Testing and Multi-Gene Panel Testing (MGPT)** - **Multi-Gene Panel Testing (MGPT):** MGPT has replaced single-gene testing, improving the detection of germline pathogenic variants. About **10–15% of GI cancer patients** have detectable pathogenic variants. - **Variants of Uncertain Significance (VUS):** Roughly 41% of individuals undergoing MGPT have at least one VUS, most of which are later reclassified as benign. VUS should not alter clinical management. ### **8. Psychological and Ethical Considerations** - Genetic testing rarely causes severe psychological harm but may increase anxiety in patients. - Ethical concerns include ensuring equitable access to testing and protecting patients from insurance discrimination. ### **9. Cascade Testing** - Testing first-degree relatives of affected individuals is essential for identifying hereditary cancer syndromes. - Despite its importance, cascade testing is underused, with only about **52% of eligible relatives undergoing testing**. - Provider-mediated outreach has been shown to improve uptake. ### **10. Emerging Technologies and Future Integration** - **Emerging Technologies:** Artificial intelligence, polygenic risk scores, and long-read sequencing are advancing precision in identifying genetic risk and reclassifying uncertain variants. - **Future Integration:** Genetic testing should become standard practice in GI clinics through mainstreaming, telehealth, and point-of-care models. Every patient should receive family history screening and appropriate genetic referrals. ### **Key Takeaways for Clinicians** 1. **Identify High-Risk Patients:** Use family history and tumor-based testing to assess hereditary cancer risk. 2. **Implement Surveillance Protocols:** Tailor screening for colorectal, gastric, and pancreatic cancers based on genetic syndrome. 3. **Promote Genetic Testing:** Advocate for MGPT to detect germline pathogenic variants and guide management. 4. **Encourage Cascade Testing:** Ensure relatives of affected individuals are tested to identify at-risk family members. 5. **Leverage Emerging Technologies:** Incorporate AI and advanced sequencing tools to enhance precision and efficiency in genetic risk assessment. 6. **Address Barriers:** Work to overcome cost, access, and awareness challenges to integrate genetic testing into routine GI practice. By adopting these strategies, clinicians can optimize care for patients with hereditary GI cancer syndromes, reduce cancer incidence, and improve survival outcomes.

The Exclusion Diet Conundrum and IBS

The exclusion diet conundrum refers to the debate surrounding the effectiveness and validity of using food-specific IgG (FS-IgG) testing to guide dietary eliminations for managing irritable bowel syndrome (IBS). IBS is a chronic gastrointestinal condition characterized by symptoms like abdominal pain, bloating, diarrhea, or constipation. Some studies suggest that removing foods identified by FS-IgG tests might improve symptoms, but this approach is controversial. One major issue is that FS-IgG likely reflects foods people commonly eat rather than indicating a harmful immune response or intolerance. IgG antibodies are also found in healthy individuals without IBS, so their role in causing symptoms is unclear. Additionally, in some cases, symptom improvement may result from coincidentally eliminating high-FODMAP foods (like wheat, lactose, or soy), which are known to trigger IBS symptoms in many people. This raises doubts about whether FS-IgG testing itself is effective. The lack of rigorous controls, reliance on self-reported adherence, and absence of clear mechanisms linking IgG to IBS symptoms further complicate the matter. Overusing IgG testing may lead to unnecessary dietary restrictions, anxiety, or even disordered eating. To resolve this conundrum, future research must focus on well-controlled studies to clarify the role of IgG in IBS and ensure safe, evidence-based dietary recommendations.

Severe Diverticulitis Among Younger Americans

The rise in severe diverticulitis among younger Americans is a concerning trend that reflects significant shifts in the disease's epidemiology. Traditionally associated with older adults, diverticulitis is now increasingly affecting individuals under 50. A large-scale study analyzing 5.2 million hospitalizations from the National Inpatient Sample revealed a 52% relative increase in severe (complicated) cases among younger patients between 2005 and 2020. This shift suggests that the disease may be presenting more aggressively in younger individuals, with a higher likelihood of requiring invasive interventions such as colectomy (29% more likely) or percutaneous drainage (58% more likely) compared to older adults. Despite the growing severity, surgical intervention rates for younger patients have declined significantly (from 34.7% to 20.3%), indicating improved disease management and more conservative treatment approaches. Younger patients also experience better outcomes, including lower mortality rates, shorter hospital stays, and reduced hospitalization costs compared to older individuals. However, the phenotype of the disease appears to differ in younger adults, potentially reflecting a more aggressive presentation or unique clinical management challenges. The underlying causes of this trend remain unclear but may involve lifestyle factors, dietary changes, obesity, and environmental influences. Given the parallel rise in early-onset colorectal cancer, further research is urgently needed to understand and address the drivers of early-onset diverticulitis in this demographic.

Long-Acting GLP-2 Analogue (Glepaglutide) and Short Bowel Syndrome

Glepaglutide is a long-acting GLP-2 (glucagon-like peptide-2) analogue designed to improve intestinal function and absorption in patients with short bowel syndrome (SBS). SBS is a condition characterized by the loss of significant portions of the small intestine, leading to malabsorption and dependency on parenteral support (PS) for nutrition and hydration. ### Mechanism of Action: GLP-2 is a naturally occurring gut hormone that plays a crucial role in intestinal growth, repair, and function. Glepaglutide, as a synthetic analogue, mimics the action of GLP-2, stimulating intestinal adaptation and regeneration. It promotes: 1. **Mucosal Growth**: Glepaglutide enhances the regeneration of the intestinal lining, which improves nutrient absorption and fluid retention. 2. **Blood Flow**: It increases intestinal blood flow, supporting better nutrient delivery and absorption. 3. **Barrier Function**: The drug strengthens the intestinal barrier, reducing the risk of bacterial translocation and infection. 4. **Reduction in Gastric Motility**: Glepaglutide slows intestinal transit time, allowing for better absorption of nutrients and fluids. ### Clinical Benefits in Short Bowel Syndrome: 1. **Reduction in Parenteral Support (PS) Dependency**: - Twice-weekly (TW) dosing of glepaglutide significantly reduces the volume of PS required. Patients on 10 mg TW achieved a mean reduction of −5.13 liters/week compared to −2.85 liters/week in the placebo group, demonstrating a significant treatment difference of −2.28 liters/week (P = 0.0039). - Once-weekly (OW) dosing showed smaller, nonsignificant reductions (−0.91 liters/week; P = 0.27), suggesting TW dosing is more effective. 2. **Clinically Meaningful Reductions**: - 65.7% of TW-treated patients achieved at least a 20% reduction in PS, compared to 38.9% on placebo (P = 0.0243). This indicates substantial improvement in intestinal absorption and functionality. 3. **Improved Autonomy**: - Over half (51.4%) of TW-treated patients were able to reduce their PS frequency by at least one day per week, compared to 19.4% of placebo-treated patients (P = 0.0043). This improvement in autonomy significantly enhances the quality of life. 4. **Complete PS Independence**: - 14% of TW-treated patients achieved enteral autonomy (complete independence from PS), compared to 11% on OW dosing and none in the placebo group. This underscores glepaglutide's potential to restore natural intestinal function. 5. **Sustained Efficacy**: - TW dosing showed early improvements in PS reduction by week 12, which were sustained through week 24. This benefit was consistent across patients with or without colon-in-continuity, indicating broad applicability. 6. **Improved Patient-Reported Outcomes**: - Nearly half (48.6%) of TW-treated patients rated themselves as “much” or “very much improved,” compared to only 5.6% in the placebo group (P < 0.0001). This highlights the drug’s impact on overall quality of life. 7. **Biological Evidence of Intestinal Adaptation**: - Serum citrulline levels, a marker of mucosal growth and intestinal adaptation, increased by 47% with TW dosing versus 19% with OW dosing and 5% with placebo (P = 0.0139). This confirms glepaglutide's ability to enhance mucosal regeneration. ### Safety and Tolerability: Glepaglutide demonstrated a favorable safety profile: - Most adverse events were mild to moderate, including injection site reactions, stoma swelling, and gastrointestinal discomfort. - Serious adverse events were primarily related to PS itself, not the drug. - Anti-drug antibodies were detected in 87% of treated patients but had no impact on efficacy or safety, affirming long-term therapeutic stability. ### Summary: Glepaglutide, as a long-acting GLP-2 analogue, offers significant benefits for patients with SBS by improving intestinal absorption, reducing PS dependency, and enhancing autonomy and quality of life. TW dosing is particularly effective, showing early, sustained, and clinically meaningful improvements. The drug is well-tolerated, with minimal safety concerns, and demonstrates biological evidence of intestinal adaptation. This makes glepaglutide a promising therapeutic option for managing SBS and restoring natural intestinal function.

Ileal Pouch Anal Anastomosis and Pouch Neoplasm

**Ileal Pouch-Anal Anastomosis (IPAA):** Ileal Pouch-Anal Anastomosis (IPAA) is a surgical procedure typically performed to restore bowel continuity after the removal of the colon and rectum. It is most commonly used in patients with **ulcerative colitis (UC)** or **familial adenomatous polyposis (FAP)**. During the procedure, the surgeon creates an internal reservoir (called the ileal pouch) using the terminal ileum, which is then connected to the anus, allowing the patient to maintain anal continence. This surgery eliminates the need for a permanent ileostomy and provides a more normal bowel function. **Conditions Leading to IPAA:** 1. **Ulcerative Colitis (UC):** Chronic inflammation of the colon and rectum that does not respond to medical therapy or leads to complications like dysplasia or cancer. 2. **Familial Adenomatous Polyposis (FAP):** A genetic condition characterized by the development of hundreds to thousands of polyps in the colon and rectum, with a high risk of colorectal cancer. 3. **Colorectal Cancer:** In cases where the cancer is localized and the patient's rectum can be preserved. 4. **Indeterminate Colitis:** In select cases where the disease is primarily limited to the colon and rectum. --- **Pouchitis:** Pouchitis is the most common complication following an IPAA procedure. It refers to inflammation of the ileal pouch, which can lead to various gastrointestinal symptoms. **Symptoms of Pouchitis:** - Increased stool frequency - Urgency - Abdominal cramping - Rectal pain - Fever - Blood or mucus in the stool - Fatigue **Risk Factors for Pouchitis:** - Ulcerative colitis as the underlying disease (higher risk compared to FAP) - Use of NSAIDs - Previous episodes of pouchitis - Dysbiosis (altered gut microbiota) - Genetic predisposition **Management of Pouchitis:** 1. **Acute Pouchitis:** - First-line treatment: **Antibiotics** (e.g., ciprofloxacin or metronidazole). - Supportive care: Hydration, anti-diarrheal agents, and probiotics. 2. **Chronic Pouchitis:** - Long-term antibiotic therapy or rotation of antibiotics. - **Probiotics**: VSL#3 is often used to maintain remission. - **Anti-inflammatory medications:** Budesonide or mesalamine may be considered. - **Biologic therapy:** In severe cases, medications like infliximab (anti-TNF) may be used. 3. **Dietary Modifications:** - Low-fiber diet during flare-ups. - Avoidance of foods that exacerbate symptoms. 4. **Surgical Intervention:** - In rare cases where pouchitis is refractory to medical therapy, surgical removal of the pouch and conversion to a permanent ileostomy may be necessary. --- **Pouch Neoplasm:** Pouch neoplasms refer to the development of malignancies or dysplasia within the ileal pouch. This is a rare but serious complication following IPAA surgery. **Types of Pouch Neoplasms:** 1. **Adenocarcinoma:** Cancer arising from the epithelial lining of the ileal pouch. 2. **Dysplasia:** Precancerous changes in the cells of the pouch lining. 3. **Other rare malignancies:** Such as neuroendocrine tumors. **Risk Factors for Pouch Neoplasms:** - **Familial Adenomatous Polyposis (FAP):** Patients with FAP are at higher risk of developing adenomas and malignancies in the pouch. - **Chronic inflammation:** Persistent pouchitis or cuffitis may increase the risk of neoplastic changes. - **Residual rectal mucosa:** In cases where a rectal cuff is left behind during surgery, dysplasia or cancer may develop in this tissue. - **Long-term use of the pouch:** The risk increases with time post-surgery. **Symptoms of Pouch Neoplasms:** - Rectal bleeding - Change in bowel habits - Unexplained weight loss - Abdominal pain - Persistent pouchitis symptoms that do not respond to treatment **Management of Pouch Neoplasms:** 1. **Diagnosis:** - **Surveillance:** Regular endoscopic evaluation of the pouch and rectal cuff (if present) is crucial for early detection. - **Biopsy:** Suspicious lesions should be biopsied for histopathological examination. 2. **Treatment:** - **Surgical intervention:** If a neoplasm is detected, surgical removal of the pouch may be necessary, often followed by conversion to a permanent ileostomy. - **Oncological management:** Chemotherapy and/or radiation therapy may be required depending on the stage and type of cancer. - **Monitoring:** Close follow-up with imaging and endoscopy to detect recurrence or new lesions. 3. **Preventive Measures:** - Regular surveillance with pouchoscopy to detect early dysplasia or malignancy. - Prophylactic removal of the rectal cuff in high-risk patients (e.g., FAP). - Management of chronic pouchitis or cuffitis to reduce inflammation. **Prognosis:** The prognosis for pouch neoplasms depends on the stage at diagnosis and the type of malignancy. Early detection through regular surveillance significantly improves outcomes. --- **Conclusion:** IPAA is a life-altering procedure that offers patients with UC or FAP a chance to maintain bowel function without a permanent ileostomy. However, it comes with risks such as pouchitis and, rarely, pouch neoplasms. Regular follow-up, appropriate management of complications, and vigilant surveillance are essential for optimizing outcomes and ensuring the long-term health of patients who undergo this procedure.

Ergosterol, visceral hypersensitivity and IBS

### Ergosterol: Ergosterol is a naturally occurring sterol compound found in fungi, particularly in fungal cell membranes. Structurally, it is similar to cholesterol, which is found in animal cells. Ergosterol is commonly present in foods derived from fungi, such as mushrooms and yeast. It has been studied for its potential health benefits, particularly in the context of gut health and immune modulation. Recent research has uncovered ergosterol's potential therapeutic role in alleviating symptoms of **irritable bowel syndrome (IBS)**. It acts through the **microbiota–metabolites–AhR signaling axis**, meaning it interacts with the gut microbiota to produce metabolites that activate the **aryl hydrocarbon receptor (AhR)**. This receptor is involved in maintaining gut immune balance and epithelial integrity, both of which are critical for healthy intestinal function. Ergosterol has demonstrated benefits such as improving intestinal motility, reducing visceral pain, decreasing colonic inflammation, enhancing gut barrier integrity, and modulating mast cell activation—all of which are key factors in IBS management. ### Visceral Hypersensitivity: Visceral hypersensitivity refers to an increased sensitivity or heightened pain perception in the internal organs, particularly in the gastrointestinal (GI) tract. It is a hallmark feature of IBS and is thought to play a central role in the chronic discomfort experienced by patients with the condition. People with visceral hypersensitivity often feel pain or discomfort in response to normal physiological processes, such as intestinal stretching or movement, which would not typically cause pain in healthy individuals. In IBS, visceral hypersensitivity contributes to symptoms such as: - **Abdominal pain**: Patients may experience sharp or chronic pain in the abdomen due to heightened sensitivity of the gut nerves. - **Bloating**: This is often exacerbated by the abnormal perception of intestinal distension. - **Altered bowel habits**: The hypersensitivity can also influence motility, leading to diarrhea, constipation, or alternating patterns of both. The mechanisms behind visceral hypersensitivity involve complex interactions between the nervous system, immune system, and gut microbiota. Dysregulation of pain signaling pathways, mast cell activation, and inflammation are key contributors. ### Role of Visceral Hypersensitivity in IBS: Visceral hypersensitivity is a core feature of IBS and is believed to be one of the primary reasons why patients experience abdominal pain and discomfort. It is often associated with abnormal communication between the gut and the brain (the gut-brain axis), leading to exaggerated responses to normal gut stimuli. Factors contributing to visceral hypersensitivity in IBS include: 1. **Gut Inflammation**: Low-grade inflammation in the gut can sensitize the nerves, making them more reactive. 2. **Gut Barrier Dysfunction**: A compromised gut barrier allows toxins and pathogens to interact with the immune system, promoting inflammation and nerve sensitization. 3. **Microbiota Imbalance**: Dysbiosis (imbalanced gut microbiota) can affect nerve signaling and increase sensitivity. 4. **Mast Cell Activation**: Mast cells release inflammatory mediators that amplify pain signals in the gut. 5. **Stress and Psychological Factors**: Stress can exacerbate visceral hypersensitivity by influencing the gut-brain axis. ### IBS and Ergosterol's Role: Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, diarrhea, constipation, or a mix of both. While the exact cause of IBS remains unclear, factors such as visceral hypersensitivity, abnormal intestinal motility, gut inflammation, and microbiota imbalance are central to its pathophysiology. The recent study on ergosterol has highlighted its potential as a promising nutritional therapy for IBS. Ergosterol works through a **microbiota-dependent mechanism**: 1. **Gut Microbiota Modulation**: Ergosterol reshapes the composition of the gut microbiota, enhancing the production of beneficial metabolites. 2. **Tryptophan Metabolism**: It promotes the production of **indole-3-lactate (ILA)**, a microbial metabolite derived from tryptophan. 3. **Activation of AhR Signaling**: ILA activates the AhR pathway, which is critical for maintaining intestinal immune balance and epithelial function. AhR activation helps reduce inflammation, improve gut barrier integrity, and regulate motility and visceral sensitivity. Interestingly, when animals in the study were treated with antibiotics (which disrupt the gut microbiota), ergosterol's beneficial effects disappeared, confirming that its action is dependent on the presence of a healthy microbiota. ### Summary: - **Ergosterol**: A fungal sterol found in food, with potential benefits for IBS by modulating gut microbiota and promoting beneficial metabolites like indole-3-lactate (ILA). - **Visceral Hypersensitivity**: A heightened sensitivity of the gut nerves, central to IBS symptoms such as pain and discomfort. - **IBS**: A chronic gut disorder involving visceral hypersensitivity, motility issues, and inflammation. Ergosterol offers a novel approach to IBS management by improving gut function through microbiota-driven mechanisms. These findings suggest that ergosterol could be developed as a natural, microbiota-based nutritional therapy for IBS, providing patients with a new option to reduce symptom severity and improve overall gut health.

FIREFLI ingestible capsule enable luminance-based diagnosis of acute mesenteric ischemia,

Yes, the FIREFLI ingestible capsule is a groundbreaking device that enables luminance-based diagnosis of acute mesenteric ischemia (AMI). AMI is a severe condition caused by insufficient blood flow to the intestines, often leading to tissue death and high mortality rates. Diagnosing AMI early is crucial, but traditional methods like CT scans and mesenteric angiography are invasive, costly, and time-consuming, which can delay treatment. FIREFLI offers a noninvasive, real-time solution for detecting AMI. The capsule is swallowed and becomes active in the alkaline environment of the small intestine. It uses three LEDs to emit pulses of white light and measures the reflected light across 10 wavelengths. By analyzing the reflected light, the device calculates a tissue luminance biomarker, which provides information about blood flow adequacy in the intestines. This luminance-based approach is more consistent and accurate than traditional color-change sensors, as it performs reliably across different individuals. The capsule is equipped with an onboard processing unit that interprets the data and wirelessly transmits the diagnosis to an external mobile device. This allows for rapid and remote assessment, making the tool highly portable and user-friendly. In animal studies, FIREFLI demonstrated a diagnostic accuracy of 90%, with 98% sensitivity and 85% specificity, showcasing its potential for clinical use. In summary, FIREFLI is a minimally invasive, highly accurate diagnostic tool that could revolutionize the early detection and treatment of AMI. Its ability to provide real-time results could significantly improve survival outcomes by enabling timely intervention.

Hyperbaric oxygen therapy for radiation enteritis

Hyperbaric oxygen therapy (HBOT) has emerged as a promising treatment for radiation enteritis (RE), a debilitating complication affecting up to 80% of patients undergoing pelvic radiotherapy, with 5–20% developing chronic severe RE. A systematic review and meta-analysis of 22 clinical studies involving 1,318 patients (8 randomized controlled trials and 14 non-randomized interventional trials) evaluated the efficacy, safety, and mechanisms of HBOT in managing RE. The findings revealed that HBOT significantly reduced the overall incidence of RE compared to standard treatments (OR = 0.32; P = 0.006) and lowered the occurrence of severe RE (grade 3 or higher) according to RTOG/EORTC criteria (OR = 0.37; P = 0.01). HBOT notably improved intestinal symptoms, as evidenced by reductions in LENT-SOMA scale scores (MD = −1.31; P = 0.03), and alleviated inflammation by reducing levels of pro-inflammatory cytokines such as IL-6, TNF-α, and CRP. It also enhanced immune function by increasing serum IgA, IgG, and IgM levels, supporting mucosal repair. Mechanistically, HBOT improves tissue oxygenation, activates Nrf2/HO-1 signaling, promotes angiogenesis via VEGF and FGF, and modulates macrophage polarization toward an anti-inflammatory M2 phenotype. The typical treatment protocol involves 2.0–2.5 ATA pressure, 90–120 minutes per session, 5 days a week, over 30–40 sessions. While combination therapies with agents like mesalazine showed synergistic benefits, HBOT alone demonstrated high adherence (>90%) and a favorable safety profile, with only mild side effects such as ear barotrauma and transient myopia. Importantly, no link to cancer recurrence was reported. Although HBOT shows significant promise in reducing RE severity and improving quality of life, further large-scale, multicenter randomized controlled trials are needed to optimize treatment protocols, evaluate long-term safety, and assess cost-effectiveness for broader clinical adoption.

Colorectal polyps in patients with limited life expectancy - BSG View

The British Society of Gastroenterology (BSG) provides guidance for managing colorectal polyps in patients with a life expectancy of less than 10 years, focusing on balancing the risks and benefits of polypectomy versus conservative management. The core challenge is evaluating the uncertain risk of polyp progression to malignancy against the procedural risks, especially in elderly or comorbid patients. A multidisciplinary team, including gastroenterologists, surgeons, geriatricians, and patient representatives, developed these recommendations using a modified Delphi process. The guideline emphasizes that most polyps have a slow progression to malignancy, with annual transition rates ranging from 0.2% for small polyps (1–5 mm) to 10% for larger ones (≥20 mm). Given that asymptomatic colorectal cancer typically takes 3–6 years to become symptomatic, conservative management may be appropriate for patients with limited life expectancy. The guideline recommends using the age-adjusted Charlson Comorbidity Index (CCI) and frailty scores like the Rockwood or Electronic Frailty Index to assess life expectancy and guide decision-making. Procedural risks, such as bleeding and perforation, increase with polyp size and comorbidities. Cold snare polypectomy is preferred for small polyps due to its lower complication rates. Shared decision-making, ethical considerations, and minimizing harm are central to the approach, with follow-up generally unnecessary unless in marginal cases. The guideline promotes patient-centered care and highlights the importance of training clinicians to assess frailty and avoid overtreatment.

Butyrate and Clostridioides difficile infection

Butyrate, a short-chain fatty acid produced by the fermentation of dietary fiber by gut microbiota, plays a critical role in maintaining intestinal health and has significant implications for Clostridioides difficile (C. difficile) infection. C. difficile is a major public health concern, causing hundreds of thousands of infections and thousands of deaths annually. It is often associated with antibiotic use, which disrupts the gut microbiota, leading to dysbiosis and reduced levels of butyrate-producing bacteria. This creates a favorable environment for C. difficile colonization and overgrowth. Butyrate contributes to intestinal homeostasis by nourishing colonocytes (intestinal cells), strengthening the gut barrier, and modulating inflammation. Research has shown that a butyrate-rich gut environment can suppress C. difficile by inhibiting its colonization and reducing its virulence. Specifically, butyrate affects bacterial metabolism, toxin production, and sporulation, key factors in the pathogenesis of C. difficile infection. Conversely, low butyrate levels, often caused by antibiotic-induced dysbiosis, weaken the gut's defenses and increase susceptibility to infection. Understanding the interplay between butyrate, gut microbiota, and C. difficile could pave the way for novel therapies. Strategies to restore butyrate levels, such as microbiome restoration, dietary interventions, or butyrate supplementation, may offer safer and more sustainable alternatives to traditional antibiotic treatments.

Ferroptosis-related genes in small intestinal NETs

The study focused on identifying ferroptosis-related genes in small intestinal neuroendocrine neoplasms (SI-NENs) and their diagnostic and therapeutic potential. Ferroptosis, an iron-dependent cell death mechanism, was analyzed using bioinformatics and machine learning on RNA sequencing datasets (GSE65286 and GSE98894). Researchers identified four key genes: **CDCA3, CDC25A, CYP4F8, and MYB**, which were experimentally validated using tissue samples from 10 healthy individuals and 14 SI-NEN patients. Among these genes, **CYP4F8** and **CDCA3** were significantly downregulated in SI-NEN tumor tissues, suggesting their role as tumor suppressors. Lower expression of these genes was associated with higher tumor grades (G2/G3) and aggressiveness, indicating their potential involvement in tumor progression. Importantly, CYP4F8 showed a strong negative correlation with Ki67 (proliferation marker) and tumor size, linking its reduced expression to increased malignancy. Gene Set Enrichment Analysis (GSEA) revealed upregulation of cancer-related and metabolic pathways tied to ferroptosis. Functional analysis highlighted pathways like ferroptosis, PPAR signaling, and transcriptional misregulation, which regulate lipid metabolism and oxidative stress. Diagnostic accuracy was demonstrated with Receiver Operating Characteristic (ROC) analysis, showing all four genes had AUC values above 0.9, confirming their potential as biomarkers. Histological validation confirmed reduced protein levels of CYP4F8 and CDCA3 in SI-NEN tissues. Molecular docking suggested therapeutic potential, with drugs like daunorubicin and quercetin showing strong binding affinity to these genes. Despite promising findings, larger multi-center studies are needed to further validate these genes as biomarkers and therapeutic targets for SI-NENs.

A value of D-dimer in acute arterial mesenteric ischemia

In acute arterial occlusive mesenteric ischemia (AOMI), baseline serum D-dimer levels hold significant prognostic value. The study found that elevated D-dimer levels were strongly associated with both short-term (30-day) and long-term (1-year) mortality. Non-survivors had markedly higher D-dimer levels compared to survivors (4.8 mg/L vs. 1.5 mg/L, p < 0.001). Elevated D-dimer reflects underlying hypercoagulability, endothelial dysfunction, and systemic inflammation, which are characteristic of severe disease progression in AOMI. Optimal cutoff values for D-dimer were identified to predict mortality outcomes effectively. For 30-day mortality, the cutoff was 0.578 mg/L (82.8% sensitivity, 75.0% specificity), while for 1-year mortality, the threshold was 0.516 mg/L (90.9% sensitivity, 60.7% specificity). Patients with D-dimer levels above these cutoffs had significantly lower survival probabilities, confirmed through Kaplan-Meier survival analysis. These findings suggest that measuring D-dimer within 24 hours of diagnosis can alert clinicians to critical disease severity, enabling timely interventions such as anticoagulation therapy or surgical consultation. Elevated D-dimer levels serve as independent predictors of mortality and are valuable in risk stratification for AOMI patients, improving clinical management and potentially survival outcomes.

IBS-Specific IgG ELISA-Based Elimination Diet in IBS

The IBS-specific IgG ELISA-based elimination diet is a personalized dietary intervention designed to address food sensitivities in individuals with irritable bowel syndrome (IBS). This approach leverages an IgG antibody assay to identify specific food triggers that may contribute to IBS symptoms, such as abdominal pain, bloating, and altered bowel habits. The study evaluating this diet aimed to improve upon methodological flaws seen in earlier IgG-related dietary research. In a randomized, double-blind, sham-controlled multicenter trial conducted across 8 centers, adults with IBS who tested positive for one or more food sensitivities via the IgG assay were assigned to either an antibody-guided elimination diet or a sham diet for 8 weeks. The experimental group excluded foods identified as triggers by the IgG assay, while the sham group followed a diet excluding random foods. The primary outcome was achieving a clinically meaningful reduction in abdominal pain intensity (≥30%) for at least 2 of the final 4 weeks of treatment. Results showed that the experimental group had significantly higher response rates compared to the sham group (59.6% vs 42.1%; P = .02). Subgroup analysis revealed stronger improvements among individuals with constipation-predominant IBS (IBS-C) and mixed-type IBS (IBS-M). These findings suggest that the IgG-guided elimination diet may serve as a safe, non-pharmacologic treatment option for IBS, particularly for patients unresponsive to conventional therapies. However, larger trials are needed to confirm these results, refine dietary protocols, and assess long-term efficacy and adherence.

TEDDY Study - Dietary Supplements, reduces Celiac Disease Risk

The TEDDY study primarily investigated dietary factors, focusing on dietary fiber intake rather than supplements, in relation to celiac disease risk among genetically predisposed children. It followed 6,520 children with HLA-DQ2 or DQ8 haplotypes from birth to age 13, analyzing dietary patterns and their impact on celiac disease development. A key finding was that higher dietary fiber intake during infancy (ages 6 months to 2 years) significantly reduced the risk of developing celiac disease later in life, independent of gluten consumption or specific food sources. This protective effect was limited to early childhood, as fiber intake after age 3 showed no significant association with celiac disease risk. The study highlighted the importance of dietary fiber in enhancing gut barrier integrity, supporting beneficial microbial colonization, and modulating immune tolerance during critical early-life windows. While maternal fiber intake during pregnancy may also play a role, the infant’s diet emerged as the dominant factor in reducing celiac risk. Foods rich in plant-based fiber, such as oats, legumes, and root vegetables, were associated with lower celiac autoimmunity. Dietary supplements were not explicitly studied as part of the TEDDY research, but the findings suggest that promoting fiber-rich diets in infancy could serve as a non-invasive preventive strategy for children genetically at risk. Future research could explore whether specific fiber supplements or prebiotics might replicate these protective effects, though current evidence emphasizes whole food sources. Additionally, further mechanistic studies are needed to confirm causality and understand fiber-driven microbial and immune interactions in preventing celiac disease.

Microbiome-Directed Therapy for Malnutrition

Microbiome-directed therapy for malnutrition represents a groundbreaking approach to addressing childhood undernutrition by targeting the gut microbiome, a critical determinant of health and growth outcomes. Traditional treatments, such as ready-to-use supplementary food (RUSF), primarily focus on providing calories but fail to address microbiome deficits. Research highlights that malnourished children often exhibit immature gut microbiota resembling those of much younger, healthy children, indicating delayed microbial maturation. This disrupted microbiome contributes to poor nutrient absorption, immunity issues, and long-term growth impairments. To counter this, scientists developed microbiota-directed complementary food (MDCF-2) aimed at restoring microbial maturity. Clinical studies comparing MDCF-2 to RUSF demonstrated that MDCF-2 promotes faster and more consistent growth recovery, despite containing fewer calories. Shotgun metagenomic sequencing identified key beneficial bacterial species, including *Prevotella copri* and *Gemmiger formicilis*, which are linked to improved growth and enriched carbohydrate metabolism pathways. This suggests enhanced energy extraction and nutrient utilization as mechanisms for its effectiveness. Additionally, plasma proteome analysis revealed improved nutrient metabolism and immune function in children on MDCF-2, emphasizing its holistic impact. This strategy offers promise for transforming malnutrition management globally, focusing on sustainable microbiome restoration rather than calorie-heavy interventions, particularly in resource-limited settings.

Imaging findings of IBS patients

Imaging studies have revealed several significant findings in patients with irritable bowel syndrome (IBS). These findings span both abdominal and brain imaging, shedding light on the structural and functional abnormalities associated with the condition. Below is a detailed summary of the imaging findings in IBS patients: ### **Abdominal Imaging Findings:** 1. **Colonic and Rectal Volumes:** - Magnetic Resonance Imaging (MRI) consistently showed **smaller colonic and rectal volumes** in IBS patients compared to healthy controls. - These findings suggest **increased bowel tone and altered motility**, which could play a role in IBS pathophysiology and aid in classification and treatment planning. 2. **Colonic Transit Times:** - IBS patients exhibited **reduced colonic transit times** compared to those with functional constipation. - This indicates distinct motility patterns, which could guide therapeutic interventions such as the use of **prokinetic agents or laxatives**. 3. **Differences by IBS Subtype:** - In **constipation-predominant IBS (IBS-C)**, imaging revealed: - Increased postprandial ascending colon volume. - Decreased descending colon volume, suggesting **retrograde movement** of colonic contents. - Such retrograde movement was absent in **diarrhea-predominant IBS (IBS-D)** and **mixed IBS (IBS-M)**. 4. **Ultrasound Findings:** - Increased **gallbladder and colon contractility**. - Impaired **gastric emptying**. - **Hyperechoic rectal walls** were observed in IBS patients. - However, ultrasound findings are limited by its **operator dependence**, reducing diagnostic reliability. 5. **CT Imaging Insights:** - Although CT imaging can provide structural details of the bowel, its utility in IBS is limited due to: - **Radiation exposure**. - Poor soft-tissue contrast, especially for detecting functional abnormalities. 6. **MRI Superiority:** - MRI emerged as the most effective imaging tool for IBS due to its: - High sensitivity. - Non-invasive nature. - Lack of radiation exposure. - Ability to visualize both **colonic** and **brain alterations** without requiring bowel preparation. --- ### **Brain Imaging Findings (Brain-Gut Axis):** 1. **Functional MRI (fMRI) Findings:** - Abnormalities were observed in brain regions associated with **pain perception**, **emotion regulation**, and **visceral sensitivity**. - These regions include the **insula**, **anterior cingulate cortex**, and **hypothalamus**. 2. **Cortical and Structural Brain Changes:** - Increased **gray matter volume** in somatosensory regions. - **Cortical thinning** in areas such as the **anterior midcingulate cortex** and **posterior insula**. - These changes are believed to be linked to **chronic stress** and **pain modulation**. 3. **Subtype-Specific Brain Alterations:** - In **diarrhea-predominant IBS (IBS-D)**: - Enlarged **thalamus** and **caudate nucleus** volumes were noted. - These alterations suggest differential neural activity and asymmetries that influence **gut motility control**. 4. **Resting-State Brain Activity:** - IBS patients displayed: - **Elevated resting-state activity** in the **postcentral**, **frontal**, and **temporal regions**. - **Reduced connectivity** in the **amygdala** and **cingulate cortex**. - These changes correlate with **visceral hypersensitivity**, a hallmark symptom of IBS. 5. **Psychological and Gender Factors:** - Imaging findings were influenced by **gender** and **cultural factors**: - Women and individuals from certain cultural backgrounds exhibited distinct patterns of **pain perception** and **cortical activation**. 6. **Clinical Relevance of Brain Findings:** - The overlap between **cortical thinning** in IBS patients and **depression** supports the use of **antidepressants** (e.g., tricyclics) for treatment. - These medications may help modulate both **pain perception** and **gut-brain signaling**. --- ### **Key Insights from Imaging Findings:** 1. IBS is associated with both **colonic** and **brain network abnormalities**. 2. MRI has emerged as the **most effective imaging modality** for IBS diagnosis due to its ability to detect structural and functional changes in both the gut and the brain. 3. Imaging findings, such as **colonic diameter changes** and **brain connectivity alterations**, could serve as **objective diagnostic markers** for IBS. 4. Subtype-specific imaging differences (e.g., IBS-C vs. IBS-D) highlight the need for personalized treatment approaches based on imaging-guided classification. --- ### **Limitations of Imaging Studies:** 1. The majority of studies were **observational** and predominantly included **female participants**, limiting generalizability. 2. There is a need for **large-scale, multicenter, and gender-balanced trials** to validate imaging-based diagnostic approaches for IBS. In conclusion, imaging studies have revealed important insights into the structural and functional abnormalities in both the gut and brain of IBS patients. MRI, in particular, holds significant potential as a diagnostic and classification tool, paving the way for more personalized management strategies based on imaging findings.

Microbiota and IBD-C

Constipation-predominant irritable bowel syndrome (IBS-C) is a subtype of IBS characterized by chronic constipation, abdominal discomfort, and altered bowel habits. The study you referenced explored the relationship between gut microbiota and IBS-C, uncovering critical insights into the microbial and metabolic disturbances associated with the condition. Below is a detailed explanation of the findings related to microbiota and IBS-C: ### 1. **Gut Microbiota Composition in IBS-C**: - **No Significant Differences in Overall Diversity**: The study found no major differences in overall microbial α-diversity (species richness within samples) or β-diversity (differences between microbial communities across samples) between IBS-C patients and healthy controls. This indicates that while the overall microbial diversity may not be altered, specific bacterial species show significant abundance variations. - **Species-Level Microbial Differences**: Six bacterial species exhibited significant differences in abundance: - **Reduced in IBS-C Patients**: - *Megasphaera elsdenii*: A beneficial bacterium involved in short-chain fatty acid (SCFA) production and bile acid metabolism. Its depletion may impair gut motility and energy metabolism. - *Bifidobacterium bifidum*: Plays a role in mucin degradation, SCFA synthesis, and maintaining intestinal barrier integrity. Reduced levels contribute to inflammation and constipation. - *Alistipes inops*: Associated with SCFA production and serotonin precursor (tryptophan) availability. Its decline weakens gut motility regulation through the gut–brain axis. - **Increased in IBS-C Patients**: - *Lactobacillus iners*: This bacterium negatively correlates with butyric acid levels, suggesting its overabundance may contribute to reduced butyrate production and impaired gut health. ### 2. **Functional Pathway Alterations in IBS-C Microbiota**: - **Upregulated Pathways**: - Protein synthesis and bacterial motility pathways were increased in IBS-C patients, potentially reflecting microbial adaptations to altered gut conditions. - **Downregulated Pathways**: - Carbohydrate metabolism and ATP transport pathways were suppressed, indicating impaired energy production and metabolic imbalances in the gut. ### 3. **Short-Chain Fatty Acids (SCFA) Metabolism**: - SCFAs like butyrate and acetate, which are crucial for colon health and gut motility, were significantly decreased in IBS-C patients. This reduction is linked to the depletion of SCFA-producing bacteria (*M. elsdenii*, *B. bifidum*, *A. inops*). ### 4. **Microbiota-Metabolite Interactions**: - Positive correlations were observed between: - *M. elsdenii* and acetic acid levels. - *A. inops* and acetic acid levels. - Negative correlation: - *L. iners* showed a negative correlation with butyric acid levels. - These interactions suggest that microbial dysbiosis directly impacts metabolite profiles, contributing to IBS-C symptoms. ### 5. **Impact of Specific Bacterial Species**: - **Role of *Megasphaera elsdenii***: - This bacterium positively influences SCFA and bile acid metabolism. Its depletion may impair gut motility and energy metabolism, exacerbating constipation symptoms. - **Impact of *Bifidobacterium bifidum* Depletion**: - Reduced levels of this species may lead to compromised mucin degradation, lowered SCFA synthesis, and weakened intestinal barrier integrity, contributing to inflammation and constipation. - **Importance of *Alistipes inops***: - The decline of *A. inops* may reduce serotonin precursor availability (tryptophan), weakening gut motility regulation via the gut–brain axis. ### 6. **Microbiota-Metabolite Interaction Network**: - The study integrated metagenomic and metabolomic data, revealing strong cross-talk between microbial dysbiosis and metabolic disturbances. This systems-level approach highlights how disrupted microbiota contributes to metabolic imbalances and IBS-C pathogenesis. ### 7. **Clinical Implications**: - **Diagnostic Biomarkers**: - The microbial and metabolic disruptions identified in IBS-C patients may serve as potential diagnostic biomarkers. - **Therapeutic Targets**: - Interventions aimed at restoring gut microbiota balance (e.g., probiotics containing *B. bifidum* or *M. elsdenii*) or modulating SCFA levels could offer promising therapeutic strategies for IBS-C. ### 8. **Conclusion**: IBS-C is characterized by gut dysbiosis, specifically the depletion of SCFA-producing bacteria (*M. elsdenii*, *B. bifidum*, *A. inops*), disrupted amino acid and carbohydrate metabolism, and mild inflammation. These factors collectively impair gut motility, contributing to the persistence of constipation and other IBS-C symptoms. The findings underscore the importance of targeting microbial and metabolic disturbances for effective management of IBS-C. In summary, the study provides a comprehensive understanding of how gut microbiota alterations and their interactions with metabolites play a critical role in IBS-C pathogenesis.

Risk of IBD in IBS patients

Irritable bowel syndrome (IBS) is linked to an increased long-term risk of developing inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). A large study using UK Biobank data followed 447,631 participants for over 14 years and found that individuals with IBS had a significantly higher chance of developing IBD. Specifically, IBS patients had a 68% higher risk of any IBD, with a 60% increased risk for UC and a 104% higher risk for CD. This elevated risk persisted even after 10 years. The study also analyzed 76,992 participants through a digestive health questionnaire and found that IBS patients had a higher prevalence of IBD. Among IBS subtypes, diarrhea-predominant IBS (IBS-D) showed the strongest link to IBD, with a 3.72 times higher likelihood of having IBD, suggesting a closer connection between IBS-D and inflammatory conditions. These findings suggest that IBS and IBD may share overlapping mechanisms. Clinically, IBS patients, especially those with persistent symptoms or IBS-D, should be monitored closely for signs of IBD. Early detection and treatment of inflammatory changes could improve outcomes and provide better disease management for these patients.

Healthy Lifestyle and Bowel Disease Risk

The study conducted by researchers at the University of Oslo in collaboration with the Song Lab at Harvard T.H. Chan School of Public Health provides compelling evidence that adopting a healthier lifestyle after undergoing bowel screening significantly reduces the risk of bowel cancer and major chronic diseases. Here's a detailed breakdown of the findings and insights related to healthy lifestyle changes and bowel disease risk: ### Key Findings: 1. **Impact of Post-Screening Lifestyle Changes**: - Individuals who improved their lifestyle after bowel screening experienced a **14% lower risk of developing bowel cancer** compared to those who maintained or worsened their habits. - Conversely, participants whose lifestyle worsened by two or more points (e.g., increased smoking, weight gain, reduced activity, or higher alcohol consumption) had a **70% higher risk of bowel cancer** and a **21% higher risk of chronic diseases**. 2. **Lifestyle Factors Assessed**: - A composite lifestyle score (1–5) was created based on: - **Smoking status**: Non-smoking or smoking cessation was linked to better health outcomes. - **Body Mass Index (BMI)**: Maintaining a healthy weight reduced cancer risk. - **Physical activity**: Regular exercise was protective against bowel cancer. - **Alcohol consumption**: Limited alcohol intake was associated with lower disease susceptibility. - **Dietary quality**: Increased intake of fiber, whole grains, dairy products, and calcium, and reduced consumption of red and processed meats contributed to better health. 3. **Protective Effect of Lifestyle Improvement**: - Even small changes, such as a one-point improvement in the lifestyle score (e.g., adopting healthier eating habits, losing weight, or becoming more physically active), demonstrated measurable health benefits. 4. **Negative Impact of Lifestyle Decline**: - The study highlighted that screening alone is insufficient in reducing bowel cancer risk. Unhealthy behavior changes post-screening sharply increased susceptibility to both bowel cancer and chronic diseases, emphasizing the importance of sustained healthy habits. ### Background Context: - Previous research estimated that nearly **50% of bowel cancer cases could be prevented** by adhering to a healthy lifestyle, including avoiding smoking, maintaining a healthy weight, eating a nutritious diet, engaging in regular physical activity, and limiting alcohol consumption. - However, earlier studies primarily focused on lifetime lifestyle patterns rather than changes made specifically after screening. ### Teachable Moment Hypothesis: - The researchers proposed the idea that bowel screening could serve as a **"window of opportunity"** to encourage individuals to adopt healthier behaviors. - This hypothesis was supported by the study findings, which demonstrated that post-screening lifestyle improvements significantly reduced disease risk. ### Study Design and Methodology: - The study analyzed data from three large U.S. cohorts, including participants who underwent colonoscopy-based bowel screening. - Participants completed detailed lifestyle and diet questionnaires before screening and at multiple time points afterward. - The follow-up period lasted up to **30 years**, allowing researchers to track bowel cancer incidence and chronic disease outcomes over the long term. ### Future Directions: - Norwegian researchers are launching a **lifestyle intervention trial** within the national Bowel Screening Programme. This project aims to test varying levels of lifestyle guidance and support over two years to promote cancer-preventive habits. - The long-term goal of this initiative is to determine whether lifestyle interventions following bowel screening can lower cancer incidence and mortality rates over time. ### Key Insights: 1. **Screening Alone Is Not Enough**: - While bowel screening helps detect and prevent cancer, its benefits are significantly amplified when combined with sustained healthy lifestyle changes. - Screening provides an opportunity to educate individuals about the importance of maintaining healthy habits. 2. **Importance of Sustained Behavior**: - Positive changes made after screening can have a lasting impact on reducing bowel cancer risk and improving overall health. - Conversely, unhealthy lifestyle choices post-screening can negate the protective effects of early detection. ### Conclusion: The study underscores the critical role of adopting and maintaining a healthy lifestyle in reducing bowel cancer risk and preventing chronic diseases, particularly after undergoing bowel screening. It highlights the importance of leveraging the "teachable moment" created by screening to encourage individuals to make meaningful and sustainable health behavior changes. By improving diet, exercise, weight management, and other lifestyle factors, individuals can significantly enhance their long-term health outcomes.

ACTION Trial

The **ACTION trial** was a significant clinical study designed to evaluate the efficacy and safety of acupuncture in treating diarrhea-predominant irritable bowel syndrome (IBS-D). Below is a detailed summary of the trial: --- ### **Background** - **Global burden of IBS-D**: IBS affects approximately 4.1% of adults worldwide, with IBS-D accounting for about one-third of all cases. It is associated with frequent loose stools, abdominal pain, reduced quality of life, and considerable psychological and socioeconomic burden. - **Limitations of standard therapies**: Common treatments, including dietary modifications, medications, and cognitive behavioral therapy, often provide incomplete relief, come with side effects, or lead to symptom recurrence. - **Rationale for acupuncture**: Acupuncture has long been used for gastrointestinal disorders, but high-quality evidence supporting its efficacy for IBS-D has been limited. --- ### **Objective** The **ACTION trial** aimed to determine whether acupuncture could improve abdominal pain and stool consistency in IBS-D patients compared to sham acupuncture. --- ### **Study Design** - **Type of trial**: Multicenter, randomized, sham-controlled clinical trial. - **Location**: Conducted across six hospitals in China. - **Timeline**: May 2021 to August 2022. - **Participants**: - A total of 584 adults were screened. - 280 adults aged 18–75 who met the Rome IV criteria for IBS-D were randomized equally into two groups: acupuncture and sham acupuncture. --- ### **Treatment Protocol** - **Duration**: Participants received 15 sessions over six weeks: - Three sessions per week during weeks 1–3. - Two sessions per week during weeks 4–6. - **Administration**: All sessions were conducted by licensed acupuncturists. #### **Acupuncture Group** - **Acupoints**: Needles were placed at eight fixed points (CV12, CV4, ST25, ST36, ST37) and one optional bilateral pair (LR3, SP6, or ST44). - **Technique**: Manual stimulation was applied to elicit the "deqi" sensation, which is a characteristic feeling of needle insertion in acupuncture. #### **Sham Control Group** - **Procedure**: Participants received identical adhesive pads, but no needles were inserted or stimulated. - **Rescue medication**: Loperamide was allowed for both groups as needed. --- ### **Primary Endpoint** - **Composite response at week 6**: Defined as: - A ≥30% reduction in the worst abdominal pain. - A ≥50% reduction in diarrhea days from baseline. --- ### **Key Results** #### **Primary Outcome** - At week 6, **57.9%** of acupuncture patients achieved the primary endpoint compared to **41.4%** in the sham group. - **Relative Risk (RR)**: 1.40 - **Statistical significance**: P = 0.008. #### **Sustained Efficacy** - Improvements were observed as early as week 3 and remained significant through week 18. - Per-protocol analysis confirmed the findings: - **58.7%** of acupuncture patients vs. **41.0%** of sham patients achieved the primary endpoint (P = 0.011). #### **Stool Consistency** - **Acupuncture group**: Mean days with loose stools decreased from 5.1 to 2.1. - **Sham group**: Mean days decreased from 5.2 to 3.0. - Significant between-group differences were evident from week 5 onward. #### **Abdominal Pain Relief** - Both groups showed improvement, but the acupuncture group achieved greater long-term reductions: - By week 18: **−2.54** (acupuncture) vs. **−1.99** (sham); P = 0.012. #### **IBS Symptom Severity** - The **IBS Symptom Severity Scale (IBS-SSS)** improved more in the acupuncture group: - Acupuncture: **−127.3**. - Sham: **−89.3**. - **P < 0.001**. - Benefits were sustained at the 12-week follow-up. #### **Adequate Relief Perception** - **61.4%** of acupuncture patients reported adequate relief compared to **35.0%** in the sham group (P < 0.001). - Differences were noticeable from week 2 onward. #### **Responder Rates** - **83%** of acupuncture patients achieved a ≥50-point reduction in IBS-SSS compared to **68.4%** in the sham group (P = 0.004). --- ### **Secondary Outcomes** - **Quality of Life (IBS-QOL)**: No significant differences between groups. - **Psychological outcomes** (e.g., PHQ-9 for depression): No significant differences. - **Bloating and stool frequency**: No significant differences between groups. --- ### **Safety and Tolerability** - **Adverse events**: Mild and transient, primarily: - Minor bleeding (11.3%). - Post-needling pain (5.7%). - No serious adverse events were reported. --- ### **Conclusion** The **ACTION trial** demonstrated that acupuncture significantly improved: - **Abdominal pain**. - **Stool consistency**. - **Global symptom relief**. - **IBS severity**. These benefits were durable, lasting up to 18 weeks, and acupuncture was well-tolerated with a favorable safety profile. This study provides robust evidence supporting the use of acupuncture as an effective treatment option for IBS-D.

Five herbs and spices that could help improve digestion

Here are **five herbs and spices** that can help improve digestion, along with detailed explanations of their benefits: ### 1. **Peppermint** - **Active Compound:** Menthol. - **Benefits:** - Relaxes gut muscles, reducing bloating, gas, and abdominal pain. - Calms inflammation and fights harmful bacteria. - **Peppermint Oil:** Clinical studies show peppermint oil capsules significantly relieve symptoms of **irritable bowel syndrome (IBS)** by reducing intestinal spasms. - **Precautions:** - Peppermint oil may worsen acid reflux by relaxing the lower esophageal sphincter. - For a milder option, **peppermint tea** is recommended. --- ### 2. **Chamomile** - **Benefits:** - Chamomile tea is well-known for calming the gut and easing indigestion, gas, and irritation. - Possesses antioxidant properties that may help prevent ulcers. - **Use in Children:** - Chamomile-based teas are effective for relieving colic and mild diarrhea in infants and children, with over half showing improvement within a week. - **Safety:** - Generally safe, but may cause allergic reactions in individuals sensitive to plants like ragweed. --- ### 3. **Carom Seeds (Ajwain)** - **Active Compound:** Thymol. - **Benefits:** - Relieves gas and bloating by boosting stomach acid production and digestive enzymes. - Animal studies suggest ajwain speeds up food transit, increases bile secretion, and has antispasmodic effects. - **Precautions:** - High doses should be avoided during pregnancy or breastfeeding due to potential risks like uterine stimulation or miscarriage. --- ### 4. **Fennel** - **Active Compound:** Anethole. - **Benefits:** - Chewing fennel seeds after meals improves digestion, reduces bloating, and freshens breath. - Anethole relaxes gut muscles, reducing cramps and improving digestion. - Fennel-based remedies, like gripe water, are used to treat infant gas, while adults with IBS report reduced cramping and bloating. - **Nutritional Note:** Fennel is high in insoluble fiber, which aids digestion. --- ### 5. **Cumin** - **Benefits:** - Stimulates digestive enzymes and bile secretion, enhancing fat digestion and nutrient absorption. - Clinical trials show cumin extract reduces IBS symptoms and accelerates food movement through the gut by around 25%. - **Scientific Evidence:** - Both animal and human studies confirm cumin’s role in improving digestion and reducing discomfort. --- ### Core Takeaway: Incorporating these **five herbs and spices – peppermint, chamomile, ajwain, fennel, and cumin** – into your diet can gently support gut function, reduce bloating, and promote overall digestive comfort. However, they should be used as complementary aids and not as replacements for medical treatment. Always consult a healthcare provider if you have chronic conditions, allergies, or are taking medications.

GI diseases, sleep disturbances, and the role of depression

The study you provided sheds significant light on the complex interplay between gastrointestinal (GI) diseases, sleep disturbances, and depression, highlighting both direct and indirect pathways through which these health concerns are interconnected. Below is a detailed breakdown of the findings and implications regarding this relationship: --- ### **GI Diseases and Sleep Disturbances** 1. **Prevalence of Sleep Problems in GI Disease Patients:** - Individuals with GI diseases were found to have a **higher prevalence of self-reported trouble sleeping** (38%) compared to those without GI diseases (24%). - Additionally, **diagnosed sleep disorders** were nearly twice as common in GI disease patients (15%) versus those without GI diseases (8%). 2. **Increased Risk of Sleep Disturbances:** - After adjusting for demographic, lifestyle, and clinical factors, GI disease remained strongly associated with sleep disturbances: - Patients with GI diseases were **70% more likely to report trouble sleeping**. - They were **1.8 times more likely to have a diagnosed sleep disorder**. - GI diseases were also linked to **shorter sleep duration**, with an adjusted β of –0.15, indicating clinically meaningful sleep loss. 3. **Consistency Across Subgroups:** - The association between GI diseases and sleep disturbances was consistent across various subgroups, including individuals without chronic conditions like hypertension, diabetes, or smoking history. - Even in patients with comorbidities such as coronary heart disease or higher gut microbiota dietary index scores, the link remained significant. - The relationship was broadly generalizable, showing no significant differences by sex, age, or presence of chronic disease. --- ### **Role of Depression as a Mediator** 1. **Depression's Contribution to Sleep Disturbances:** - Mediation analysis revealed that depression partially explained the link between GI diseases and sleep disturbances: - Depression accounted for **21% of the effect on sleep problems**. - It explained **19% of the effect on diagnosed sleep disorders**. - Depression contributed to **27% of the association with reduced sleep duration**. 2. **Not the Sole Pathway:** - While depression was a significant mediator, it did not fully account for the relationship between GI diseases and sleep disturbances. Other mechanisms likely play a role, including: - **Systemic inflammation:** Chronic GI diseases often involve inflammatory processes that can disrupt sleep. - **Visceral hypersensitivity:** Heightened sensitivity in the gut may lead to discomfort that interferes with sleep quality. - **Metabolic dysfunction:** GI diseases can alter metabolic pathways, which may impact sleep regulation. 3. **Gut-Brain Axis and Shared Pathways:** - The study reinforces the concept of the **gut-brain axis**, emphasizing that GI diseases and sleep disorders may share mechanistic pathways through brain–gut–immune signaling. - The vagus nerve and gut microbiota are key players in this bidirectional communication, linking GI health with psychological and sleep outcomes. --- ### **Clinical Implications** 1. **Need for Integrated Care:** - The findings highlight the importance of addressing both psychological and GI symptoms to improve sleep health in affected patients. - Depression, as a mediator, suggests that managing mental health could mitigate sleep disturbances in GI disease patients. 2. **Fragmented Care:** - External experts pointed out that GI physicians often do not inquire about sleep issues, while sleep specialists may overlook GI symptoms. This fragmented approach can hinder effective treatment. - Multisystem evaluations and cross-specialty referrals are essential for holistic care. 3. **Call for Holistic Management:** - Clinicians should adopt integrative care strategies that consider the overlapping symptoms of GI diseases, sleep disturbances, and depression. - Psychological interventions, anti-inflammatory treatments, and dietary modifications targeting gut health may improve sleep outcomes. --- ### **Future Directions** 1. **Longitudinal Studies:** - The study emphasizes the need for longitudinal research to establish causality: - Do GI diseases directly cause sleep disturbances? - Does poor sleep exacerbate GI disease symptoms? - Or do both stem from shared underlying mechanisms, such as systemic inflammation or microbiota dysregulation? 2. **Exploration of Other Pathways:** - Future research should investigate additional mediators beyond depression, such as the role of systemic inflammation, microbiota alterations, and autonomic nervous system dysfunction. 3. **Expanding Analytic Approaches:** - The study’s sample size was underpowered for advanced machine-learning analyses. Larger datasets and innovative analytic techniques could uncover more nuanced relationships. --- ### **Conclusion** The complex relationship between GI diseases, sleep disturbances, and depression underscores the need for multidisciplinary care and research. Depression plays a significant, but not exclusive, role in mediating the effects of GI diseases on sleep health. Other pathways, such as inflammation and gut-brain signaling, contribute to this interplay. Clinicians should adopt a holistic approach to address the overlapping symptoms, while researchers should focus on uncovering causality and shared mechanisms to guide future interventions.

Alopecia Areata and immune-mediated GI) conditions

Alopecia areata (AA), an autoimmune disorder characterized by hair loss, has been found to be significantly associated with an increased risk of various gastrointestinal (GI) immune-mediated conditions, according to a comprehensive study that analyzed data from the TriNetX global research database. Below is a detailed summary of the findings: --- ### **Key Associations Between Alopecia Areata (AA) and Immune-Mediated GI Conditions:** 1. **Microscopic Colitis (MC):** - **Risk:** Patients with AA had nearly double the odds of developing microscopic colitis (MC) compared to controls (OR 1.88; P < .001). - **Subtypes:** - Lymphocytic colitis (OR 1.83; P < .001). - Collagenous colitis (OR 1.80; P = .003). - **Age Difference:** Patients with both AA and MC were younger (mean age 59.6 years) compared to those with MC but without AA (mean age 62.8 years). This suggests that AA may accelerate or unmask MC in predisposed individuals. 2. **Celiac Disease:** - **Risk:** AA was associated with a significantly higher risk of celiac disease (OR 1.87; P < .001). - **Mechanisms:** This reflects shared autoimmune pathways between AA and celiac disease, as both are linked to dysregulated immune responses. 3. **Crohn’s Disease:** - **Risk:** Patients with AA had increased odds of developing Crohn’s disease (OR 1.75; P < .001). - **Implication:** This suggests systemic immune dysregulation in AA patients, contributing to the development of inflammatory bowel diseases (IBD) like Crohn’s disease. 4. **Eosinophilic Esophagitis:** - **Risk:** Patients with AA had an elevated risk of eosinophilic esophagitis (OR 1.59; P < .001). - **Overlap:** This highlights the broader atopic and autoimmune overlap in AA patients. 5. **Ulcerative Colitis:** - **Risk:** A more modest but still significant association was observed with ulcerative colitis (OR 1.38; P < .001). - **Significance:** This reinforces the link between AA and GI autoimmune overlap, albeit with a lower magnitude compared to other conditions. --- ### **Clinical Implications:** 1. **Systemic Autoimmune Spectrum:** - The study underscores that AA is not just a dermatologic condition but part of a broader systemic autoimmune spectrum, with significant overlap with GI immune-mediated diseases. 2. **Added Clinical Burden:** - Patients with AA face additional morbidity from concurrent GI autoimmune conditions, which can complicate disease management and reduce quality of life. 3. **Younger Presentation:** - The earlier onset of GI conditions like MC in AA patients suggests that AA may accelerate or unmask these diseases in genetically or immunologically predisposed individuals. --- ### **Recommendations for Management:** 1. **Proactive Screening:** - Clinicians managing AA should proactively screen for GI symptoms such as chronic diarrhea, bloating, or unexplained abdominal pain, which may indicate underlying immune-mediated GI conditions. 2. **Referral to Gastroenterology:** - Dermatologists treating AA should consider referring patients with persistent or unexplained GI symptoms to gastroenterologists for further evaluation. 3. **Multidisciplinary Care:** - Given the systemic nature of AA and its associations with GI conditions, a multidisciplinary approach involving dermatologists, gastroenterologists, and possibly immunologists is recommended for optimal patient care. --- ### **Shared Mechanisms:** 1. **Immune Dysregulation:** - Both AA and GI autoimmune disorders are associated with dysregulated T-cell–mediated immune responses, suggesting common pathogenic pathways. 2. **Atopic-Autoimmune Overlap:** - The elevated risk of eosinophilic esophagitis in AA patients also points to a shared atopic-autoimmune mechanism. --- ### **Public Health Significance:** - Alopecia areata affects a large population worldwide. Awareness of its strong associations with GI immune-mediated diseases can lead to earlier detection, better management, and improved outcomes for affected individuals. --- ### **Conclusion:** The study highlights a robust link between alopecia areata and several immune-mediated GI conditions, particularly microscopic colitis, celiac disease, Crohn’s disease, eosinophilic esophagitis, and ulcerative colitis. These findings emphasize the need for heightened vigilance, proactive screening, and multidisciplinary care to address the systemic nature of AA and its associated comorbidities.

Diagnostic accuracy of tTG level in Paediatric Celiac Disease

The diagnostic accuracy of tissue transglutaminase IgA (tTG-IgA) levels in pediatric celiac disease was assessed in a large North American study involving 4019 children under 18 years from 12 hospitals across Canada and the United States between 2016–2021. Here are the key findings related to the diagnostic accuracy of tTG-IgA levels: ### **1. Overall Diagnostic Accuracy:** - Elevated tTG-IgA levels predicted biopsy-confirmed celiac disease with a **positive predictive value (PPV) of 82.6%**. This indicates that while tTG-IgA is a good diagnostic tool, it is not perfect. ### **2. High-Level Antibody Threshold (≥10x Upper Limit of Normal [ULN]):** - Among children with tTG-IgA levels **≥10 times the ULN**, the PPV rose significantly to **94.9%**, showing strong predictive value. - However, this threshold is not absolute, as **5% of children with tTG-IgA ≥10x ULN did not have diagnostic histology**, including **2% with completely normal biopsies**. This highlights the risk of relying solely on serology for diagnosis. ### **3. False Positives Exist:** - Even at high antibody levels, some children do not have biopsy-confirmed celiac disease. This underscores the importance of histological confirmation to avoid misdiagnosis and unnecessary dietary restrictions. ### **4. Laboratory Variability:** - The performance of tTG-IgA assays varied widely between laboratories: - For elevated tTG-IgA values, PPV ranged from **71.5% to 88.8%**. - For tTG-IgA levels **≥10x ULN**, PPV ranged from **89.3% to 97.3%**. - This variability highlights the need for standardized testing protocols and thresholds across laboratories. ### **5. Impact of Comorbidities:** - **Type 1 Diabetes:** Children with type 1 diabetes showed lower predictive accuracy, with a PPV of **89%** at tTG-IgA levels **≥10x ULN**, suggesting comorbid conditions may affect test performance. - **Down Syndrome:** Limited data was available for children with Down syndrome, but they often have higher baseline autoantibody levels, which could complicate interpretation. ### **6. EMA Testing:** - Endomysial IgA antibody (EMA) testing provided only marginal improvement in specificity. Surprisingly, **76% of non-celiac children with high tTG-IgA levels also tested positive for EMA**, indicating that EMA is not completely reliable in ruling out false positives. ### **7. Potential Early Signal:** - Some children with high tTG-IgA levels but normal biopsies may later develop celiac disease. This suggests that elevated antibodies could precede visible intestinal damage, warranting close monitoring of such cases. ### **8. Premature Gluten Restriction:** - Concerns were raised about children being unnecessarily placed on gluten-free diets based solely on serology without biopsy confirmation. This can impose significant dietary, social, and psychological burdens, especially in North America. ### **9. Clinical Confirmation is Essential:** - Experts emphasize that elevated tTG-IgA levels, even at **≥10x ULN**, should always be confirmed by a gastroenterologist and biopsy before initiating a gluten-free diet. This ensures diagnostic accuracy and prevents unnecessary lifelong dietary restrictions. ### **10. Unanswered Questions:** - The study highlighted unanswered questions regarding why some children have persistently high tTG-IgA levels without enteropathy. Further research is needed to understand this phenomenon. ### **11. Prospective Monitoring:** - Children with high tTG-IgA levels but normal biopsies should be monitored closely over time, as they may develop celiac disease later. ### **12. Guideline Implications:** - While elevated tTG-IgA levels are highly suggestive of celiac disease, biopsy remains the gold standard for diagnosis in North America. Unlike European guidelines, which allow non-biopsy diagnosis under strict conditions, North American guidelines continue to emphasize histological confirmation. ### **Clinical Implication:** - Elevated tTG-IgA levels are highly suggestive but not definitive for pediatric celiac disease. Diagnosis must be confirmed histologically to ensure accuracy, avoid unnecessary dietary restrictions, and account for variability in assay performance and comorbid conditions. In summary, while tTG-IgA levels, especially at high thresholds (≥10x ULN), demonstrate strong predictive value for celiac disease, they are not infallible. Biopsy remains essential for definitive diagnosis in pediatric patients to avoid misdiagnosis, unnecessary lifestyle changes, and ensure proper management.

CAMs and GI Disorders

Complementary and Alternative Medicine (CAM) is increasingly being recognized as a valuable adjunct in the management of gastrointestinal (GI) disorders, particularly as the prevalence of these conditions rises due to modern lifestyle factors such as stress, ultraprocessed diets, obesity, depression, and infections. Below is a detailed exploration of the role of CAM in GI disorders, supported by the context provided: --- ### **Prevalence of CAM Use in GI Disorders** - **Widespread Use:** Up to 44% of patients with GI disorders use CAM therapies, often without informing their healthcare providers. This highlights the need for physicians to proactively inquire about CAM use to avoid risks of hidden interactions and to provide appropriate guidance. - **Patient Appeal:** CAM is attractive to patients because it offers a sense of control, especially when conventional treatments fail to fully resolve symptoms. The holistic approach of CAM addresses not just physical symptoms but also psychological and lifestyle factors. --- ### **Barriers and Opportunities in CAM Integration** - **Disclosure Gap:** Many patients do not disclose their use of CAM due to fear of judgment or the belief that it is not clinically relevant, which can lead to missed opportunities for physicians to guide safe and effective use. - **Educational Gap:** CAM is rarely covered in medical training, leaving many gastroenterologists unfamiliar with therapies their patients are actively using. Bridging this gap through education and awareness is essential. - **Integrative Model:** Experts advocate for an integrative gastroenterology model, combining standard medical care with evidence-based CAM therapies to address the growing burden of GI diseases. --- ### **Evidence-Based CAM Therapies for GI Disorders** 1. **Mind-Body Medicine:** - Interventions like cognitive behavioral therapy (CBT), mindfulness, hypnotherapy, and yoga have demonstrated efficacy in functional GI disorders like irritable bowel syndrome (IBS). - These therapies are gaining mainstream acceptance as scientific evidence accumulates, particularly in their ability to address the neuro-gut connection. 2. **Nutritional Supplements and Herbal Therapies:** - **L-Glutamine:** Effective in postinfectious IBS with diarrhea and intestinal hyperpermeability, supporting gut barrier repair. - **Ginger and Vitamin B6:** Evidence-supported treatments for nausea, including pregnancy-related nausea, though caution is advised for ginger in patients on antiplatelet therapy. - **Peppermint and Caraway:** Extensively studied for functional dyspepsia, with significant reductions in bloating and epigastric pain. - **Curcumin:** Known for its anti-inflammatory effects in the GI tract. - **Bovine Colostrum:** Supports mucosal immunity and healing. - **Mucosal Protectants:** Compounds like zinc-carnosine, marshmallow root, slippery elm, and licorice support gut barrier function and reduce inflammation. These may also be useful in transitioning patients off proton pump inhibitors (PPIs). 3. **Probiotics:** - Specific strains, such as *Saccharomyces boulardii*, help prevent dysbiosis during antibiotic therapy. Targeted probiotics can also be used post-treatment to restore gut health. 4. **Acupuncture:** - Widely studied in various GI disorders such as constipation, GERD, IBD, ileus, pancreatitis, and gastroparesis. - Functional MRI studies show acupuncture modulates brain connectivity in regions associated with visceral sensation, pain regulation, and emotion, providing mechanistic plausibility for its efficacy. 5. **Herbal Combinations:** - **STW-5 (Iberogast):** A combination of multiple herbs, shown to improve symptoms in GERD and epigastric pain, with clinical trials supporting its efficacy. --- ### **Lifestyle and Behavioral Guidance** - CAM practitioners emphasize the importance of lifestyle changes to complement medical and CAM treatments. Key recommendations include: - Eating slowly and mindfully. - Reducing greasy and processed foods. - Avoiding lying down immediately after meals. - Ensuring adequate fiber intake. These strategies not only help manage symptoms but also address underlying contributors to GI disorders. --- ### **Evolving Acceptance of CAM in GI Disorders** - Therapies once considered fringe, such as mind-body medicine and concepts like intestinal permeability ("leaky gut"), are gaining legitimacy as scientific evidence accumulates. - The integrative approach to gastroenterology is increasingly recognized for its potential to accelerate symptom relief, reduce reliance on medications, and improve overall quality of life for patients with functional and inflammatory GI disorders. --- ### **Concerns with Overuse of Conventional Treatments** - Overprescription of proton pump inhibitors (PPIs) is a concern, as they are often prescribed without confirming true hyperacidity. This can lead to risks like infections, nutrient malabsorption, and rebound hyperacidity. CAM therapies, such as mucosal protectants and lifestyle changes, may serve as alternatives or adjuncts to reduce reliance on PPIs. --- ### **Clinical Implications** Gastroenterologists should: 1. Proactively inquire about CAM use during patient consultations. 2. Stay informed about evidence-based CAM therapies to provide safe and effective recommendations. 3. Integrate CAM with standard care to offer a holistic approach to managing GI disorders. By combining conventional medicine with evidence-supported CAM, healthcare providers can address both the physical and psychological dimensions of GI disorders, ultimately improving patient outcomes and satisfaction.

Sarcopenia in Crohn's Disease

Sarcopenia in Crohn's Disease (CD), particularly in pediatric patients, is a significant clinical concern. Below is a detailed summary of its prevalence, prognostic value, clinical implications, and management considerations based on the study findings: ### **Definition of Sarcopenia** - Sarcopenia refers to the loss of skeletal muscle mass and function. In this study, it was defined using MRI measurements of the total psoas muscle area at the L3–L4 vertebral level. A z-score of less than -2 standard deviations (SD) was considered diagnostic for sarcopenia. --- ### **Prevalence** - **High prevalence:** Sarcopenia was detected in 59% (46 out of 78) of children newly diagnosed with Crohn's Disease. This highlights that muscle loss is a common issue at diagnosis in pediatric CD. --- ### **Prognostic Value** 1. **Relapse Risk:** - **At 6 months:** Children with sarcopenia faced a significantly higher risk of disease relapse compared to those without sarcopenia (Odds Ratio [OR] 7.5; P = .04). - **At 12 months:** The risk remained elevated (OR 5.9; P = .01), indicating that sarcopenia is a consistent predictor of relapse. 2. **Relapse-Free Survival:** - Sarcopenic children had markedly lower relapse-free survival rates (Hazard Ratio 2.7; 95% Confidence Interval [CI] 1.4–4.5), underscoring sarcopenia's impact on disease progression. 3. **Independent Predictor:** - Sarcopenia remained an independent predictor of relapse even after adjusting for confounding factors (adjusted OR 1.7; P = .04). --- ### **Clinical Implications** 1. **Disease Severity:** - Sarcopenia may reflect more aggressive disease, as children with sarcopenia were more likely to require therapeutic escalation (e.g., advanced treatments). 2. **Growth and Development:** - Persistent sarcopenia during childhood could negatively impact growth, pubertal development, and long-term health outcomes. Muscle loss in growing children is particularly concerning, as it can impair physical and metabolic development. 3. **Hospitalization and Complications:** - While relapse risk was clearly elevated, differences in hospitalization rates, complications, and corticosteroid use were less consistent across the study cohort. 4. **Resolution of Sarcopenia:** - At 24 months, MRI re-evaluation showed that 39% of children with sarcopenia experienced resolution, while 61% had persistent muscle loss. Children with unresolved sarcopenia had significantly lower muscle mass compared to those whose sarcopenia improved (P = .01). --- ### **Underlying Mechanisms** 1. **Malnutrition:** - Sarcopenia likely reflects malnutrition, which is common in CD due to reduced nutrient absorption, dietary restrictions, and anorexia associated with chronic illness. 2. **Systemic Inflammation:** - Chronic inflammation in CD accelerates muscle breakdown, contributing to sarcopenia. Elevated inflammatory markers may exacerbate muscle loss, highlighting the need for effective inflammation control. --- ### **Management Considerations** 1. **Early Assessment:** - Muscle mass evaluation at diagnosis should be part of the baseline workup in pediatric CD. MRI-based assessment of psoas muscle area is feasible, reproducible, and non-invasive, making it a valuable tool for sarcopenia screening. 2. **Nutritional Support:** - Addressing sarcopenia requires integrating nutritional interventions (e.g., high-protein diets, caloric supplementation) into CD management strategies. Nutritional therapy could help improve muscle mass and overall health outcomes. 3. **Inflammation Control:** - Effective management of systemic inflammation may aid muscle mass recovery and reduce the risk of sarcopenia persistence. Anti-inflammatory therapies could indirectly support muscle health. 4. **Therapeutic Target:** - Sarcopenia should not only be viewed as a marker of disease severity but also as a therapeutic target. Interventions aimed at improving muscle mass could potentially reduce relapse rates and improve disease outcomes. --- ### **Study Limitations** 1. **Single-Center Study:** - The study was conducted in a single pediatric gastroenterology and hepatology unit in Rome, which may limit the generalizability of findings. 2. **Retrospective Design:** - The retrospective nature of the study introduces potential biases and limits the ability to establish causality. 3. **Lack of Pediatric-Specific Guidelines:** - There are no established pediatric-specific guidelines for defining or managing sarcopenia, making the interpretation of findings more challenging. --- ### **Conclusion** Sarcopenia is highly prevalent at diagnosis in children with Crohn's Disease and serves as a strong predictor of relapse risk. It reflects both malnutrition and systemic inflammation, emphasizing the need for early identification and targeted interventions. Addressing sarcopenia through nutritional support, inflammation control, and therapeutic escalation could improve disease control, reduce relapses, and support healthy growth and development in pediatric CD patients.

Proteome-Based Biopsy Scoring for Mucosal Remodeling in Celiac Disease

**Proteome-Based Biopsy Scoring for Mucosal Remodeling in Celiac Disease** refers to a novel approach that utilizes mass spectrometry–based proteomics to assess mucosal changes in the small intestine of individuals with celiac disease. This method provides a more advanced, objective, and reproducible way to evaluate the extent of mucosal remodeling, which is a key feature of the disease. ### Key Highlights of the Study: 1. **Mass Spectrometry–Based Proteomics**: - This technique analyzes the protein composition of duodenal biopsy samples. - It identifies and quantifies specific proteins that reflect the state of the intestinal mucosa. 2. **Objective Assessment**: - Unlike traditional histological examination, which can be subjective and dependent on the pathologist's interpretation, proteomic scoring offers an orientation- and observer-independent evaluation. - This ensures consistency and minimizes variability in diagnosing and monitoring the disease. 3. **Correlation with Histology**: - The proteomic scores showed a strong correlation with traditional histological findings, confirming the reliability of this method as a diagnostic and monitoring tool. 4. **Distinguishing Disease States**: - The scoring system effectively differentiated between active celiac disease (characterized by ongoing mucosal damage) and remission (where the mucosa has healed due to adherence to a gluten-free diet). 5. **Monitoring Treatment Responses**: - Proteomic scoring was sensitive enough to detect changes in the mucosa in response to treatment, including adherence to a gluten-free diet or experimental therapies. - This makes it a valuable tool for assessing the efficacy of new treatments being developed for celiac disease. 6. **Scalability and Reproducibility**: - The method is scalable, meaning it can be applied across larger patient populations. - It is also reproducible, making it a reliable tool for both clinical practice and research. ### Implications for Celiac Disease Management: - **Improved Monitoring**: This method could revolutionize how clinicians monitor mucosal healing in patients with celiac disease, offering a more precise and less subjective alternative to histology. - **Therapeutic Evaluation**: It provides a robust tool for evaluating the effectiveness of new therapies, which is critical as the field moves beyond the gluten-free diet to explore additional treatment options. - **Personalized Care**: By providing detailed insights into mucosal health, proteomic scoring could help tailor treatment plans to individual patients based on their specific disease activity. ### Conclusion: Proteome-based biopsy scoring represents a significant advancement in the management of celiac disease. By offering a scalable, reproducible, and objective method for assessing mucosal remodeling, it has the potential to improve patient outcomes, streamline disease monitoring, and accelerate the development of new therapies.

Prediction Models for Early Celiac Disease in Genetically Susceptible Children

The study titled **"Prediction Models for Early Celiac Disease in Genetically Susceptible Children"** comes from the PreventCD project, which aimed to understand and predict the development of celiac disease in children at high genetic risk. Below is a detailed breakdown of the study: ### Background: Celiac disease is an autoimmune disorder triggered by gluten in genetically predisposed individuals. The primary genetic susceptibility comes from the presence of specific *HLA-DQ2* and *HLA-DQ8* alleles. However, not all genetically predisposed individuals develop the disease, and predicting who will is a major clinical challenge. The PreventCD study followed **944 genetically high-risk children** (those with a family history of celiac disease and carrying the relevant HLA-DQ alleles) over a **12-year period** to investigate the factors that influence the development of the disease and to create models for early prediction. --- ### Key Findings: 1. **Genetic Risk and Gender:** - Children with the **HLA-DQ2 homozygous genotype** were at the highest risk of developing celiac disease. - The risk was further amplified when combined with being female, as girls were found to have a higher likelihood of developing celiac disease compared to boys. 2. **Impact of Gluten Intake:** - Early introduction of gluten into the diet was associated with a **modest increase in the risk** of developing celiac disease. This reinforces the importance of considering dietary factors in genetically susceptible children. 3. **Risk Stratification:** - Based on the study data, new **prediction models** were developed to stratify children into different risk groups for celiac disease. These models take into account genetic, demographic, and environmental factors to estimate the likelihood of disease development. 4. **External Validation:** - The prediction models were externally validated, confirming their reliability and applicability beyond the original study cohort. This ensures that the models can be used in broader clinical settings. --- ### Implications: 1. **Personalized Screening:** - The new prediction models allow for **personalized screening strategies**. Instead of a "one-size-fits-all" approach, children at the highest risk (e.g., HLA-DQ2 homozygous girls) can be monitored more closely, while those at lower risk may require less frequent screening. 2. **Earlier Diagnosis:** - By stratifying children into risk groups, healthcare providers can identify those most likely to develop celiac disease earlier, potentially leading to earlier diagnosis and intervention. Early diagnosis is critical to prevent complications such as malnutrition, growth issues, and long-term autoimmune damage. 3. **Tailored Dietary Recommendations:** - The findings regarding gluten intake suggest that dietary advice could be tailored for high-risk children. For example, delaying gluten introduction or modifying the amount of gluten in the diet may help reduce risk. --- ### Conclusion: The PreventCD study has made significant progress in understanding the development of celiac disease in genetically susceptible children. With the creation of validated prediction models, it is now possible to implement **personalized medicine approaches** for early screening and diagnosis. This represents a major step forward in managing celiac disease, improving outcomes, and reducing the burden of the disease on children and their families.

CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis

CD19 CAR T-cell therapy, a treatment traditionally used for certain types of B-cell malignancies, has shown promise in a case of severe, multidrug-resistant ulcerative colitis (UC). This novel approach led to drug-free remission and mucosal healing, offering hope for patients with refractory inflammatory bowel disease (IBD) who do not respond to conventional therapies. ### Understanding the Context: - **Ulcerative Colitis (UC):** UC is a chronic inflammatory condition of the colon and rectum, characterized by symptoms such as diarrhea, abdominal pain, rectal bleeding, and fatigue. For some patients, the disease is resistant to multiple lines of therapy, including corticosteroids, immunosuppressants, biologics (e.g., anti-TNF agents), and small molecules (e.g., JAK inhibitors). - **Multidrug-Resistant UC:** This refers to cases where patients fail to achieve remission despite using all available standard treatments, leaving them with limited options and a high risk of complications like colectomy (surgical removal of the colon). ### CD19 CAR T-Cell Therapy: - **Mechanism of Action:** CD19 CAR T-cell therapy involves engineering a patient’s T cells to express a chimeric antigen receptor (CAR) that specifically targets CD19, a protein expressed on the surface of B cells. Once infused back into the patient, these modified T cells seek out and destroy CD19-expressing B cells. - **Why Target B Cells in UC?** Although UC is primarily thought to be mediated by T cells, B cells also play a significant role in the immune dysregulation seen in UC. B cells contribute to inflammation by producing autoantibodies, presenting antigens, and secreting pro-inflammatory cytokines. Targeting B cells may help reset the immune system and reduce inflammation. ### The Breakthrough Case: - **Patient Profile:** The therapy was used in a patient with severe, multidrug-resistant UC who had exhausted all other treatment options. - **Outcome:** CD19 CAR T-cell therapy led to drug-free remission and complete mucosal healing. This means the patient no longer required medications to control their disease, and the lining of their colon showed no signs of active inflammation on endoscopy. - **Significance:** This is a groundbreaking result because it demonstrates that B-cell depletion through CD19 CAR T-cell therapy can effectively treat refractory UC, a condition that previously had very few solutions. ### Implications for the Future: - **Novel Therapeutic Approach:** This case highlights the potential of B-cell targeting as a new avenue for treating UC and potentially other forms of IBD, such as Crohn's disease. - **Further Research Needed:** While this outcome is promising, it represents a single case. Larger clinical trials are necessary to confirm the safety, efficacy, and long-term outcomes of CD19 CAR T-cell therapy in UC and to identify which patients are most likely to benefit. - **Potential Risks:** CAR T-cell therapy is associated with risks, including cytokine release syndrome (CRS) and immune suppression, which need to be carefully managed in non-cancer indications like UC. ### Conclusion: The success of CD19 CAR T-cell therapy in a patient with multidrug-resistant UC marks a significant step forward in the treatment of refractory IBD. It underscores the importance of exploring innovative immune-modulating therapies for patients who have run out of conventional options. If validated in larger studies, this approach could revolutionize the management of severe UC and improve the quality of life for many patients.

ARFID and IBD

Avoidant/restrictive food intake disorder (ARFID) and inflammatory bowel disease (IBD) share a complex relationship. ARFID is an eating disorder characterized by restrictive eating patterns often driven by anxiety, sensory sensitivity, or fear of adverse consequences, such as gastrointestinal discomfort or other negative physical outcomes. It appears to be relatively common among patients with IBD, as demonstrated by recent research. ### Key Insights on ARFID and IBD: 1. **Prevalence of ARFID in IBD Patients**: - A cross-sectional study involving 325 adults with confirmed IBD found that **17.8% of participants met criteria for ARFID** based on validated DSM-5–aligned screening tools. - Importantly, ARFID was observed in **16.3% of patients with inactive disease**, suggesting that the disorder is not exclusively linked to active inflammation but may persist even when the disease is under control. 2. **Impact on Psychosocial Functioning**: - Patients with ARFID were generally **younger**, had **shorter disease duration**, and reported **worse psychosocial functioning** compared to those without ARFID. - This highlights the psychological toll of restrictive eating behaviors, which can exacerbate emotional distress and impair quality of life. 3. **Role of GI Symptom-Specific Anxiety**: - Among patients with inactive IBD, **gastrointestinal (GI) symptom-specific anxiety** emerged as the **only significant predictor of ARFID**. - This finding suggests that psychological factors, such as fear of GI discomfort or adverse reactions to food, may drive and sustain restrictive eating behaviors even in the absence of active inflammation. 4. **ARFID in Crohn’s Disease vs. Ulcerative Colitis**: - The prevalence of ARFID did not differ significantly between patients with **Crohn’s disease** and those with **ulcerative colitis**, indicating that the disorder is equally relevant across different types of IBD. 5. **Clinical Implications**: - Restrictive eating associated with ARFID can lead to **nutritional deficiencies**, worsening the overall health and quality of life for IBD patients. This is particularly concerning in a population already vulnerable to malnutrition due to the underlying disease. - The study underscores the importance of **assessing eating behaviors** in IBD care pathways. Early identification and intervention for ARFID could help mitigate its negative effects on nutrition and psychosocial well-being. ### Recommendations for IBD Care: - **Multidisciplinary Approach**: Raising awareness of ARFID among healthcare providers treating IBD is crucial. Integrating **psychological, nutritional, and medical strategies** into care plans can address the disorder comprehensively and improve long-term outcomes. - **Psychological Support**: Since anxiety—particularly GI symptom-specific anxiety—is a key driver of ARFID in IBD patients, psychological interventions such as **cognitive-behavioral therapy (CBT)** or **anxiety management techniques** may be beneficial. - **Nutritional Counseling**: Nutritional support tailored to the unique needs of IBD patients with ARFID can help restore balanced eating patterns and prevent deficiencies. - **Patient Education**: Educating patients about the relationship between food intake, IBD symptoms, and anxiety may reduce fear-driven food avoidance and promote healthier eating habits. ### Conclusion: ARFID is a significant concern in the IBD population, affecting nearly one in five patients. Its prevalence in inactive disease highlights the role of psychological factors rather than active inflammation in driving restrictive eating behaviors. Addressing ARFID in IBD care pathways through a multidisciplinary approach could improve nutritional status, psychosocial functioning, and overall quality of life for these patients.

PLANET study

The **PLANET study** is a research initiative that is prospectively investigating the exposure to **micro- and nanoplastics** in **pregnant women** and their **children**. It is part of the growing body of research aimed at understanding how environmental pollutants, specifically micro- and nanoplastics, impact human health, particularly during critical developmental periods such as pregnancy and early childhood. ### Key Aspects of the PLANET Study: 1. **Focus on Micro- and Nanoplastics Exposure**: - Microplastics (<5 mm) and nanoplastics (<1 µm) are pervasive in the environment and can enter the human body through ingestion (e.g., contaminated food and water, particularly bottled water) and inhalation (e.g., airborne plastic particles). - Nanoplastics are especially harmful because they can penetrate tissues more easily and carry adsorbed toxic chemicals, potentially leading to inflammation and other health issues. 2. **Target Population**: - The study specifically looks at **pregnant women** and their **children**, recognizing that exposure during pregnancy could have long-term health implications for both the mother and the developing fetus. - Pregnancy is a critical window of vulnerability because environmental exposures during this time can influence fetal development and shape disease risk later in life. 3. **Health Implications**: - Micro- and nanoplastics have been detected in human tissues, including the colon, liver, kidney, brain, placenta, and vascular plaques. These exposures are linked to inflammation, changes in the gut microbiome, and potentially increased risk for diseases like Crohn’s disease. - The study aims to explore how these plastic particles affect maternal health, fetal development, and the child’s health outcomes over time. 4. **Broader Context**: - The PLANET study is part of a larger effort to understand how environmental factors, such as pollution and toxic substances, contribute to chronic diseases like Crohn’s disease. - It complements research into other environmental contributors, such as toxic metals, air pollution, and access to green space. 5. **Potential Outcomes**: - By studying the effects of micro- and nanoplastics exposure in pregnant women and children, the PLANET study could provide valuable insights into preventive strategies to reduce exposure and mitigate health risks. - The findings may inform public health policies, such as improving water filtration systems, reducing the use of single-use plastics, and promoting healthier environments for vulnerable populations. In summary, the PLANET study is a forward-looking investigation into how micro- and nanoplastics exposure during pregnancy affects maternal and child health, contributing to the broader understanding of environmental influences on chronic diseases like Crohn’s disease. It highlights the importance of addressing environmental pollutants to protect future generations.

PFAS, Pesticides and IBD

Per- and polyfluoroalkyl substances (PFAS) and agricultural pesticides are increasingly recognized as environmental factors that contribute to the risk of inflammatory bowel diseases (IBD), particularly Crohn's disease. Here’s a detailed breakdown of their roles and mechanisms: ### PFAS and Crohn’s Disease: PFAS, often called "forever chemicals," are synthetic compounds widely used in consumer products such as food packaging, nonstick cookware, waterproof textiles, and other household items. These chemicals are highly persistent in the environment and accumulate in human tissues over time, posing significant health risks. #### Evidence Linking PFAS to Crohn’s Disease: 1. **Occupational Studies**: Early data from occupational cohorts, such as those involving workers at DuPont, initially highlighted the association between PFAS exposure and IBD. 2. **Military-Recruit Sera Studies**: Longitudinal studies on military recruits showed that higher levels of PFAS mixtures in blood were associated with increased odds of developing Crohn’s disease, even years before diagnosis. This association was observed across multiple pre-diagnosis timepoints. 3. **Early-Life Exposure**: Research on newborn dried blood spots revealed that higher PFAS levels correlated with elevated fecal calprotectin, a marker of intestinal inflammation. This suggests that PFAS exposure early in life may predispose individuals to Crohn’s disease later. #### Mechanisms of Action: PFAS contribute to Crohn’s disease through biologically plausible mechanisms: - **Impairment of Intestinal Barrier Integrity**: PFAS disrupt the epithelial barrier in the gut, allowing harmful substances to penetrate and trigger inflammation. - **Alteration of IgG Glycosylation**: PFAS affect immune system function by altering IgG glycosylation, which may promote mucosal inflammation and immune dysregulation. ### Pesticides and Crohn’s Disease: Agricultural pesticides, particularly those used in intensively farmed regions, have also been implicated in Crohn’s disease pathogenesis. Rural areas with high pesticide use have shown clusters of Crohn’s disease cases. #### Evidence Linking Pesticides to Crohn’s Disease: 1. **Geographical Clustering**: Regions like Northern France and Denmark have reported higher Crohn’s disease incidence in areas with intensive farming. Danish nationwide data demonstrated a dose-dependent risk of Crohn’s disease associated with early-life exposure to agricultural land use. 2. **Timing of Exposure**: High pesticide exposure 6–10 years before Crohn’s disease onset was associated with increased risk, indicating a latency period between exposure and disease development. 3. **Specific Chemicals**: Studies have identified certain biocides, such as the herbicide propyzamide, as particularly problematic. Propyzamide has been shown to directly disrupt epithelial barriers in the gut. #### Mechanisms of Action: Pesticides contribute to Crohn’s disease through: - **Disruption of Epithelial Barriers**: Similar to PFAS, pesticides can impair the gut’s protective barrier, making it more susceptible to inflammation. - **Environmental Impact**: Agricultural chemicals may alter the microbiome or introduce toxins that exacerbate intestinal inflammation and immune system dysregulation. ### Combined Impact of PFAS and Pesticides: Both PFAS and pesticides are modifiable environmental factors that increase the risk of Crohn’s disease. Their combined impact is particularly concerning in rural and agricultural settings where exposure to both streams is likely. ### Implications for Public Health and Clinical Practice: 1. **Exposure Assessment**: Clinical histories should include detailed exposure assessments for PFAS and pesticides, especially for patients with suspected or diagnosed Crohn’s disease. 2. **Preventive Measures**: Public health actions should aim to reduce contact with these chemicals across the life course. This includes stricter regulations on PFAS use and agricultural pesticide application. 3. **Research and Advocacy**: Further research is needed to refine our understanding of how these chemicals interact with genetic and environmental factors in Crohn’s disease pathogenesis. Advocacy for safer chemical alternatives and improved environmental policies is critical. ### Conclusion: The evidence strongly supports PFAS and pesticides as modifiable contributors to Crohn’s disease, emphasizing the importance of reducing exposure to these chemicals to mitigate risk. Their role in disrupting gut barrier integrity and immune function provides a mechanistic link to the inflammation characteristic of Crohn’s disease, underscoring the need for both clinical vigilance and public health interventions.

Obesity and response to IBD treatment

Obesity has been identified as a significant factor influencing the response to treatment in patients with inflammatory bowel disease (IBD). A large registry-based study from the Initiative on Crohn and Colitis evaluated 1,066 patients initiating various therapies, including thiopurines with allopurinol, vedolizumab, ustekinumab, ozanimod, filgotinib, and tofacitinib. These patients were categorized into three groups based on their body mass index (BMI): normal weight (<25), overweight (25–29.9), and obesity (≥30). The primary outcome assessed was steroid-free clinical remission at week 24, defined using disease-specific activity indices. ### Key Findings: 1. **Reduced Remission in Obese Patients**: - Patients with obesity had significantly lower rates of steroid-free clinical remission at week 24 compared to those with normal weight (35.3% vs. 48.6%). - Obesity was independently associated with reduced odds of achieving remission, with an adjusted odds ratio of 0.537 (P = .005). 2. **Overweight Patients Showed Temporary Benefit**: - Overweight patients demonstrated higher odds of achieving remission at week 12. However, this benefit did not persist at later time points. 3. **Long-term Outcomes**: - By week 52, remission rates were comparable across all BMI categories, suggesting that the impact of BMI on treatment response may be more pronounced in the early phases of treatment. - Treatment discontinuation rates did not differ significantly across BMI groups at any follow-up interval. ### Potential Mechanisms: The reduced efficacy of IBD treatment in obese patients may be attributed to several factors: - **Altered Drug Pharmacokinetics**: Obesity can affect drug absorption, distribution, metabolism, and elimination, potentially reducing the effectiveness of therapies. - **Increased Systemic Inflammation**: Obesity is associated with a pro-inflammatory state, which may exacerbate IBD symptoms and hinder treatment response. - **Microbiome-Related Mechanisms**: Obesity can alter gut microbiota composition, which may interact with IBD pathophysiology and treatment efficacy. ### Clinical Implications: 1. **Addressing Weight in IBD Management**: - These findings highlight the importance of addressing obesity as part of IBD management. - Nutritional counseling and lifestyle interventions should be incorporated to optimize both general health and therapeutic outcomes for obese IBD patients. 2. **Personalized Treatment Strategies**: - Clinicians should consider the potential impact of obesity when selecting and monitoring IBD therapies. - Further research is needed to explore whether specific treatments or dosing adjustments could mitigate the impact of obesity on treatment response. In summary, obesity appears to hinder early treatment efficacy in IBD, likely due to a combination of biological and pharmacological factors. While remission rates eventually equalize across BMI categories by week 52, addressing obesity through integrated care approaches may enhance early treatment outcomes and overall disease management.

Hypogonadism and Bone Health in IBD

**Hypogonadism and Bone Health in IBD (Inflammatory Bowel Disease)** Hypogonadism is a common complication in patients with IBD, and it has significant implications for bone health. The interplay of poor nutrition, chronic inflammation, and the use of glucocorticoids in IBD contributes to hypogonadism, which in turn exacerbates bone loss and increases the risk of osteoporosis. Below is a detailed explanation of the mechanisms and effects of hypogonadism on bone health in IBD: --- ### **1. Causes of Hypogonadism in IBD** - **Poor Nutrition:** IBD often leads to malnutrition due to dietary restrictions, malabsorption, or reduced appetite. This can impair the production of gonadal steroids. - **Chronic Inflammation:** Persistent inflammation in IBD disrupts the hypothalamic-pituitary-gonadal axis, leading to reduced secretion of sex hormones like testosterone and estrogen. - **Glucocorticoid Therapy:** Long-term use of systemic glucocorticoids, a common treatment for controlling IBD inflammation, suppresses gonadal function. --- ### **2. Impact of Hypogonadism on Bone Health** - **Low Gonadal Steroids:** Hypogonadism results in reduced levels of testosterone and estrogen, which are critical for maintaining bone health. - **Estrogen (in both men and women):** Plays a key role in suppressing bone resorption by osteoclasts. - **Testosterone:** Stimulates bone formation and inhibits bone resorption. - **Bone Resorption vs. Formation:** Low levels of these hormones shift the balance toward increased bone resorption and decreased bone formation, leading to a net loss of bone density. --- ### **3. Additional Risk in Children with IBD** - **Delayed Puberty:** Hypogonadism can delay the onset of puberty in children with IBD. Since puberty is a critical window for bone mass accrual, delayed puberty adds an additional risk for low bone density and long-term osteoporosis. --- ### **4. Role of Glucocorticoids in Bone Loss** - **Direct Effects on Bone:** - Glucocorticoids reduce calcium absorption in the gut and increase calcium excretion in the kidneys, leading to secondary hyperparathyroidism and bone loss. - They impair both bone formation and bone resorption, with the primary issue being a failure of bone formation. - **Indirect Effects on Hypogonadism:** - Glucocorticoids suppress the hypothalamic-pituitary-gonadal axis, worsening hypogonadism and its effects on bone health. - **Growth Hormone (GH)–IGF-1 Axis:** Glucocorticoids also impair the GH–IGF-1 axis, which is crucial for bone growth and maintenance. --- ### **5. RANKL–OPG Pathway and Bone Loss** The RANKL–OPG pathway is central to the regulation of bone remodeling and is affected in IBD: - **RANKL (Receptor Activator of NF-kappa B Ligand):** - Produced by osteoblasts, RANKL binds to its receptor, RANK, on osteoclast precursors, stimulating their differentiation and activity, leading to bone resorption. - **OPG (Osteoprotegerin):** - OPG acts as a decoy receptor for RANKL, preventing it from binding to RANK and thereby inhibiting bone resorption. - **In IBD and Glucocorticoid Therapy:** - Chronic inflammation, glucocorticoids, and estrogen deficiency increase RANKL levels and decrease OPG levels, tipping the balance toward bone resorption. - Interestingly, in some IBD patients, OPG levels may be elevated as a protective adaptive response, but it may not be sufficient to counteract the elevated RANKL. --- ### **6. Special Notes on Glucocorticoids** - **Systemic Steroids:** These have a strong negative effect on bone health and are a major contributor to bone loss in IBD. - **Budesonide (Local Steroid):** Budesonide is thought to have a lesser impact on bone density compared to systemic steroids, but evidence on its bone-sparing effects is mixed. - **Main Issue with Glucocorticoids:** The primary problem is the suppression of bone formation rather than just an increase in bone resorption. --- ### **Conclusion** Hypogonadism in IBD, driven by poor nutrition, chronic inflammation, and glucocorticoid therapy, has profound effects on bone health. It leads to reduced levels of gonadal steroids, delayed puberty in children, and an imbalance in bone remodeling processes. The combined effects of hypogonadism, glucocorticoid use, and alterations in the RANKL–OPG pathway significantly increase the risk of osteoporosis and fractures in IBD patients. Addressing these factors through proper management of inflammation, minimizing glucocorticoid use, and optimizing nutrition and hormone levels is critical for preserving bone health in this population.

Ultraprocessed Food and Premature Death

Ultraprocessed foods (UPFs) have been linked to higher rates of premature death, according to a global analysis conducted across eight countries. The study highlights a clear dose–response pattern: for every 10% increase in daily energy intake from UPFs, the risk of all-cause mortality rises by 2.7%. This finding underscores the significant health risks associated with diets high in UPFs. ### Key Findings: 1. **Country Variations in UPF Consumption**: - The proportion of UPFs in daily diets varies widely across countries. For instance, Colombia has the lowest share, with UPFs contributing 15% of daily caloric intake, while the United States has the highest, exceeding 50%. - This variation in consumption directly correlates with the estimated premature deaths attributable to UPFs. In Colombia, 4% of premature deaths were linked to UPFs, whereas in the US and UK, the figure reached 14%. 2. **Impact on Premature Deaths**: - In the United States alone, UPFs were estimated to contribute to 124,000 premature deaths in 2018. - These findings highlight the significant burden of UPF consumption on public health. 3. **What Are UPFs?**: - Ultraprocessed foods are industrial formulations that typically contain little to no whole food content. They are often high in unhealthy ingredients such as fats, sugars, and additives. - Examples include sugary drinks, packaged snacks, instant meals, and fast food. 4. **Public Health Implications**: - Researchers have declared UPFs a "public health concern" and emphasized the need for policy interventions beyond individual education. - Suggested measures include: - **Taxes** on UPFs to discourage consumption. - **Subsidies** for fresh and whole foods to make healthier options more accessible. - **Improved labeling** to help consumers identify and avoid UPFs. - **Restrictions on marketing** to limit the promotion of UPFs, particularly to vulnerable populations like children. 5. **Study Limitations**: - The analysis relied on observational data and broad NOVA food categories, which classify foods based on their level of processing. - While this introduces some limitations, the consistency of findings across multiple countries strengthens the argument that UPFs are detrimental to health. ### Global Health Priority: The study’s findings make a compelling case for reducing UPF intake as a global health priority. The widespread consumption of UPFs, especially in countries like the US and UK, poses a significant challenge to public health systems. Addressing this issue will require coordinated efforts from governments, health organizations, and the food industry to implement effective policies that promote healthier diets and reduce the prevalence of UPFs in food systems.

Obesity and Gut Microbiota

Obesity and gut microbiota are intricately linked, as the microbial composition and functions in the gut play a significant role in energy balance, metabolism, and fat storage. The gut microbiota refers to the trillions of microorganisms, including bacteria, viruses, fungi, and other microbes, that reside in the gastrointestinal tract. These microbes are not only crucial for digestion but also influence various physiological processes that can contribute to obesity. ### How Gut Microbiota Contribute to Obesity: 1. **Energy Harvest and Storage**: - Gut bacteria break down complex carbohydrates from dietary fiber into smaller sugars and **short-chain fatty acids (SCFAs)**, which are absorbed by the body as energy. - SCFAs, such as acetate, propionate, and butyrate, influence metabolic pathways: - **Acetate** stimulates fat and cholesterol synthesis, contributing to fat storage. - **Propionate** regulates gluconeogenesis (glucose production) and cholesterol levels. - **Butyrate** impacts satiety hormones (like leptin) and nutrient absorption, potentially influencing appetite and food intake. 2. **Altered Gut Microbiota in Obesity**: - In individuals with obesity, the composition of gut microbiota changes, often showing an imbalance between beneficial and harmful bacteria. - This altered microbiota leads to: - Increased energy harvest from food, promoting fat storage. - Elevated fat and glucose production. - Reduced energy expenditure due to decreased thermogenesis and beta-oxidation (fat burning processes). 3. **Bile Acid Metabolism**: - Gut microbes regulate bile acid metabolism, which is essential for digesting and absorbing dietary fats. - Changes in gut microbiota can impair bile acid function, leading to increased fat absorption and storage. 4. **Inflammation and Insulin Resistance**: - An imbalanced gut microbiota can trigger chronic inflammation by producing harmful molecules that disrupt the gut barrier. - This inflammation is associated with insulin resistance, a key factor in obesity and metabolic disorders. ### Preventing or Managing Obesity Through Gut Microbiota: A healthy gut microbiota can help prevent or manage obesity by promoting balanced energy metabolism and reducing fat storage. Strategies to support gut health include: 1. **Dietary Interventions**: - **Fiber-rich diet**: Consuming plenty of fruits, vegetables, whole grains, and legumes supports beneficial gut bacteria that produce SCFAs. - **Avoiding ultraprocessed foods**: These foods can disrupt gut microbiota and promote inflammation. - **Probiotic and prebiotic foods**: Yogurt, kefir, fermented vegetables, and foods high in prebiotic fibers (like garlic, onions, and bananas) can enhance beneficial bacteria. 2. **Minimizing Antibiotic Use**: - Unnecessary or frequent use of antibiotics can disrupt gut microbial balance, reducing diversity and beneficial bacteria. 3. **Lifestyle Factors**: - Regular physical activity has been shown to positively influence gut microbiota composition. - Stress management can also help maintain gut health, as stress can negatively impact the microbiota. ### Emerging Therapies: The gut microbiota is a promising target for innovative obesity treatments, including: - **Fecal microbiota transplantation (FMT)**: Transferring gut microbes from healthy individuals to obese patients to restore microbial balance. - **Microbiome-targeted drugs**: Developing medications that modulate gut microbiota to improve metabolism and reduce fat storage. - **Personalized nutrition**: Tailoring diets based on an individual's gut microbiota composition for optimal weight management. ### Conclusion: The gut microbiota plays a central role in the complex interplay between diet, metabolism, and obesity. By influencing energy harvest, fat storage, and satiety, gut microbes can either promote or prevent obesity. Maintaining a healthy gut microbiota through diet, lifestyle, and emerging therapies offers a promising approach to managing obesity and improving overall metabolic health.

DGBI and Carbohydrate intolerance

**Disorders of Gut-Brain Interaction (DGBI) and Carbohydrate Intolerance:** **Overview of DGBI:** Disorders of Gut-Brain Interaction (DGBI) encompass a group of conditions characterized by abnormal communication between the gut and the brain. These disorders include conditions such as irritable bowel syndrome (IBS), functional dyspepsia, and functional constipation, among others. DGBI are not caused by structural abnormalities or diseases but rather by dysfunction in the gut-brain axis, leading to symptoms like abdominal pain, bloating, diarrhea, constipation, and altered bowel habits. **Carbohydrate Intolerance in DGBI:** Carbohydrate intolerance is a condition where the body has difficulty digesting certain types of carbohydrates, such as lactose (milk sugar) and fructose (fruit sugar). In a French study of 301 adults with DGBI, carbohydrate intolerance was found to be highly prevalent: - **Prevalence:** More than half (59%) of the participants had carbohydrate intolerance, involving lactose, fructose, or both. Additionally, 44% showed evidence of carbohydrate malabsorption on breath testing. - **Breakdown of Intolerance:** - 47 patients were intolerant to lactose only. - 54 patients were intolerant to fructose only. - 77 patients were intolerant to both lactose and fructose. **Who Is Most Affected?** - **Gender:** Women were more likely to have carbohydrate intolerance compared to men. - **Multiple DGBIs:** Patients with multiple DGBI conditions were also more likely to experience carbohydrate intolerance. **Clinical Impact:** Carbohydrate intolerance in DGBI patients was associated with worse clinical outcomes: - **Worsened IBS Symptoms:** Patients with carbohydrate intolerance experienced more severe IBS symptoms compared to those without intolerance. - **Somatic Complaints:** These individuals reported more somatic complaints, which are physical symptoms not explained by underlying organic disease (e.g., fatigue, headaches, muscle pain). - **Lower Quality of Life:** Carbohydrate intolerance negatively impacted patients' overall quality of life. **Key Findings:** - **Lactose Maldigestion:** Lactose maldigestion was strongly linked to carbohydrate intolerance and correlated with the severity of somatic symptoms. - **Fructose Malabsorption:** Fructose malabsorption alone was not significantly associated with worse symptoms or somatic complaints. **Implications for Management:** Carbohydrate intolerance is common in DGBI and contributes to the severity of symptoms. Identifying and addressing carbohydrate intolerance, particularly lactose-related intolerance, may help guide personalized treatment strategies. For example: - **Dietary Adjustments:** Eliminating or reducing problematic carbohydrates (e.g., lactose or fructose) from the diet may alleviate symptoms. - **Improved Quality of Life:** Targeted dietary interventions can potentially improve the quality of life for DGBI patients. **Conclusion:** Carbohydrate intolerance plays a significant role in exacerbating symptoms and reducing the quality of life in individuals with DGBI. Understanding the specific type of carbohydrate intolerance (lactose, fructose, or both) and tailoring management strategies accordingly could lead to better outcomes for these patients.

Auto-Brewery Syndrome (ABS)

**Auto-Brewery Syndrome (ABS)**, also referred to as **gut fermentation syndrome**, is a rare and likely underdiagnosed medical condition in which gut microbes (bacteria and/or yeast) ferment carbohydrates into ethanol (alcohol) within the gastrointestinal tract. This leads to elevated blood alcohol levels, causing symptoms of intoxication even when the individual has not consumed any alcoholic beverages. ### **Key Features of Auto-Brewery Syndrome (ABS):** #### **Symptoms:** - **Intoxication-like effects** without alcohol consumption: - Slurred speech - Dizziness - Poor coordination - Cognitive impairment - **Brain fog** and difficulty concentrating - Fatigue - Social, legal, or professional issues similar to those faced by individuals with alcohol use disorder (e.g., DUI charges or workplace concerns) - Potential mood changes, irritability, or confusion #### **Underlying Cause:** The condition is caused by an overgrowth of ethanol-producing microbes in the gut. These microbes ferment dietary carbohydrates (like sugar or starch) into alcohol. The most commonly implicated organisms include: - **Klebsiella pneumoniae** - **Escherichia coli (E. coli)** - Occasionally, certain **yeast species** (e.g., *Saccharomyces cerevisiae*, also known as brewer's yeast) #### **Diagnosis:** Diagnosis of ABS is challenging and often delayed due to its rarity and the nonspecific nature of its symptoms. The following diagnostic tools are used: 1. **Oral Glucose Challenge Test**: - The patient consumes a glucose-rich solution, and blood alcohol levels are monitored over time. - A rise in blood alcohol levels above the legal driving limit (without alcohol consumption) confirms gut-driven ethanol production. 2. **Stool Analysis**: - Stool samples are analyzed to identify ethanol-producing microbes, such as *Klebsiella pneumoniae* or *E. coli*. - Studies of fermentation pathways may reveal heightened microbial activity leading to excess ethanol production. 3. **Blood Alcohol Testing**: - Elevated blood alcohol levels in the absence of alcohol ingestion provide critical evidence. #### **Treatment Options:** Treatment for ABS focuses on reducing the overgrowth of ethanol-producing microbes and restoring gut microbial balance. Approaches include: 1. **Selective Antibiotics**: - Used to target and reduce overgrowth of specific ethanol-producing bacteria like *Klebsiella pneumoniae* or *E. coli*. 2. **Probiotics and Prebiotics**: - Probiotics (beneficial bacteria) and prebiotics (compounds that promote the growth of healthy gut microbes) may help restore a balanced gut microbiome. 3. **Antifungal Medications**: - If yeast (e.g., *Saccharomyces cerevisiae*) is involved, antifungal drugs may be prescribed. 4. **Dietary Modifications**: - Reducing carbohydrate and sugar intake can limit the substrate available for fermentation by gut microbes. 5. **Fecal Microbiota Transplant (FMT)**: - A promising treatment in which healthy donor stool is transplanted to the patient to restore a balanced gut microbiome. - One patient in a recent study achieved long-term remission after repeated FMT treatments. #### **Recent Research and Findings:** - In a 2019 case, *Klebsiella pneumoniae* was identified as a major cause of ABS in one patient. - Dr. Bernd Schnabl from UC San Diego created the largest cohort of ABS patients to date, studying 22 individuals with confirmed cases. - Stool studies revealed that *E. coli* and *Klebsiella pneumoniae* were the primary ethanol-producing microbes, with heightened fermentation pathways during symptom flares. #### **Prevalence and Underdiagnosis:** Although ABS is still considered rare, it may be more common than currently recognized. Many patients may have mild symptoms, such as fatigue or brain fog, which are often attributed to other conditions. Physicians are encouraged to consider ABS in cases of unexplained intoxication or cognitive symptoms, especially when blood alcohol levels are inexplicably elevated. ### **Key Takeaways:** - Auto-Brewery Syndrome is a condition where gut microbes produce alcohol, leading to symptoms of intoxication without alcohol consumption. - Diagnosis involves glucose challenge tests, blood alcohol testing, and stool analysis for ethanol-producing microbes. - Treatments include antibiotics, probiotics, dietary changes, antifungals, and fecal microbiota transplants. - While rare, ABS may be underdiagnosed, and awareness among healthcare providers is crucial for timely identification and management.

Extra bacterial Gut Ecosystem

The gut ecosystem is predominantly composed of bacteria, but emerging research highlights the importance of other microbial entities, such as fungi and bacteriophages, which play crucial roles in maintaining gut health and influencing disease outcomes. These "extra-bacterial" components of the gut microbiome are increasingly recognized as key players in the gut ecosystem. ### **Fungi in the Gut Ecosystem** Fungi, while representing less than 1% of the microbiome's genetic content, contribute 1–2% of its biomass and have disproportionately significant effects on the immune system. Their roles in the gut ecosystem include: 1. **Immune Modulation**: - Fungi can interact with the host's immune system in complex ways. For instance, certain species of *Candida* have dual roles: - **Beneficial Effects**: They can support metabolic health under specific conditions. - **Pathogenic Effects**: In certain immune contexts or morphological states, *Candida* species can drive inflammatory diseases like inflammatory bowel disease (IBD). 2. **Fungal Diversity**: - The fungal population in the gut is much smaller compared to bacteria, but their interactions with the host and other microbes can lead to significant health outcomes. - Dysbiosis within the fungal community is associated with various gastrointestinal disorders, including IBD and metabolic syndromes. ### **Bacteriophages in the Gut Ecosystem** Bacteriophages (phages) are viruses that infect bacteria and are highly abundant in the gut microbiome. They are emerging as critical modulators of bacterial populations and potential therapeutic agents. Their roles include: 1. **Bacterial Population Control**: - Phages are considered the strongest modulators of bacterial populations in the gut. They can selectively infect and lyse specific bacterial species, helping maintain microbial balance. 2. **Therapeutic Potential**: - Phage therapy, once sidelined due to the widespread use of antibiotics, is re-emerging as a promising tool to combat multidrug-resistant bacterial infections and chronic gastrointestinal diseases. - Engineered phage cocktails, such as CRISPR-enhanced phages like SNIPR001, are being developed to target specific pathogens like *E. coli* in vulnerable patients, such as those undergoing stem cell transplants. 3. **Phages in Disease-Specific Research**: - *Enterococcus faecalis*: Studied in the context of alcoholic hepatitis. - *Adherent-invasive E. coli*: Targeted in Crohn’s disease. - *Klebsiella pneumoniae*: Investigated in inflammatory bowel disease (IBD) and primary sclerosing cholangitis. 4. **Challenges in Phage Therapy**: - Narrow host ranges: Phages often infect only specific bacterial strains, requiring careful selection for therapeutic use. - Acid sensitivity: Phages can be degraded in the acidic environment of the stomach, posing delivery challenges. - Resistance testing: Bacteria can evolve resistance to phages, necessitating ongoing research to develop effective strategies. - Immune interactions: Phages can interact with the host immune system, which may influence their efficacy and safety. ### **Why Fungi and Phages Matter in the Gut Ecosystem** - **Therapeutic Frontiers**: Both fungi and phages represent promising avenues for microbiome-driven disease management, especially in conditions like IBD, Crohn’s disease, and infections caused by multidrug-resistant bacteria. - **Complex Interactions**: Their interactions with bacteria, the immune system, and the host's physiology underscore their importance in the gut ecosystem. - **Research Gaps**: While their therapeutic potential is significant, challenges such as narrow host ranges (phages), immune context (fungi), and delivery methods remain areas of active investigation. ### **Conclusion** The gut ecosystem is not limited to bacteria; fungi and bacteriophages are integral components that influence health and disease. Their roles in immune modulation, bacterial population control, and therapeutic applications make them essential players in microbiome research and disease management. As research advances, fungi and phages are likely to become key tools in addressing microbiome-driven diseases.

Obefazimod (ABX464) in Ulcerative Colitis

Obefazimod, also known as ABX464, is a first-in-class small molecule with a novel mechanism of action specifically designed to treat moderate-to-severe ulcerative colitis (UC). Below is a detailed overview of its features, mechanism, clinical trials, and safety profile: ### **Mechanism of Action** Obefazimod works by upregulating **miR-124**, a naturally occurring anti-inflammatory microRNA. This upregulation leads to the downregulation of key pro-inflammatory cytokines such as **TNF-α**, **IL-6**, and **IL-17**, which are heavily involved in the inflammatory process of UC. By modulating these cytokines, Obefazimod acts as a natural brake on inflammation, offering a non-immunosuppressive approach to managing UC. This upstream mechanism is unique and differentiates Obefazimod from other therapies in the UC treatment landscape. ### **Clinical Trials** #### **Phase 2b Trials** - **Efficacy:** Obefazimod demonstrated significant efficacy in achieving clinical remission in patients with moderate-to-severe UC. - **Safety:** The trials established the drug's safety profile, paving the way for further investigation in larger Phase 3 trials. #### **Phase 3 Trials (ABTECT-1 and ABTECT-2)** - **Primary Endpoint:** Obefazimod achieved the FDA’s primary endpoint of clinical remission at Week 8, particularly with the 50 mg dose. - **Optimal Dose:** The 50 mg dose emerged as the preferred option due to its effectiveness and better tolerability compared to higher doses. ### **Long-Term Safety & Efficacy** In 2-year open-label extension studies: - Patients who initially received 100 mg and later switched to the 50 mg dose maintained **clinical remission** and **mucosal healing** over the long term. - This suggests that the lower dose is effective for sustained disease control and maintenance therapy. ### **Safety Profile** - **Favorable Tolerability:** The 50 mg dose was better tolerated, with fewer adverse events compared to the 100 mg dose. This makes it the preferred long-term maintenance dose. - **Non-Immunosuppressive:** Unlike conventional immunosuppressive therapies, Obefazimod’s mechanism avoids the risks associated with widespread immune suppression, such as infections or malignancies. ### **Unique Positioning** Obefazimod represents a **differentiated treatment option** in the UC landscape due to its: 1. **Novel Mechanism:** It targets inflammation upstream via miR-124 regulation rather than suppressing the immune system directly. 2. **First-in-Class Status:** It is the first therapy of its kind, offering a new pathway for managing moderate-to-severe UC. 3. **Non-Immunosuppressive Nature:** This makes it an attractive option for patients seeking alternatives to traditional immunosuppressive or biologic therapies. ### **Conclusion** Obefazimod (ABX464) is a promising therapeutic option for patients with moderate-to-severe UC. Its unique mechanism of action, favorable safety profile, and demonstrated efficacy in clinical trials position it as a potential game-changer in the UC treatment landscape. The drug’s ability to provide long-term remission and mucosal healing without immunosuppression makes it a compelling choice for both induction and maintenance therapy.

Binge Eating Disorder (BED)

Binge Eating Disorder (BED) is a serious and common eating disorder characterized by recurrent episodes of consuming large quantities of food in a short period, often accompanied by feelings of loss of control, distress, and guilt. Unlike bulimia nervosa, BED episodes are not followed by compensatory behaviors such as vomiting, excessive exercise, or fasting. BED is recognized as a distinct diagnosis in the *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition* (DSM-5). ### Key Features of BED: 1. **Recurrent Binge Episodes**: Eating an unusually large amount of food within a discrete time period (e.g., within 2 hours) and feeling a lack of control during the episode. 2. **Associated Emotional Distress**: Feelings of shame, guilt, or disgust often follow binge episodes. 3. **Frequency**: To meet diagnostic criteria, binge eating episodes typically occur at least once a week for three months. 4. **No Compensatory Behaviors**: BED differs from bulimia nervosa in that individuals do not engage in purging or other compensatory behaviors to counteract the binge. ### Causes and Risk Factors: The exact cause of BED is not fully understood, but it is believed to arise from a combination of biological, psychological, and environmental factors: - **Biological Factors**: Genetic predisposition, hormonal imbalances, or neurotransmitter dysregulation (e.g., serotonin or dopamine). - **Psychological Factors**: Emotional distress, low self-esteem, and a history of trauma or abuse. - **Environmental Factors**: Societal pressure to conform to certain body standards, family history of eating disorders, or exposure to dieting behaviors. ### Health Consequences: BED is associated with significant physical and psychological health risks, including: - **Physical**: Obesity, type 2 diabetes, high blood pressure, heart disease, and gastrointestinal issues. - **Psychological**: Depression, anxiety, and social isolation. ### Current Treatments for BED: Treatment for BED focuses on addressing the underlying psychological and physiological factors contributing to the disorder. The main treatment options include: 1. **Psychotherapy**: - **Cognitive-Behavioral Therapy (CBT)**: The most evidence-based treatment for BED, CBT helps individuals identify and change negative thought patterns and behaviors related to binge eating. - **Dialectical Behavior Therapy (DBT)**: Focuses on improving emotional regulation and coping mechanisms. - **Interpersonal Therapy (IPT)**: Addresses interpersonal issues that may contribute to binge eating. 2. **Pharmacotherapy**: - **Lisdexamfetamine (Vyvanse)**: The first FDA-approved medication specifically for BED. It is a stimulant that helps reduce binge episodes but carries potential side effects such as insomnia, increased heart rate, and anxiety. - **Topiramate**: An anticonvulsant that has shown efficacy in reducing binge episodes but is associated with side effects like cognitive impairment and fatigue. - **Selective Serotonin Reuptake Inhibitors (SSRIs)**: Sometimes prescribed to manage co-occurring depression or anxiety, which can indirectly reduce binge eating. 3. **Lifestyle Interventions**: - Structured meal planning and nutritional counseling can help individuals establish healthy eating patterns. - Physical activity and stress management techniques are often incorporated into treatment plans. ### Emerging Treatments: GLP-1 Receptor Agonists (GLP-1 RAs): GLP-1 receptor agonists, such as semaglutide and liraglutide, are medications originally developed for type 2 diabetes and obesity. They work by suppressing appetite, promoting satiety, and reducing food-related reward mechanisms. These effects make them a potential treatment for BED. However, their use in BED is still in the experimental stage. #### Evidence for GLP-1 RAs in BED: - Early small studies suggest that GLP-1 RAs may reduce binge episodes and improve appetite control in individuals with BED. - Mechanisms include reducing anticipatory food reward and promoting feelings of fullness, which are directly relevant to the disorder. #### Concerns and Limitations: - **Lack of Robust Evidence**: Current studies are limited by small sample sizes, short durations, and open-label designs, making it difficult to draw definitive conclusions. - **Psychiatric Safety Concerns**: A pharmacovigilance analysis of FDA reports identified over 8,000 psychiatric adverse events linked to GLP-1 RAs, including binge eating and other disordered eating behaviors. This raises concerns about their safety in individuals with BED. - **Need for Large-Scale Trials**: Experts emphasize the need for well-designed, large-scale, controlled trials to establish the efficacy and safety of GLP-1 RAs in treating BED. ### Summary: BED is a complex disorder that requires a comprehensive, individualized treatment approach. While cognitive-behavioral therapy and certain medications like lisdexamfetamine and topiramate are the current mainstays of treatment, emerging therapies like GLP-1 receptor agonists show promise. However, their use remains experimental, and further research is needed to confirm their safety and effectiveness. If you or someone you know is struggling with BED, seeking help from a healthcare professional specializing in eating disorders is crucial.

Auricular Vagus Nerve Stimulation in Constipation-Predominant IBS

Auricular vagus nerve stimulation (taVNS) has emerged as a promising non-invasive neuromodulation therapy for managing constipation-predominant irritable bowel syndrome (IBS-C). A randomized controlled trial has demonstrated that taVNS offers significant benefits across multiple dimensions of IBS-C, targeting both physiological and psychological aspects of the condition. Here’s a detailed breakdown of its effects: ### **Key Findings from the Study** 1. **Symptom Improvement:** - **Abdominal Pain:** Patients receiving taVNS experienced a notable reduction in abdominal pain compared to those in the sham (placebo) group. - **Stool Frequency and Bowel Satisfaction:** taVNS significantly improved stool frequency, promoting better bowel movements, and enhanced overall bowel satisfaction. - **Psychological Symptoms:** Psychological symptoms, such as anxiety and stress, which are commonly associated with IBS-C, were also alleviated. - **Quality of Life:** The therapy led to a marked improvement in the overall quality of life for patients. 2. **Physiological Mechanisms:** - **Enhanced Vagal Tone:** taVNS increased vagal tone, which is critical for promoting parasympathetic nervous system activity and regulating gut function. - **Rectal Sensory Thresholds:** Improved rectal sensory thresholds suggest a normalization of gut hypersensitivity, a hallmark of IBS. - **Acetylcholine Levels:** taVNS increased acetylcholine levels, which is essential for modulating gut motility and secretion. - **Gut Microbiome Modulation:** taVNS influenced the gut microbiota composition, with an increase in beneficial bacteria like *Bifidobacterium*. This was accompanied by higher levels of short-chain fatty acids (SCFAs), which play a role in gut health and motility. 3. **Safety and Tolerability:** - Adverse events associated with taVNS were mild and self-limiting, making it a safe therapeutic option for IBS-C patients. ### **Mechanism of Action:** The therapeutic benefits of taVNS are attributed to its ability to modulate the **gut–brain–microbiota axis**, a bidirectional communication network between the central nervous system, the enteric nervous system, and the gut microbiota. By stimulating the auricular branch of the vagus nerve, taVNS enhances parasympathetic activity, reduces gut inflammation, and restores gut motility and sensitivity. ### **Advantages of taVNS:** - **Non-Invasive:** Unlike other invasive neuromodulation techniques, taVNS is applied transcutaneously, making it a more accessible option. - **Multifaceted Benefits:** It addresses both the physical symptoms (e.g., constipation, pain) and psychological comorbidities (e.g., anxiety) of IBS-C. - **Gut Microbiome Impact:** The modulation of the gut microbiome and the increase in SCFAs suggest long-term benefits for gut health. ### **Clinical Implications:** taVNS represents a novel, safe, and effective treatment for IBS-C, particularly for patients who may not respond to conventional therapies such as dietary adjustments, laxatives, or pharmacological agents. Its ability to simultaneously target the gut, brain, and microbiota makes it a comprehensive therapeutic approach. ### **Future Directions:** Further studies are warranted to: - Explore the long-term effects of taVNS. - Identify optimal stimulation parameters (e.g., frequency, duration) for different patient populations. - Investigate its potential synergy with other IBS-C treatments, such as probiotics or dietary interventions. In conclusion, auricular vagus nerve stimulation is a groundbreaking therapy for IBS-C, offering significant symptom relief and mechanistic benefits through its modulation of the gut–brain–microbiota axis. Its safety, non-invasiveness, and broad therapeutic effects make it a valuable addition to the IBS-C treatment toolkit.

Intestinal Ultrasound–Defined Active IBD in Pregnancy and Adverse Obstetric Outcomes

The use of intestinal ultrasound (IUS) to monitor disease activity in pregnant women with inflammatory bowel disease (IBD) has been shown to have significant prognostic value in predicting adverse obstetric outcomes. The findings of the study highlight the following key points: ### 1. **Role of IUS in Defining Active IBD:** - IUS was used to assess disease activity in pregnant women with IBD, focusing on parameters like **bowel wall thickness** and **hyperemia** (increased blood flow in the bowel wall). - Active disease as detected by IUS was strongly associated with adverse pregnancy outcomes. ### 2. **Adverse Obstetric Outcomes Linked to Active IBD:** - **Preterm Delivery:** Pregnant women with active IBD on IUS had a higher likelihood of delivering preterm. - **Low Birth Weight (LBW):** Infants born to mothers with active IBD were more likely to have low birth weights. - **NICU Admission:** Newborns from mothers with active IBD required neonatal intensive care unit (NICU) admission more frequently. - **Preeclampsia:** Active IBD was associated with a higher risk of preeclampsia, a pregnancy complication marked by high blood pressure and potential organ damage. - **Gestational Diabetes:** There was also a link between active IBD and an increased risk of gestational diabetes. ### 3. **Independence from Clinical and Biochemical Measures:** - The associations between IUS-defined active IBD and adverse outcomes were **independent of clinical symptoms or biochemical markers**. - Clinical and biochemical measures often showed **poor concordance** with IUS findings, suggesting that IUS provides unique and valuable information that may not be captured by traditional methods. ### 4. **Prognostic Value of IUS:** - The study underscores the prognostic utility of IUS in pregnancy, as it enables early identification of women at higher risk for adverse maternal and neonatal outcomes. - IUS serves as a **safe, non-invasive tool** that can guide the management of IBD in pregnant women, potentially improving outcomes. ### 5. **Clinical Implications:** - The findings support the integration of IUS into routine care for pregnant women with IBD. - Regular monitoring with IUS may allow for timely interventions to mitigate risks associated with active disease. In summary, intestinal ultrasound-defined active IBD in pregnancy is strongly associated with adverse obstetric outcomes, including preterm delivery, low birth weight, NICU admission, preeclampsia, and gestational diabetes. The study highlights the unique value of IUS as a reliable, non-invasive tool for monitoring disease activity and guiding clinical management to improve both maternal and neonatal outcomes.

Habitual Dietary Patterns and Quality in Irritable Bowel Syndrome

The study on habitual dietary patterns and quality in Irritable Bowel Syndrome (IBS) highlights significant differences in the dietary habits and overall diet quality of IBS patients compared to matched population controls. Here are the key findings and insights: ### Dietary Patterns in IBS Patients: 1. **Reduced Consumption of Certain Foods**: - IBS patients consumed **less carbohydrate**, **dairy**, **bread**, and **vegetables** compared to the general population. This could be due to symptom-triggering concerns or dietary restrictions to manage IBS symptoms. 2. **Increased Consumption of Other Foods**: - IBS patients tended to consume **more fats**, **nuts**, **snacks**, and **lactose-free dairy**. These changes might reflect adaptations to avoid symptom triggers like lactose or high-FODMAP foods. 3. **Dietary Diversity**: - IBS patients exhibited reduced dietary diversity, potentially limiting the range of nutrients they consume. ### Overall Diet Quality in IBS Patients: 1. **Poorer Diet Quality**: - IBS patients generally had a poorer diet quality compared to controls. This was evident in their failure to meet key dietary recommendations. - Specifically, fewer IBS patients met the recommended intake for **fiber** and **saturated fat**. 2. **Impact on Symptoms and Psychological Health**: - The study found that poorer diet quality and reduced dietary diversity were associated with: - **Greater IBS symptom severity**. - **Higher levels of gastrointestinal-specific anxiety** (e.g., fear of eating certain foods due to symptom flares). - **Increased psychological distress**, which could include stress, anxiety, or depression. ### Factors Influencing Diet Quality in IBS: 1. **Younger Age**: - Younger IBS patients were more likely to have poorer diet quality, possibly due to less experience with managing their condition or suboptimal dietary habits. 2. **Female Sex**: - Female IBS patients were more likely to have poorer diet quality, which may reflect sex-specific differences in symptom perception, dietary choices, or psychological factors. 3. **Symptom Severity**: - Patients with more severe IBS symptoms tended to have poorer diet quality, possibly because they avoided a broader range of foods to prevent symptom exacerbation. ### Implications for IBS Management: 1. **Personalized Dietary Strategies**: - The findings emphasize the importance of **personalized dietary interventions** tailored to individual IBS patients. These strategies could help improve diet quality, manage symptoms, and address psychological distress. - For example, working with a dietitian to implement a **low-FODMAP diet** or reintroduce tolerated foods could enhance dietary diversity and quality. 2. **Addressing Psychological Factors**: - Since psychological distress and anxiety are linked to diet quality and symptom severity, a holistic approach that includes psychological support (e.g., cognitive-behavioral therapy) may be beneficial. 3. **Focus on Nutritional Balance**: - Encouraging IBS patients to meet dietary recommendations for fiber, healthy fats, and other essential nutrients could improve overall health and potentially reduce symptom severity. ### Conclusion: IBS patients often have distinct dietary patterns and poorer diet quality compared to the general population. These dietary habits are influenced by symptom management strategies, psychological factors, and demographic characteristics. Personalized dietary and psychological interventions are essential for improving diet quality, managing IBS symptoms, and enhancing overall well-being.

FUT7 Enhances Regulatory T-Cell Homing and Immunosuppression in IBD

Yes, the research findings support the conclusion that FUT7 enhances regulatory T-cell (Treg) homing and immunosuppression in inflammatory bowel disease (IBD). Here's a detailed explanation based on the context provided: 1. **FUT7 and Its Role in Tregs**: - FUT7 is critical for the expression of fucosyltransferase 7, an enzyme involved in the synthesis of selectin ligands, which are essential for Tregs to home to inflamed tissues, such as the intestine during IBD. - In IBD, FUT7 expression in Tregs is diminished, which impairs their ability to migrate to the gut and exert their immunosuppressive functions. 2. **Impact of Reduced FUT7 Expression in IBD**: - The diminished expression of FUT7 in Tregs leads to reduced intestinal homing and weakened suppressive capacity. This contributes to the exacerbation of intestinal inflammation, as Tregs play a critical role in maintaining immune homeostasis and preventing excessive immune responses. 3. **Mouse Model Insights**: - Studies using mouse models of colitis demonstrated that Fut7 deficiency worsens the severity of colitis. This highlights the importance of FUT7 in Treg function and the maintenance of intestinal immune balance. - Conversely, restoring Fut7 expression in Tregs enhanced their suppressive capacity, improved their homing ability to the intestine, and significantly reduced intestinal inflammation. 4. **Therapeutic Potential of FUT7**: - Therapeutic delivery of FUT7 via a targeted nanocarrier was shown to effectively alleviate colitis in experimental models without causing adverse effects. This suggests that FUT7-based therapies could restore Treg function and intestinal immune homeostasis in IBD patients. 5. **Key Takeaway**: - The findings establish FUT7 as a key regulator of Treg-mediated immune homeostasis in the gut. By promoting Treg homing and enhancing their immunosuppressive functions, FUT7 plays a crucial role in mitigating intestinal inflammation. - FUT7 represents a promising therapeutic target for the management of IBD, offering a novel approach to address the underlying immune dysregulation associated with the disease. In summary, FUT7 enhances the ability of regulatory T cells to home to the intestine and suppress inflammation, making it a critical factor in controlling IBD and a potential focus for future therapeutic interventions.

The IntAct Trial: ICG Fluorescence Angiography in Rectal Cancer Surgery

The IntAct trial investigated the use of indocyanine green (ICG) fluorescence angiography as a tool to reduce anastomotic leaks during rectal cancer surgery. Anastomotic leaks, which occur when the surgical connection between two sections of the bowel fails, are a significant complication in rectal cancer surgery, leading to increased morbidity, prolonged hospital stays, and higher healthcare costs. ### Key Findings of the IntAct Trial: 1. **Primary Outcome:** - The trial aimed to determine whether ICG fluorescence angiography could significantly reduce clinical anastomotic leaks. However, the reduction in clinical leaks was not statistically significant. 2. **Overall Leak Reduction:** - Despite the primary outcome not reaching statistical significance, the use of ICG fluorescence angiography was associated with a reduction in the overall number of anastomotic leaks, particularly in less severe grades (grades A and B). 3. **Intraoperative Adjustments:** - Surgeons using ICG fluorescence angiography made more intraoperative adjustments to improve the perfusion of the anastomosis. This suggests that the technique provided valuable real-time feedback on blood flow, allowing surgeons to optimize the surgical connection. 4. **Postoperative Outcomes:** - Postoperative outcomes, including quality of life and mortality, were similar between the ICG group and the control group. This indicates that while ICG may help reduce certain complications, it did not significantly impact broader postoperative recovery metrics. 5. **Cost-Effectiveness:** - The trial found modest cost savings associated with ICG use, suggesting that the technique could be cost-effective. By potentially avoiding some anastomotic leaks, hospitals may reduce the need for additional interventions and extended hospital stays. 6. **Severe Leaks:** - The study noted that severe leaks (grade C) are likely influenced by factors beyond perfusion, such as patient comorbidities, surgical technique, or underlying disease biology. As a result, ICG fluorescence angiography may be less effective in preventing these more severe complications. ### Implications of the IntAct Trial: The IntAct trial highlights the potential benefits of ICG fluorescence angiography in rectal cancer surgery, particularly in reducing less severe anastomotic leaks and providing intraoperative guidance for surgeons. However, its impact on clinical leak rates overall and severe leaks was limited. The technique may still be a valuable tool in the surgical armamentarium, especially given its potential cost-effectiveness and ability to improve perfusion during surgery. Future research may focus on refining the use of ICG, identifying patient populations that would benefit most, and addressing factors contributing to severe leaks.

Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer

The study you are referring to investigated the use of low-dose aspirin as a preventive strategy for recurrence in patients with localized colorectal cancer harboring alterations in the PI3K pathway. Below is a detailed summary of the findings and implications: ### Key Findings: 1. **Patient Population**: The trial focused on patients with localized colorectal cancer who had alterations in the PI3K pathway, including PIK3CA hotspot mutations and other PI3K pathway alterations. 2. **Efficacy of Aspirin**: - **PIK3CA Hotspot Mutations**: Aspirin significantly reduced the incidence of cancer recurrence in patients with PIK3CA hotspot mutations. This suggests a strong benefit of aspirin in this specific molecular subgroup. - **Other PI3K Pathway Alterations**: Aspirin also appeared beneficial in patients with other PI3K pathway alterations, though the effect was more pronounced in the PIK3CA-mutated group. 3. **Three-Year Disease-Free Survival**: - Patients receiving aspirin had a higher three-year disease-free survival rate compared to those receiving a placebo. This indicates that aspirin effectively delays or prevents cancer recurrence in this population. 4. **Adverse Events**: - While aspirin was effective, it was associated with a somewhat higher frequency of severe adverse events compared to placebo. This highlights the need for careful patient selection and monitoring during aspirin therapy. ### Implications: 1. **Personalized Medicine**: - The study underscores the importance of molecular profiling in colorectal cancer. Patients with PI3K pathway alterations, particularly PIK3CA hotspot mutations, may derive significant benefit from low-dose aspirin as part of their treatment strategy. 2. **Preventive Strategy**: - Low-dose aspirin could be considered an effective and relatively low-cost option to prevent recurrence in patients with localized colorectal cancer and PI3K pathway alterations. 3. **Risk-Benefit Assessment**: - Although aspirin is generally well-tolerated, the increased risk of severe adverse events warrants a risk-benefit assessment before initiating therapy. Patients with contraindications to aspirin (e.g., bleeding disorders, peptic ulcer disease) may not be suitable candidates. 4. **Future Research**: - Further studies are needed to confirm these findings in larger, more diverse populations and to explore the mechanisms by which aspirin exerts its anti-cancer effects in PI3K-altered colorectal cancer. ### Conclusion: Low-dose aspirin is a promising preventive treatment for recurrence in patients with localized colorectal cancer harboring PI3K pathway alterations. It is particularly effective in those with PIK3CA hotspot mutations. However, the potential for severe adverse events necessitates careful patient selection and monitoring. This study supports the integration of molecular profiling into clinical decision-making to identify patients who may benefit most from aspirin therapy.

Dietary nutrient patterns and the risk of IBS

The study investigated the relationship between dietary nutrient patterns and the risk of developing Irritable Bowel Syndrome (IBS) in a diverse Iranian population. Here are the detailed findings and insights: --- ### **Study Overview** - **Objective:** To determine whether specific nutrient-based dietary patterns are linked to the likelihood of developing IBS. - **Design:** A multicenter case-control study conducted in three provinces of western Iran (Khorramabad, Urmia, and Kermanshah) between 2021 and 2023. - **Participants:** - 317 IBS patients (diagnosed using Rome III criteria). - 601 healthy controls. - Total: 901 participants, with a case-to-control ratio of 1:2. - **Exclusion Criteria:** Chronic diseases, gastrointestinal surgery, pregnancy, smoking, alcohol use, and special diets were excluded to minimize confounding variables. --- ### **Dietary Assessment** - **Tool Used:** A validated 168-item Food Frequency Questionnaire (FFQ). - **Data Analysis:** Nutrient intake data were analyzed with Nutritionist IV software to calculate macronutrient and micronutrient levels. - **Nutrient Patterns Identified:** Principal Component Analysis (PCA) revealed three major nutrient patterns: 1. **Pattern I:** Rich in antioxidants (β-carotene, vitamin C, vitamin A, lutein, vitamin E, etc.). 2. **Pattern II:** Rich in maltose, fiber, glucose, and fructose. 3. **Pattern III:** High in sugars (sucrose, galactose, lactose) and caffeine. - Together, these patterns explained **63.59% of the variance** in dietary intake, capturing the primary dietary trends in the study population. --- ### **Key Findings** #### **1. Pattern I: Antioxidants** - **Effect on IBS Risk:** Higher adherence to this pattern was associated with a **25% reduced odds of IBS** (OR = 0.75, CI 0.62–0.92). - **Implication:** Antioxidants, such as carotenoids and vitamins, appear to have protective effects against IBS development. - **Demographics:** Adherence to Pattern I was higher among educated, married, and non-smoking individuals. #### **2. Pattern II: Fiber and Monosaccharides** - **Effect on IBS Risk:** This pattern showed an even stronger protective effect, with a **48% reduced odds of IBS** (OR = 0.52, CI 0.42–0.64). - **Implication:** Dietary fiber and fruit-based sugars (e.g., fructose, glucose) may play a significant role in protecting against IBS, despite known issues with fructose malabsorption in some IBS patients. - **Demographics:** Pattern II was more common among physically active individuals. #### **3. Pattern III: Sugars and Caffeine** - **Effect on IBS Risk:** No significant relationship was found between this pattern and IBS risk (OR = 0.95, CI 0.80–1.12). - **Implication:** While sugars and caffeine are often suspected IBS triggers, this study did not find evidence supporting a direct link. - **Demographics:** Pattern III was more common among males and individuals with lower education levels. --- ### **Additional Insights** - **Symptom Severity:** None of the nutrient patterns were associated with the severity of IBS symptoms. While Patterns I and II reduced the odds of developing IBS, they did not influence how severe the disease was in those who had it. - **Age and Weight:** - No significant age differences were observed across Pattern I tertiles. - Patterns II and III were associated with higher age. - Pattern I was linked to slightly higher weight and BMI. - **Nutrient Sources:** In the Iranian population, fruits were the primary source of fructose and fiber in Pattern II, explaining its protective role despite potential fructose malabsorption in IBS patients. --- ### **Context with Other Studies** - The findings align with prior research suggesting that: - **Antioxidants, fiber, and phytochemicals** promote gut health and reduce IBS risk. - However, the study contrasts with some research that implicates **caffeine and sugars** as IBS risk factors, as no significant relationship was found for Pattern III. --- ### **Strengths of the Study** - **Large Sample Size:** Inclusion of 901 participants provided robust statistical power. - **Multicenter Design:** Enhanced diversity and generalizability of findings. - **Adjustment for Confounders:** Controlled for factors like age, gender, marital status, energy intake, and physical activity. - **Focus on Nutrient Patterns:** Analyzed dietary patterns rather than individual nutrients, offering a more realistic view of diet complexity. --- ### **Clinical Implications** - **Dietary Recommendations for IBS Prevention:** - Diets rich in **antioxidants** (e.g., vitamins A, C, E, and carotenoids) may reduce IBS risk. - High **fiber** and **fruit-based sugars** (e.g., from fruits) are protective and should be encouraged. - **Sugars and caffeine** do not appear to have a significant impact on IBS risk, but individual tolerance should still be considered. - These findings can inform guidelines for nutritional strategies targeting IBS prevention. --- ### **Conclusion** The study highlights the importance of nutrient-based dietary patterns in IBS risk. Specifically, antioxidant-rich and fiber-rich diets may offer protective benefits, while high sugar and caffeine intake show no clear association. These insights could help shape future dietary recommendations for IBS prevention and management.

12-week low FODMAP diet and levels of GLP-1 in IBS

The study investigated the effects of a 12-week low FODMAP diet (LFD) on GLP-1 (glucagon-like peptide-1) levels in patients with moderate-to-severe irritable bowel syndrome (IBS). Here is a detailed breakdown of the findings and their implications: --- ### **1. GLP-1 Levels and the Low FODMAP Diet** - **Baseline and Post-Diet GLP-1 Levels**: - Fasting plasma GLP-1 levels increased significantly after the 12-week LFD intervention. - Before the diet, the average GLP-1 level was **3.3 pM**, which rose to **3.6 pM** post-diet (**p = 0.027**). - While the absolute increase in GLP-1 levels was modest, the change was consistent across the cohort, suggesting that the LFD can modulate enteroendocrine signaling in IBS patients. - **Mechanisms Behind GLP-1 Modulation**: - The authors hypothesize that the LFD may improve **intestinal barrier function**, which in turn influences GLP-1 secretion. - High-FODMAP diets are known to disrupt the intestinal barrier, while GLP-1 analogs have been shown to enhance barrier integrity. This interaction may explain the observed increase in GLP-1 levels. - Additionally, GLP-1 is involved in regulating **gut motility**. The reduction in dietary FODMAPs may alter gut motility indirectly through GLP-1 signaling. --- ### **2. Symptom Improvement and GLP-1** - **Clinical Symptom Reduction**: - IBS symptoms improved significantly after the LFD, as measured by the **IBS Severity Scoring System (IBS-SSS)**. Scores decreased from **269.8** (moderate-to-severe IBS) to **155.3** (mild IBS) (**p < 0.001**). - Improvements were also observed in specific symptoms like pain, bloating, and diarrhea, as assessed by the **Gastrointestinal Symptom Rating Scale (GSRS-IBS)**. - **Correlation Between GLP-1 and Symptoms**: - Surprisingly, changes in GLP-1 levels were **not correlated** with changes in IBS-SSS scores, body weight, or GSRS scores. - This indicates that the symptom improvements and the hormonal changes (GLP-1 increase) may occur through partially independent mechanisms. --- ### **3. FODMAP Reduction and GLP-1** - **Dietary Adherence**: - The LFD intervention led to a dramatic reduction in FODMAP intake, from **24.8 g/day** to **2.1 g/day** (**p < 0.001**). This confirms strong adherence to the diet under guided conditions. - **Impact of FODMAP Reduction on GLP-1**: - High-FODMAP diets are known to increase gut fermentation and gas production, which can exacerbate IBS symptoms. By reducing FODMAP intake, the diet likely alleviates these effects, indirectly influencing GLP-1 secretion and gut motility. --- ### **4. Hypotheses on GLP-1 and IBS Pathophysiology** The study provides several mechanistic insights into the potential role of GLP-1 in IBS: - **Intestinal Barrier Function**: - LFD may enhance the intestinal barrier, and GLP-1 secretion could be a downstream effect of this improvement. - **Gut Motility**: - GLP-1 is known to slow gastric and small intestinal motility. While its effect on colonic motility remains debated, both FODMAP intake and GLP-1 are thought to influence motility, suggesting a potential overlap in their mechanisms. - **Visceral Hypersensitivity**: - Both LFD and GLP-1 analogs have been shown to reduce visceral hypersensitivity, which is central to IBS symptoms. This could be another pathway through which dietary changes and GLP-1 interact. --- ### **5. Clinical Implications** - The observed rise in GLP-1 after the LFD could partially explain why both dietary interventions and GLP-1 analogs (e.g., ROSE-010) provide symptom relief in IBS. - Targeting GLP-1 pathways may represent a promising therapeutic strategy for IBS, especially in combination with dietary interventions like the LFD. --- ### **6. Safety and Feasibility of LFD** - The study highlights the **nutritional safety** of the LFD when implemented under professional supervision. While weight loss was noted, no major micronutrient deficiencies were reported during the 12-week intervention. --- ### **7. Future Directions** - Larger, controlled trials are needed to: - Investigate the diet–hormone interactions in IBS across different subtypes (IBS-D, IBS-M, etc.). - Examine the role of GLP-1 changes in healthy controls versus IBS patients. - Further elucidate the mechanisms behind the observed GLP-1 changes and their relationship to symptom relief. --- ### **Conclusion** The 12-week low FODMAP diet significantly increased fasting GLP-1 levels in IBS patients, while also leading to substantial symptom improvement, particularly in pain, bloating, and diarrhea. However, the lack of correlation between GLP-1 changes and symptom relief suggests that these effects may occur through independent or overlapping mechanisms. The findings highlight the potential of combining dietary strategies with GLP-1–targeted therapies for managing IBS.

Factors associated with symptom relief in patients with irritable bowel syndrome

The study identifies several demographic, lifestyle, psychological, and physiological factors associated with symptom relief in patients with irritable bowel syndrome (IBS). Here’s a detailed breakdown of the findings: --- ### **1. Demographic Factors** - **Age**: The average age of the cohort was 45 years, but specific age-related differences in symptom relief were not highlighted. - **Gender**: Females had a slightly higher likelihood of symptom relief (54.5%) compared to males (45.9%). This could be due to gender differences in stress response, hormonal influences, or healthcare-seeking behavior. - **IBS Subtype**: - Patients with mixed-type IBS (IBS-M) showed the highest likelihood of symptom relief (55%) compared to diarrhea-predominant IBS (IBS-D, 39.9%) and constipation-predominant IBS (IBS-C, 40.5%). - The variability in symptoms in IBS-M may allow for greater responsiveness to interventions. --- ### **2. Lifestyle Factors** - **Exercise**: - Daily exercise (≥30 minutes of moderate-intensity activity) was a strong predictor of symptom relief, with a 65.5% relief rate compared to 35% in those who did not exercise. - A dose-response relationship was observed, with patients exercising 3–5 times per week also showing significant benefit (53% relief rate). - **Smoking and Alcohol Consumption**: - While these were associated with worse baseline symptom severity, they were not directly linked to symptom relief rates. However, lifestyle counseling may help reduce the overall symptom burden. --- ### **3. Psychological Factors** - **Depression**: - Lower depression scores were significantly associated with better symptom outcomes (OR = 0.93). Depression worsens gut-brain axis function, contributing to IBS severity, so addressing mental health is critical. - **Stress**: - High stress levels were associated with lower symptom relief rates (39%) compared to those with low stress (58%). Stress likely exacerbates IBS through hormonal and autonomic dysregulation. - **Anxiety**: - Anxiety showed some association with symptom relief in univariate analysis but lost significance in multivariate analysis, suggesting that depression and stress play stronger roles in symptom outcomes. --- ### **4. Social and Family Support** - **Family Support**: - Strong family support was associated with a higher relief rate (60.5%) compared to those with poor support (35%). Family involvement likely enhances treatment adherence, coping, and psychological well-being. --- ### **5. Baseline Symptom Severity** - **Symptom Severity**: - Patients with higher baseline symptom severity were more likely to report symptom relief (OR = 1.20). This may reflect greater motivation to adhere to treatment and lifestyle changes, or possibly a regression-to-the-mean effect. --- ### **6. Physiological and Biological Markers** - **CRP Levels and Gut Microbiota Diversity**: - Neither C-reactive protein (CRP) levels nor gut microbiota diversity were independent predictors of symptom relief. While these markers are relevant to IBS pathophysiology, their role in predicting symptom improvement appears limited. --- ### **7. Medication Adherence** - **Adherence**: - Higher medication adherence showed a trend toward better outcomes, though it was not statistically significant. This indicates that lifestyle and psychological factors may have a stronger influence on symptom relief than medication alone. --- ### **8. Financial and Economic Factors** - **Financial Stress**: - Financial burden did not significantly impact symptom relief outcomes. This suggests that psychosocial support and coping mechanisms may outweigh economic factors in determining IBS symptom improvement. --- ### **9. Predictive Model Performance** - The predictive model, which included factors like symptom severity, exercise, depression, stress, and family support, had an area under the curve (AUC) of 0.76, indicating good reliability in predicting symptom relief. --- ### **Clinical Implications** - IBS management should take a **holistic approach** that integrates: - **Lifestyle interventions**: Regular physical activity (e.g., daily or 3–5 times/week). - **Mental health support**: Addressing depression and stress through therapy or stress management techniques. - **Social support**: Encouraging family involvement to improve adherence and coping. - These low-cost, non-pharmacological strategies can complement pharmacological or dietary therapies to enhance patient outcomes. --- ### **Summary of Key Predictors of Symptom Relief** 1. **Positive Predictors**: - Daily exercise (≥30 minutes of moderate-intensity activity). - Strong family support. - Lower depression and stress levels. - Higher baseline symptom severity. 2. **Negative Predictors**: - High stress levels. - Poor family support. - Lack of regular physical activity. 3. **Non-Significant Predictors**: - CRP levels and gut microbiota diversity. - Financial stress. - Anxiety (in multivariate analysis). By focusing on these factors, healthcare providers can develop more personalized and effective IBS management plans.